Ventral Tegmental Area Regulation Of Stress-Induced Reinstatement Of Cocaine-Seeking Behavior by Blacktop, Jordan Michael
Marquette University
e-Publications@Marquette
Dissertations (2009 -) Dissertations, Theses, and Professional Projects
Ventral Tegmental Area Regulation Of Stress-
Induced Reinstatement Of Cocaine-Seeking
Behavior
Jordan Michael Blacktop
Marquette University
Recommended Citation
Blacktop, Jordan Michael, "Ventral Tegmental Area Regulation Of Stress-Induced Reinstatement Of Cocaine-Seeking Behavior"
(2014). Dissertations (2009 -). Paper 338.
http://epublications.marquette.edu/dissertations_mu/338
VENTRAL TEGMENTAL AREA REGULATION OF STRESS-INDUCED 
REINSTATEMENT OF COCAINE-SEEKING BEHAVIOR 
 
 
 
 
 
 
 
 
by 
 
Jordan M. Blacktop, B.S. 
 
 
 
 
 
 
A Dissertation submitted to the Faculty of the Graduate School, 
Marquette University, 
in Partial Fulfillment of the Requirements for 
the Degree of Doctor of Philosophy 
 
 
 
 
 
Milwaukee, Wisconsin 
May 2014 
  
ABSTRACT 
Ventral Tegmental Area Regulation of Stress-Induced Reinstatement of Cocaine-
Seeking Behavior 
Jordan M. Blacktop, B.S. 
Marquette University, 2013 
 
No FDA approved medications currently exist for the prevention of drug craving, 
drug seeking, and relapse to cocaine use. Stress is a major factor in causing 
relapse in cocaine dependent individuals. Cocaine use is positively correlated with 
stress-induced craving and relapse outcomes. Corticotropin-releasing factor 
(CRF) is a 41-amino acid neuropeptide that plays an important role in the stress 
response and in the reinstatement rodent model of stress-induced relapse. CRF is 
released during stress in brain regions associated with the effects of drugs of 
abuse, notably the ventral tegmental area (VTA). This dissertation addresses key 
unknown mechanisms behind drug-induced neuroplasticity and how that 
neuroplasticity gates the ability of stress to cause relapse. Chapter two reports that 
stress and intra-VTA CRF administration produces robust reinstatement in animals 
allowed extended long-access (LgA) but not short-access (ShA) cocaine self-
administration. Moreover, LgA cocaine use increases susceptibility to stressor-
induced relapse in part by augmenting CRF receptor 1 (CRF-R1) dependent 
regulation of VTA neurocircuitry. Chapter three characterizes VTA dopamine 
neuron activation under conditions where stress reinstates cocaine seeking. 
Dopamine neuron activation was significantly increased in ShA but not LgA rats. 
However, when examined across groups only in rats that display relapse in 
response to stress is a significant increase in dopamine neuron activation 
observed. This suggests that stress-induced reinstatement is associated with 
increased activation of VTA dopamine neurons. Lastly, chapter 4 addresses the 
necessity of VTA glutamate and GABA receptors in footshock and intra-VTA CRF 
dependent reinstatement of cocaine seeking. Intra-VTA administration of NMDA, 
AMPA, and GABAA receptor antagonists fail to block reinstatement. In contrast, 
GABAB receptor antagonism blocked reinstatement by both footshock and intra-
VTA CRF suggesting GABAB activation is necessary for CRF actions in the VTA. 
The findings from this dissertation provide much needed insight into the 
neuroadaptations that occur in the VTA to regulate later stressor induced relapse 
in cocaine addicts. The hope is that these findings will help with the understanding 
and eventual long-term management of stressor-induced relapse in abstinent 
cocaine addicts. 
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CHAPTER 1 
 
BACKGROUND AND SIGNIFICANCE 
 
ADDICTION AND SOCIETY 
 The World Drug Report estimates that 5% of the world’s population uses 
illegal drugs, with the economic burden exceeding several hundred billion dollars 
annually (UNODC, 2010). Moreover, the National Drug Intelligence Center 
(NDIC) estimates that drug abuse costs the United States approximately 120 
billion dollars in lost productivity, 61 billion in drug-related crime, and 11 billion in 
drug addiction related healthcare (NDIC, 2011). Combining medical, criminal, 
economic, and social impact, addiction costs Americans upwards to half a trillion 
dollars a year (Jacobs, 2012). Importantly, drug addiction treatment has been 
shown to significantly decrease addiction associated-health and social costs by a 
far greater margin than the cost of implementing the treatment itself (Jacobs, 
2012).  
Treatment is much less expensive than its alternative, such as incarceration 
of these addicted persons (Jacobs, 2012). According to several conservative 
estimates, every $1 invested in addiction treatment programs yields a return of 
between $4 to $7 in reduced drug-related crime, criminal justice costs, and theft 
(Jacobs, 2012). Even more astonishing, when the savings related to health care 
are included, the total savings can exceed the costs by a ratio of 12 to 1 (Jacobs, 
2012). Thus, it makes humane, economical sense to invest in developing better 
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treatments for addiction. Not only will this help the addicted individual, it will also 
give back to society through less interpersonal conflicts, increased workplace 
productivity, and fewer drug-related accidents (Jacobs, 2012). In summary, more 
effective treatment can help reduce the costs of addiction on society while also 
rehabilitating the addicted individual. 
ADDICTION 
 Addiction is chronic relapsing neuropathy of the brain (O'Brien and 
McLellan, 1996) that results from long-term or even permanent changes to the 
circuitry of motivated behavior. The long-term or permanent changes in the 
circuitry of motivated behavior is referred to as drug-induced neuroplasticity. 
Drug-induced neuroplasticity in the circuitry of motivated behavior produces loss 
of control over drug intake, decreased drive for natural rewards, and increased 
relapse vulnerability even following periods of prolonged drug abstinence. 
Although, the initial decision to take the drug is a voluntary decision, as the 
motivation to use the drug takes over and the drug changes brain function, the 
person’s ability to exert control over drug intake is impaired (Volkow and Fowler, 
2000, Kalivas and Volkow, 2005, Jacobs, 2012).  
Human addicts do not maintain a steady state of use but instead increase 
the amount of drug used over time (Edwards, 1986, Gawin and Kleber, 1988, 
Gawin, 1991). As addiction develops there is transition to higher doses with 
longer bingeing duration (Ellinwood, 1977, Gawin and Kleber, 1986, Jekel et al., 
1986, Gawin and Ellinwood, 1988). Therefore, the transition from recreational 
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drug use to drug addiction involves gradual escalation of drug intake over time 
(Edwards, 1986, O'Brien, 1986, Marlatt et al., 1988, Gawin, 1991). This is 
referred to as loss of control over drug intake. Additionally, addicts report 
generalized anhedonia with decreased reward perception to normal everyday life 
experiences (food, sex, hobbies, etc.) (Hall, 1988). Perception of reward is now 
primarily oriented around use of the drug. As addiction progresses addicts use 
the drug to feel “normal” and to avoid the dysphoric effects of withdrawal that 
come with abstinence. 
WITHDRAWAL AND ABSTINENCE 
 Following cessation of drug use by human addicts a state of withdrawal 
can occur consisting of irritability, anxiety, anhedonia, and depression lasting 
from several hours to days (Gawin and Kleber, 1986). Recurrent cycles of drug 
binges followed by drug cessation with consequent severe dysphoria fuel the 
vicious cyclic nature of addiction. Following cessation of drug use there are three 
main stages that occur: (1) acute withdrawal, (2) early abstinence, (3) and 
protracted abstinence (Heilig et al., 2010). Acute withdrawal occurs 48-72 hours 
in humans a timecourse thought to correspond to 24-48 hours after cessation of 
drug use in rats (Heilig et al., 2010). Acute withdrawal is characterized by 
disruptions in sleep, increased anxiety, irritability, and crashing (Walsh et al., 
2009). Early abstinence occurs 3-6 weeks in humans a timecourse thought to 
correspond to 1-2 weeks after cessation of drug use in rats (Heilig et al., 2010). 
Early abstinence is characterized by craving, anxiety, uncertainty (Dudish-
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Poulsen and Hatsukami, 2000), severe depressive-like symptoms, and irritability 
(Gawin and Kleber, 1986). Protracted abstinence consists of abstinence past 3 
months in humans and greater than two weeks in animals (Kuhar and Pilotte, 
1996, Heilig et al., 2010). During protracted abstinence there is a decrease or 
absence of reward perception to normal pleasurable events (Gawin et al., 1986, 
Gawin, 1991, Heilig et al., 2010). 
PROTRACTED ABSTINENCE 
 During protracted abstinence, normally insignificant and/or stressful 
challenges can provoke dysphoria, craving, and relapse (Sinha et al., 1999, 
Heilig et al., 2010). Human clinical observations reveal that addicts experience 
anhedonia, depression, and dysphoria during prolonged periods of abstinence 
from drugs (Dole et al., 1966, Martin and Jasinski, 1969). Unlike the acute 
physical withdrawal symptoms that occur during the first 24-48 hours of drug 
abstinence, dysphoria can persist for extended periods of time during the 
protracted abstinence phase (Gawin, 1991, Ahmed and Koob, 1998, Aston-
Jones and Harris, 2004). Protracted abstinence from drug abuse has also been 
defined as a syndrome with “the persistence of a dysregulated reward system 
long after acute withdrawal” (Koob, 2010). Protracted abstinence is further 
characterized by low-level dysphoric symptoms due to drug abstinence with a 
persistent high relapse vulnerability. 
 
5 
 
TREATMENT DURING PROTRACTED ABSTINENCE 
 Non-pharmacological treatment for abstinent addicts involves teaching 
skills for adaptive coping to cravings triggered by cues, stress and other stimuli 
(Marlatt, 1990, Marlatt, 1996). Initial studies did attempt to use cue exposure 
therapy (Drummond, 1995) to treat human addicts. Initial studies reported cue 
exposure therapy unsuccessful (Marlatt, 1996), however, this line of research is 
ongoing. The current treatment standard consists of a combination of 
pharmacological intervention, depending on the drug of abuse, and cognitive 
behavioral therapy. Cognitive behavioral therapy (CBT) is thought to function by 
suppressing drug seeking through strengthening inhibitory control circuits, 
increasing non-drug reinforced incentive salience, and strengthen executive 
function, especially at times of high relapse risk (Marlatt, 1985). At all stages of 
drug abstinence in addicts there is persistent craving and high relapse 
susceptibility. 
DSM-V CRITERIA: SUBSTANCE USE DISORDER AND CRAVING 
 The Diagnostic and Statstical Manual of Mental disorders (DSM) is the 
American Psychological Association (APA) classification and diagnostic resource 
used to diagnose psychiatric disorders. As understanding of psychiatric disorders 
evolves so must the DSM. The DSM-V substance-related disorders has 
combined the DSM-IV abuse and dependence categories into one substance use 
disorder category. Within the criteria legal problems is removed and importantly 
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replaced with craving. Total criteria include: (1) hazardous use, (2) 
social/interpersonal problems related to use, 3) neglected major roles to use, (4) 
withdrawal, (5) tolerance, (6) use larger amounts/longer, (7) repeated attempts to 
quit/control use, (8) much time spent using, (9) physical problems related to use, 
(10) activities given up to use, (11) and craving (DSM-V, 2013). To qualify for a 
substance use disorder, two or more abuse criteria within 12-month period must 
occur (Hasin et al., 2013). Drug craving is a hallmark in the diagnosis of 
substance us disorders (O'Brien et al., 1998, Miller and Goldsmith, 2001, Waters 
et al., 2004, Weiss, 2005, Heinz et al., 2009). 
CRAVING 
 Craving is a strong desire or urge. Drug craving can be defined as an 
urgent abnormal/obsessive desire, longing, or yearning for the drug. Drug craving 
is associated with an unpleasant feeling that can be alleviated by use of the drug. 
This often is often observed as the chasing of drug-induced euphoria, 
comparable to that experienced upon initial drug use, which can be spurred upon 
by stimuli that induce craving for the drug.  Anti-craving medications are currently 
being investigated with the hope that they will help in the long-term management 
of addiction (O'Brien, 2005). Repeated cycles of drug-induced euphoria, drug 
abstinent-induced dysphoria, and drug craving makes addiction cyclic in nature. 
Craving facilitates the cyclic nature to the addiction process by facilitating 
relapse. Addicts currently abstinent from drug use are still at risk for relapse due 
to drug-induced neuroplasticity within the reward system. In essence, drugs of 
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abuse hijack the endogenous reward/motivation systems, providing a 
neurochemical framework for high relapse susceptibility. 
RELAPSE 
 Addiction is hard to treat because of compulsive drug seeking and high 
relapse vulnerability following periods of prolonged abstinence (Mendelson and 
Mello, 1996, O'Brien and McLellan, 1996, O'Brien, 1997). The high rate of 
relapse following abstinence from drug use is considered to be one of the 
fundamental obstacles to the long-term management of drug addiction (O'Brien, 
2005, Kalivas and O'Brien, 2008). Drug craving and relapse to both drug seeking 
and drug use can be triggered by: (1) exposure to the previously self-
administered drug (drug-induced relapse) (Meyer, 1979, Jaffe et al., 1989, de 
Wit, 1996), (2) stimuli associated with drug taking (cue-induced relapse) 
(Childress, 1992, Carter and Tiffany, 1999), and (3) exposure to stressors 
(stress-induced relapse). 
THEORETICAL ASPECTS OF ADDICTION 
 Common to all drugs of abuse is activation of the midbrain dopamine 
system (Snyder, 1986, Cooper, 1991) which have been implicated in reward, 
euphoria, satisfaction, cognition, alertness, and motivation  (Wise and Bozarth, 
1982, Robbins et al., 1989, Di Chiara, 1995). Drugs of abuse are not only 
rewarding but also reinforcing (White, 1989), increasing the likelihood that the 
behavior of using the drug will be repeated. These findings provided the 
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framework behind the dopamine reward hypothesis. The dopamine reward 
hypothesis states that dopamine plays an essential role in motivated behavior 
and the rewarding effects of drugs of abuse (Wise and Rompre, 1989). However, 
increases in dopamine are not only associated with reward but also prediction of 
reward and salience of reward related stimuli (Robinson and Berridge, 1993, 
Schultz, 1998).  
Drug-induced neuroplasticity has been posited to attribute incentive 
salience or wanting to drug-related stimuli that would otherwise be normally 
ambiguous (Robinson and Berridge, 1993). Drug use in essence changes the 
function of the reward system so that stimuli associated with drug use have 
increased incentive salience (Robinson and Berridge, 1993). Salience refers to 
the characteristics of stimuli that arouse and/or elicit an attentional response 
(Horvitz, 2000). Salience applies to reward, aversion, and new and unexpected 
stimuli that can affect the motivation to seek an anticipated reward, resulting in 
the facilitation of conditioned learning (Schultz, 2001, McClure et al., 2003). 
Importantly, incentive salience can transform drug-associated stimuli into an 
intense craving for the drug (Robinson and Berridge, 1993). 
Repeated drug exposure can also lead to adaptations in the reward 
circuitry that oppose or neutralize the effects of the drug. In this way, addiction 
has been hypothesized to involve neuroadaptations that combat the effects of the 
drug on the brain (Wikler, 1973, Solomon and Corbit, 1974).The opponent 
process theory of addiction states that the rewarding effects of drugs are 
automatically opposed by “anti-reward” signaling such that removal of withdrawal 
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and craving now drives drug use instead of the addition of euphoria (Solomon 
and Corbit, 1974, Koob and Le Moal, 2008). In other words, there is a shift from 
positive reinforcement to negative reinforcement. This theory of addiction centers 
around physiological homeostasis that has been disrupted upon continued drug 
use. Allostasis is the concept of changes in physiology that occur due to 
environmental-induced deviations from a normal homeostatic set point (Sterling, 
1988, McEwen and Stellar, 1993). The opponent process theory of addiction 
defines addiction as hedonic homeostatic dysregulation (Koob and Le Moal, 
1997). This is very similar to Newton’s third law of motion stating that for every 
action there is an equal and opposite reaction (Newton, 1686) but simply applied 
to the effects of the drug on neurophysiology.  
Since there is substantial evidence for the dopamine reward, the incentive 
salience, and the opponent process theories of addiction, it is likely that addiction 
itself would best be described as a powerful combination of all three theories. 
Euphoric vivid memories are made during the uncontrolled binges of drug use 
that can increase the incentive salience of drug associated cues (Gawin and 
Kleber, 1986, Gawin and Ellinwood, 1988). These cues can produce drug craving 
during abstinence facilitating relapse. During abstinence an addict is in a state of 
anhedonia that is exacerbated when coupled with drug craving produced by drug 
associated stimuli in the environment of the user. In essence, dopamine 
regulates the euphoric effects of the drug and incentive salience of drug related 
stimuli, while the opponent process produces the anhedonic state, which interact 
to trigger overwhelming drug craving induced by cues, drug, or stress. This 
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overwhelming drug craving provides the neurochemical framework for both loss 
of control over drug seeking/use and high relapse susceptibility.  
COCAINE AND SOCIETY 
 One drug of abuse that has a particularly high rate of developing addicts 
following recreational use is the euphoric psychostimulant cocaine. More than 23 
million Americans have used cocaine at some time, and the number of frequent 
users, at least weekly, has remained steady since 1991 at ~ 600,000 (O'Brien, 
2011). Approximately 16% of the United States general populace has used 
cocaine at least once in their life while 17% of those that try cocaine become 
addicted (Wagner and Anthony, 2002). These statistics are consistent with other 
studies reporting that 10 to 15% of those who try cocaine develop addiction 
within the first 10 years of first trying the drug (Wagner and Anthony, 2002). 
Crack cocaine has a substantially higher dependence/addiction and relapse rate 
compared to powdered intra-nasal cocaine. It has been estimated that 
approximately 63% of crack cocaine users develop dependence within 8 years of 
first trying the drug (Falck et al., 2008). These statistics suggest that 
approximately 1.6 to 2.7 percent of the United States general populace is 
addicted to cocaine (Wagner and Anthony, 2002).  
The number cocaine initiates has declined (SAMHSA, 2012). However, 
there are still 1,800 new initiates per day (SAMHSA, 2012). Moreover, the 
percentage of individuals that try cocaine and become addicted hasn’t changed, 
and the percent of cocaine addicts that are unemployed has increased 
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(SAMHSA, 2012). Cocaine is the primary abused substance reported for 13% of 
all admissions into substance abuse programs in the United States (SAMHSA, 
2009).  The decrease in initiates but stable number of cocaine addicts could be 
explained by the fact that federal agencies are seizing 30% less cocaine in the 
continental United States (NDIC, 2011) allowing for those addicted to continue to 
have access to cocaine. This is even more problematic when combined with 
recent reports that relapse rates following treatment for cocaine dependence 
typically exceed 45% within 6 to 12 months of treatment (Hall et al., 1991, McKay 
et al., 1998, McKay et al., 1999). Most importantly, there still remains no food and 
drug administration (FDA) approved pharmacotherapy for the treatment of 
cocaine addiction (de Lima et al., 2002, Lima et al., 2003, Vocci and Elkashef, 
2005). In summary, it is clear there is great need of improvement in treatment 
strategies to address the public health concern of cocaine addiction. 
MECHANISM OF ACTION OF COCAINE 
 Research in human subjects has demonstrated that cocaine elicits a 
profound feeling of euphoria producing a reinforcing positive mood state.  This 
has been described as a “rush” or “high” that is directly tied to a dramatic 
increase in dopamine concentrations in the nucleus accumbens (Koob and 
Bloom, 1988, Volkow et al., 1999a, Di Chiara, 2002). This rush can further be 
characterized by augmentation of confidence, well-being, alertness, emotion, 
hedonic drive (sex), communication, satiation, and disinhibition (Ellinwood, 1977, 
Van Dyke et al., 1982, Gawin and Kleber, 1985, Johanson and Fischman, 1989). 
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The reinforcing effects of cocaine correlate with its ability to block the dopamine 
transporter (DAT) at the synapse increasing concentrations of dopamine at 
critical brain sites (Ritz et al., 1987). Cocaine also blocks norepinephrine (NE) 
and serotonin (5-HT) reuptake (Ritz et al., 1990, O'Brien, 2011) having dramatic 
effects on mood and arousal states (Gawin and Kleber, 1984).  
COCAINE CRAVING AND THE HUMAN BRAIN 
 Functional imaging studies on human addicts have given insight into the 
areas of the brain that are dysfunctional and correlated with intense cocaine 
craving. Structural abnormalities indicative of decreased function have been 
found in the prefrontal cortex (PFC) of human cocaine addicts. These 
abnormalities include decreased perfusion, glucose metabolism, and gray matter 
(Volkow et al., 1991, Volkow et al., 1992, Volkow and Fowler, 2000, Franklin et 
al., 2002, Matochik et al., 2003, Volkow et al., 2004). The PFC is involved in 
executive function, decision making, risk/reward assessment, and impulse 
control. Therefore, it has been hypothesized that irresistible drug cravings and 
decreased impulse control that ultimately lead to relapse of drug use are the 
result of decreased prefrontal cortical activity (Kaufman et al., 2003, Hester and 
Garavan, 2004, Volkow et al., 2004, Ersche et al., 2008, Li et al., 2008). This has 
been collectively referred to as drug-induced hypofrontality. In addition to 
hypofrontality, cocaine craving is also associated with dysfunctional striatal-limbic 
responses (Sinha et al., 2005, Wong et al., 2006). These are two main 
downstream targets of the midbrain dopamine system and of glutamatergic 
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projections from the PFC. This indicates that aberrant dopamine and or 
corticostriatal signaling is a phenotype of addicts that is associated with drug 
craving (Sinha, 2013).   
Drug seeking is facilitated by impairment of prefrontal cortical mechanisms 
that in a healthy non-addicted individual, would inhibit harmful behaviors (Hyman 
et al., 2006). The medial prefrontal cortex (mPFC) is involved in both activation 
and suppression of drug-seeking behavior. Moreover, there appears to be 
aberrant communication between this brain region and midbrain dopamine 
neurons (Gu et al., 2010), and the nucleus accumbens (McFarland et al., 2003). 
This is thought to reflect devaluation of non-drug goals within the PFC (Montague 
et al., 2004), with drug-related goals undermining proper PFC function in the 
control of behavior (Paulus et al., 2005). Perhaps this streamlines drug-related 
motivation at the expense of natural motivation. In summary, drug craving is an 
unpleasant feeling and, when combined with aberrant dopamine signaling the 
ability to suppress drug use, is hindered, which facilitates relapse. This may be 
one mechanism involved in loss of control in drug seeking/intake seen in human 
addicts.  
STRESS AND COCAINE CRAVING IN HUMAN ADDICTS 
 One cause of intesnse cocaine craving that precipitates relapse in human 
addicts is stress exposure. Stress is unpredictable and unavoidable in today’s 
society for virtually everyone. For this reason, stress is a significant obstacle in 
maintaining abstinence because it facilitates the vicious cycle of addiction 
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(Ludwig and Wikler, 1974, Littman, 1977, Marlatt, 1978, Bradley et al., 1989, 
Wallace, 1989, Sinha et al., 1999, Sinha, 2001). Stress can take the form of a 
perceived threat (anxiety), loss of a family member, a divorce, job dissatisfaction, 
amongst other things. Stress is embedded throughout the entire process of 
addiction. Stress appears to be a core factor in the initial decision to try a drug, 
continued drug use, development of addiction, and relapse to drug use following 
abstinence.  
States of stress and stressor exposure have long been positively 
associated with relapse to drug seeking and drug use (Marlatt, 1980, Kreek and 
Koob, 1998, Koob and Kreek, 2007). Stressful stimuli increase cocaine craving in 
human addicts (Sinha et al., 1999, Back et al., 2010). Specifically, human 
cocaine users in a drug free state exposed to stressful imagery scripts display 
increased craving for drug, anxiety, heart rate, and even stress hormone levels 
(Sinha et al., 2000). Stress-induced cocaine craving is characterized by 
decreased activity in areas associated with control and regulation of 
emotion/distress (anterior cingulate cortex, hippocampus) (Sinha et al., 2005) 
with increased activity in areas associated with reward (caudate, dorsal striatum) 
(Sinha et al., 2005). Importantly, the magnitude of drug craving is positively 
correlated with the amount of cocaine previously used (Fox et al., 2005). 
A prior history of higher frequency cocaine use is associated with 
augmented stress-induced craving measured in a laboratory setting in cocaine-
dependent individuals (Fox et al., 2005, Back et al., 2010). This augmented 
stress-induced cocaine craving is correlated with higher relapse rates in 
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abstinent cocaine addicts (Sinha et al., 1999, Sinha et al., 2000, Sinha, 2001, 
Sinha et al., 2006, Sinha, 2008, 2009, Back et al., 2010). Stress perceived in the 
environment of a cocaine addict can cause relapse through craving because of 
an atypical stress response (Kreek, 1987). The addiction phenotype (Figure 1) 
involves a maladaptive stress response characterized by enhanced emotional 
responsiveness, drug craving, and decreased adaptive coping (Sinha, 2001). 
 
Figure 1: Addiction stress and relapse; neuroadaptations in brain stress and 
reward circuits results in a maladaptive stress response in human addicts (Sinha, 
2001).  
 
 
 
 
 
 
 
 
 
 
COCAINE ADDICTION AND THE SELF-ADMINISTRATION ANIMAL MODEL 
OF RELAPSE 
 
 Although, human brain imaging and anecdotal reports of craving have 
been useful in determining a key role of stress in the addiction process it is very 
difficult to determine what is exactly happening at those brain regions beyond 
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changes in receptor binding (PET) and cerebral blood flow (fMRI) (Malonek and 
Grinvald, 1996, Volkow et al., 2001). In order to study the intricacies of addiction, 
animal models have been developed. In humans, craving is based on anecdotal 
reports from human addicts themselves. In laboratory animals craving is inferred 
from the behavioral response in the form of drug seeking (lever pressing) 
following abstinence or extinction.  
As the duration of abstinence/withdrawal increases there are also 
increases in cue-induced craving in both subjective reports in humans and drug 
seeking in laboratory animals (Grimm et al., 2001, Bedi et al., 2011). This 
phenomenon is referred to as an incubation of drug craving (Grimm et al., 2001, 
Pickens et al., 2011). In contrast to cues, studies investigating incubation in 
response to both drug and stress have produced mixed results (Tran-Nguyen et 
al., 1998, Shalev et al., 2001, Deroche-Gamonet et al., 2003, Marinelli et al., 
2003, Lu et al., 2004, Shepard et al., 2004, Sorge et al., 2005).  
The reinstatement rodent model of relapse has provided a strong 
framework to investigate the neuromechanisms of relapse induced by cues, drug, 
and stress (Shaham et al., 2003). Reinstatement is simply a restoration of drug-
seeking behavior (Stewart, 1987a, Bouton, 1991, Catania, 1992). The 
reinstatement model allows researchers to characterize the processes in the 
brain that contribute to the maladaptive behavior of relapse in a way that cannot 
be studied in people. This dissertation primarily utilizes the rodent reinstatement 
model of relapse to further characterize the neuromechanisms of stress-induced 
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relapse to cocaine-seeking behavior. This model is described in further detail in 
the following section. 
The same stimuli that can provoke craving and relapse in human addicts 
can reinstate cocaine-seeking behavior in laboratory animals, even after periods 
of prolonged abstinence. In abstinent human cocaine addicts augmented drug 
craving and relapse probability can be triggered by exposure to: (1) the 
previously self-administered drug (Meyer, 1979, Jaffe et al., 1989, Preston et al., 
1992), (2) stimuli previously associated with drug use (Childress, 1992, Carter 
and Tiffany, 1999), and (3) exposure to acute stress (Sinha, 2001, Fox et al., 
2005). In the rodent reinstatement model of relapse vigorous active drug-seeking 
behavior can be induced by (1) priming injections of the drug (Gerber and 
Stretch, 1975), (2) cocaine predictive cues (Weiss et al., 2000), and (notable for 
this dissertation) (3) acute stress exposure (Erb et al., 1996, Ahmed and Koob, 
1997, 1998, Shaham et al., 1998, Shaham et al., 2000, Mantsch et al., 2008a, 
Mantsch et al., 2008b, Shalev et al., 2010). 
SELF-ADMINISTRATION MODEL  
 Drugs abused by humans will be self-administered by laboratory animals 
(Schuster and Thompson, 1969). Cocaine appears to have similar effects on 
brain function in both humans and rodents. As mentioned earlier, drugs of abuse 
exert their reinforcing effects through increased dopamine signaling (Snyder, 
1986, Koob and Bloom, 1988, Wise and Rompre, 1989, Cooper, 1991). When 
humans or laboratory animals self-administer cocaine there are large and fast 
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increases in nucleus accumbens (striatal) dopamine signaling (Hurd et al., 1989, 
Pettit and Justice, 1989, 1991, Laruelle et al., 1995, Wise et al., 1995, Breiter et 
al., 1997, Volkow et al., 1999b, Volkow et al., 2002), an effect that has long been 
associated with reward. Moreover, when dopamine terminals are depleted in the 
nucleus accumbens cocaine self-administration drops significantly (Pettit et al., 
1984), suggesting that increasing dopamine neurotransmission in the nucleus 
accumbens is essential for cocaine self-administration. 
The drug-self-administration model involves the laboratory animal learning to 
perform an operant task, such as lever pressing, to receive intravenous infusions 
of drug (Weeks, 1962). In this model the reinforcing properties of drugs can be 
measured in animals, such as rats,  equipped with intravenous catheters 
connected to lever-regulated pumps, which provide direct systemic 
administration of drug in response to operant lever pressing (O'Brien, 2011). 
These animals will work to obtain injections of the same drugs that are abused by 
humans in roughly the same order of potency (O'Brien, 2011). Moreover, 
evidence suggests that contingent drug-induced neuroplasticity, as seen in the 
self-administration model, can be distinct from noncontingent drug-induced 
neuroplasticity (Stewart, 1987b, Goudie, 1989, Stewart, 1992, Dworkin et al., 
1995, Hemby et al., 1997, Badiani et al., 1998, Robinson et al., 1998, Markou et 
al., 1999).  
Human addicts do not maintain a steady state of use but instead increase 
the amount of drug used over time (Edwards, 1986, Gawin and Kleber, 1988, 
Gawin, 1991), thus resulting in a gradual escalation of drug intake (Edwards, 
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1986, O'Brien, 1986, Marlatt et al., 1988, Gawin, 1991). This escalation of drug 
use is also closely associated with loss of control over drug intake (DSM-V, 
2013). Escalation is thought to represent evidence of drug-induced 
neuroplasticity. Loss of control over drug intake, as seen in the human condition 
(DSM-V, 2013), can be established, in the form of escalation, in animals allowed 
extended daily access to cocaine for self-administration (Ahmed and Koob, 1998, 
Mantsch et al., 2004, Mantsch et al., 2008a, Mantsch et al., 2008b). Extended 
cocaine self-administration access has been termed long-access (LgA) self-
administration. 
SHORT-ACCESS AND LONG-ACCESS MODELS OF COCAINE SELF-
ADMINISTRATION 
 
 Researchers have utilized short-access (ShA), 1-2 hours of cocaine self-
administration access per day, and long-access (LgA), 6-10 hours of cocaine 
self-administration access per day, models to study cocaine abuse/addiction. 
Long-access self-administration (14 x 6 hrs) results in very high levels of drug 
intake ( > 70 mg/kg/day), which are substantially higher than the total intake in 
short access animals (~ 15 mg/kg/day) (Mantsch et al., 2008a). Under both ShA 
and LgA conditions, rats learn—often on the first day of exposure—to lever-press 
for intravenous drug, such as cocaine. Short-access self-administration sessions 
produce stable, controlled, and regulated responding for drug (Ahmed and Koob, 
1999, Mantsch et al., 2008a). On the other hand, long-access (LgA) self-
administration produces a progressive escalation in cocaine self-administration 
(Figure 2) (Ahmed and Koob, 1997, 1998, 1999, Ahmed et al., 2003, Ahmed and 
20 
 
Koob, 2004, Mantsch et al., 2008a, Blacktop et al., 2011). Progressive escalation 
is simply a gradual increase in drug taking across consecutive self-administration 
sessions. Escalation of self-administration in laboratory animals thought to be 
analogous to the loss of control of drug taking seen in human addicts (Ahmed 
and Koob, 1998). 
Figure 2: Escalation of drug SA in long-access rats (LgA/closed circles) but not 
in short-access (ShA/open circle) or saline (Sal/closed triangle). The asterisk (*) 
indicates significant escalation from the previous SA session (Blacktop et al., 
2011). These findings are reproducing those originally reported by Ahmed and 
Koob (1998). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EXTINCTION 
 The next step in the preclinical animal model of relapse after self-
administration is commonly extinction. In order to study relapse using the SA 
approach, it is first necessary to reduce drug-seeking behavior which can be 
accomplished by extinction. Extinction permits a decrease of drug-reinforced 
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
S hA  S A
LgA  S A
S a l S A
* * *
*
B a s 1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4
S e lf-A d m in is tra t io n  D a y
In
fu
s
io
n
s
/S
e
s
s
io
n
21 
 
behavior to pre-training baseline levels allowing the researcher to test for 
reinstatement of drug seeking (Stretch et al., 1971, Stewart, 1987a). Simply, 
extinction is decreased self-administration behavior when the drug and its 
pharmacological effects have been removed (Yap and Miczek, 2008); i.e. 
replacing cocaine with saline (Figure 3) (Shalev et al., 2002). Importantly, during 
extinction the animal is presented with previously drug associated stimuli (self-
administration chamber with levers, lights, etc.) in the absence of the drug (Sorg, 
2012). Following 14 days of cocaine self-administration training, it takes about 10 
days of daily 2 hour extinction sessions before response rates drop back to their 
infrequent pre-training level (Mantsch et al., 2008a, Blacktop et al., 2011). 
Moreover, there are no differences in extinction rates between LgA and ShA 
animals. 
 
 
Figure 3: Extinction of drug-seeking behavior in short-access (ShA/open circle) 
and long-access rats (LgA/closed circles) compared to saline controls (Sal/closed 
triangle). Refer to chapter two figure 1B. (Blacktop et al., 2011). 
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Extinction is defined as a reduction in drug-seeking when the contingency is 
broken between the drug-seeking behavior or drug-predicting stimuli and drug 
reward (Millan et al., 2011). Extinction is an active learning process. During 
extinction, the animal is not unlearning that the active lever results in drug 
reinforcement, but learning that the previously active lever no longer results in 
drug reinforcement. This produces conflicting associations between the original 
drug-seeking associations and the extinction associations (Millan et al., 2011). 
Therefore, extinction doesn’t erase drug seeking but rather counteracts it.  
The major caveat to the self-administration model of relapse is that human 
addicts do not typically go through extinction. However, extinction may represent 
an important component of cognitive behavioral therapy. Cognitive behavioral 
therapy is thought to suppress drug seeking by strengthening inhibitory control 
circuits, increasing non-drug reinforced incentive salience, and strengthening 
executive function at times of high relapse risk (Marlatt, 1985). Although 
extinction and cognitive behavioral therapy are not the same they both are 
thought to function by strengthening neural circuits that inhibit drug seeking. 
REINSTATEMENT  
 Reinstatement refers to the restoration of a previously drug-reinforced 
behavior following its suppression, typically through extinction (Stewart, 1987a, 
Bouton, 1991, Catania, 1992). The dependent variables that are measured 
during a reinstatement session are non-reinforced responses on the lever that 
previously delivered drug (active lever) and responses on a second lever not 
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previously associated with drug infusions (inactive lever). Reinstatement is a 
significant increase in active lever responses representative of drug seeking, 
usually without a significant increase in inactive responses representative of 
nonspecific or generalized response activity (Catania, 1992, Shalev et al., 2002, 
Shaham et al., 2003). 
Reinstatement of drug seeking in the rodent model has been hypothesized to 
be the acute failure of extinction training to inhibit drug seeking (de Wit and 
Stewart, 1981, Crombag and Shaham, 2002). The important balance between 
driving and inhibiting drug seeking appears to involve different inputs from the 
medial prefrontal cortex to different regions of the nucleus accumbens (Cornish 
et al., 1999, McFarland and Kalivas, 2001, McFarland et al., 2003, McFarland et 
al., 2004, Fuchs et al., 2008, Peters et al., 2008, Van den Oever et al., 2010). 
This will be discussed in further detail in the following mesocorticolimbic 
dopamine system section and in chapter five.  In summary, the reinstatement 
model is not perfect but is still a very powerful tool for addiction research. The 
same drugs abused by humans will be administered by the rodent, and the same 
stimuli that precipitate relapse in humans reinstate drug seeking in the rodent. 
STRESS-INDUCED REINSTATEMENT 
 During stress-induced reinstatement a stressful stimulus is administered 
prior to an otherwise normal extinction session, usually within the self-
administration chamber. The most common external stimuli to induce stress-
induced reinstatement of drug seeking is unpredictable, uncontrollable, 
intermittent electric footshock delivered through the grid of the self-administration 
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chamber. Intermittent footshock reinstates drug seeking in rats previously trained 
to self-administer cocaine (Erb et al., 1996, Ahmed and Koob, 1997, Mantsch 
and Goeders, 1999, Sutton et al., 2000). Intermittent unpredictable footshock 
stress not only reinstates cocaine seeking but also reinstates drug seeking for 
most drugs of abuse, including heroin, nicotine, and alcohol (Erb et al., 1998, 
Shaham et al., 1998, Le et al., 2000, Bruijnzeel et al., 2009). 
 
Figure 4: Stress-induced reinstatement of extinguished cocaine-seeking 
behavior in LgA but not ShA rats, which his specific to the active lever (Mantsch 
et al., 2008a, Blacktop et al., 2011, Graf et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
Importantly, our laboratory reports that footshock stress only reliably 
reinstates drug seeking in rodents with a history of LgA cocaine self-
administration (Figure 4) (Mantsch et al., 2008a, Blacktop et al., 2011, Graf et al., 
2011), supporting other studies reporting inconsistent reinstatement in ShA 
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animals (Shelton, 2005). It should be noted that others do report stress-induced 
reinstatement in ShA animals (Erb et al., 1996, Shaham et al., 1998, Shaham et 
al., 2000). However, our findings that stress-induced reinstatement occurs more 
reliably in animals with long-access cocaine self-administration history is 
consistent with intake dependent stress reactivity in humans. Human studies 
report that higher frequency cocaine user’s exhibit augmented cocaine craving in 
response to stress, increasing the probability of relapse (Fox et al., 2005, Sinha 
et al., 2006).  
Although, escalation is observed in LgA animals and not ShA animals 
(Ahmed and Koob, 1998, Mantsch et al., 2008a, Blacktop et al., 2011), there is 
no evidence reporting escalation as the cause of stress-induced reinstatement to 
cocaine seeking. However, both escalation of drug intake and augmented 
reinstatement are intake-dependent and characterize human addiction. LgA 
animals also show augmented reinstatement by cocaine priming (Mantsch et al., 
2004, Madayag et al., 2011) and cocaine cues (Loweth et al., 2013) as compared 
to ShA animals. This suggests an intake-dependent neuroplastic change in the 
circuitry of motivated behavior that augments the ability of cocaine priming, 
cocaine cues, and footshock stress to reinstate cocaine in LgA relative to ShA 
animals. Intake dependent drug-induced changes in the circuitry of motivated 
behavior, as seen in the human condition, can be further characterized in the 
laboratory by comparing the neurological differences between drug naïve, ShA, 
and LgA access animals. Therefore, this dissertation characterizes the 
neuromechanisms regulating augmented stress-induced reinstatement of 
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extinguished cocaine-seeking behavior observed following LgA self-
administration with the goal of understanding the neuroplasticity responsible for 
the transition to addiction. 
STRESS 
 Stress is a general response to demands on the body (Selye, 1936) 
involving alterations in physiological homeostasis (Burchfield, 1979). Stress has 
been simplistically and controversially defined as a nonspecific response of the 
body to a demand that is characterized by the production of glucocorticoids and 
therefore hypothalamic-pituitary-adrenal (HPA) axis activation (Selye, 1936, 
1937). The HPA axis is comprised of the hypothalamus, anterior pituitary gland, 
and the adrenal cortex. A stressor causes the initial cascade of the HPA axis in 
the form of release of corticotropin releasing factor (CRF) from neurons in the 
paraventricular nucleus (PVN) of the hypothalamus which project to the external 
zone of the median eminence. These neurons release CRF into the 
adenohypophyseal portal circulation (Whitnall, 1993), where CRF activation of 
CRF receptors on anterior pituitary corticotrophs results in the synthesis, 
processing, and release of proopiomelanocortin (POMC). POMC is a large 
precursor protein which is proteolytically cleaved to produce several biologically 
active peptides including β-endorphin and adrenocorticotrophin hormone (ACTH) 
(Turnbull and Rivier, 1997, Goeders, 2007). POMC-derived ACTH then circulates 
throughout general circulation until it reaches the adrenal glands stimulating the 
biosynthesis of adrenocorticosteroids to be released from the adrenal gland 
(Figure 5). These adrenocorticosteroids are notably referred to as glucocorticoids 
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which consist of cortisol in humans and corticosterone in rodents (Vale et al., 
1981).  
 
Figure 5: Schematic illustrating simplified HPA axis signaling. Stress results in 
release of CRF from the PVN of the hypothalamus to the anterior pituitary 
activating CRF receptors resulting in ACTH release throughout the general 
circulation. ACTH stimulates the release of adrenocorticosteroids from the 
adrenal gland, notably corticosterone in rodents and cortisol in humans. 
Corticosterone provides negative feedback to the PVN. The bed nucleus of the 
stria terminalis (BNST) and central nucleus of the amygdala (CeA) are two key 
anatomical regions enriched in CRF containing neurons with afferents throughout 
the brain that can function in conjunction with or independently from HPA axis 
activity. 
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Two adrenocorticosteroid receptors have been identified, both of which 
bind corticosterone  and are expressed in the brain (Joels and de Kloet, 1994). 
One is normally fully occupied at basal levels of corticosterone due to its high 
affinity (Reul and de Kloet, 1985), and is referred to as the type I 
mineralocorticoid receptor (MR). The other glucocorticoid receptor has lower 
affinity for corticosterone and is more likely to be occupied during times of stress 
when the plasma levels of corticosterone are elevated (Reul and de Kloet, 1985). 
This is referred to as the GR type II receptor (glucocorticoid receptor). 
Circulating glucocorticoids released by the adrenal glands promote the 
mobilization of energy stores and augment sympathetic nervous system effects 
(Ulrich-Lai and Herman, 2009), alerting and maintaining homeostasis of an 
organism challenged by either environmental or physiological changes (Herman 
and Cullinan, 1997). Circulating glucocorticoids exert prominent negative 
feedback through activation of GR type II receptors at the PVN which inhibit 
further CRF release to maintain tolerable limits of glucocorticoid secretion 
(Herman and Cullinan, 1997). This appears not to be the only negative feedback 
mechanism, with others occurring from GR activation of neuronal inhibitory 
pathways that work in parallel with negative steroidal feedback (Dobrakovova et 
al., 1982, Jacobson et al., 1988, Jacobson and Sapolsky, 1991, Bradbury et al., 
1993, Diorio et al., 1993, Herman, 1993). 
The neurobiological stress response involves physiological homeostatic 
imbalances implicating both the HPA axis and the autonomic sympathetic 
nervous system (Selye, 1937, 1951, Korf et al., 1973, Dallman et al., 1987, 
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Abercrombie et al., 1988, Valentino et al., 1993, Herman and Cullinan, 1997). As 
first elegantly described by Axelrod and Reisine (1984) homeostatic demands 
(stress) involve release of ACTH from the anterior pituitary, glucocorticoids from 
the adrenal cortex, epinephrine from the adrenal medulla, and norepinephrine 
from sympathetic nerves (Axelrod and Reisine, 1984). Therefore, stressful stimuli 
can be conveyed to the brain activating both the HPA axis and autonomic neural 
systems with the goal of minimizing net cost while maintaining physiological 
homeostasis (Ulrich-Lai and Herman, 2009). 
The maintenance or re-establishment of homeostasis in response to 
stress also involves both autonomic and neuroendocrine stress signaling (Ulrich-
Lai and Herman, 2009).  This signaling involves the limbic forebrain, 
hypothalamus, and the brainstem allowing for the integration of a prior stress 
response to memory (Ulrich-Lai and Herman, 2009). This allows not only for the 
appropriate physiological response to homeostatic challenges, but also the ability 
to have a stress system that responds according to prior experience. In this light, 
stress is adaptive and good for the organism. Therefore, it is not surprising there 
are different categories of stress. Stress itself has been viewed as a variation in 
physiological homeostasis whereby hyperstress (overstress), hypostress 
(understress), distress (damaging stress), or eustress (good stress) have been 
characterized (Selye, 1983).  
In summary, stress can be defined broadly as actual or anticipated 
homeostasis disruption to an organism’s physiology involving the HPA axis, the 
autonomic nervous system, and key brain regions regulating these systems. In 
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addition to the study of acute stressors and their regulation of cocaine seeking, 
this dissertation will refer to stress as increased distress produced by prolonged 
variation in physiological homeostasis (e.g., long-access cocaine use) that 
results in a maladaptive physiological response (e.g., drug seeking in response 
to stress), and not simply activation of the HPA axis. 
STRESS AND COCAINE SELF-ADMINISTRATION 
 Stress is embedded in the entire process of cocaine addiction from the 
first decision to try the drug to repetitive relapses following extended periods of 
abstinence. Acute cocaine use is, in fact, physiologically stressful to an organism 
by way of activation of the HPA axis and autonomic nervous system (Rivier and 
Vale, 1987, Saphier et al., 1993, Goeders, 2002, Koob and Kreek, 2007). 
Cocaine self-administration stimulates the release of corticosterone and 
epinephrine from the adrenals in rats (Chiueh and Kopin, 1978, Moldow and 
Fischman, 1987) consistent with changes in physiological homeostasis and 
increased arousal (Axelrod and Reisine, 1984). Much of this section will focus on 
corticosterone and not epinephrine interactions with cocaine use because it is 
better studied and characterized.  
Corticosterone (Cort) is regulated by cocaine self-administration and 
cocaine self-administration is regulated by corticosterone. Daily administration of 
Cort facilitates the acquisition of stable cocaine self-administration (Mantsch et 
al., 1998). Cocaine self-administration increases plasma Cort levels, an effect 
blocked by GR type II receptor agonists (Mantsch et al., 1998) likely through 
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negative feedback. Cort levels at the end of a self-administration session are 
positively correlated with the amount of drug administered (Mantsch and 
Goeders, 2000). Moreover, cocaine self-administration and its escalation can be 
significantly attenuated by inhibiting corticosterone synthesis or surgically 
removing adrenal glands, the primary physiological source of Cort (Piazza et al., 
1994, Goeders and Guerin, 1996a, Goeders et al., 1998, Graf et al., 2011). 
Chronic stress during cocaine self-administration can produce Cort-dependent 
escalating patterns of intake in ShA animals, comparable to what is seen without 
chronic stress in LgA animals (Mantsch and Katz, 2007). Altogether, these 
findings suggest that corticosterone regulates cocaine-induced neuroplasticity 
which can in turn regulate cocaine self-administration. 
Stress-induced corticosterone secretion can regulate dopamine in the 
nucleus accumbens (Piazza and Le Moal, 1996), and rats will self-administer 
corticosterone under certain conditions (Deroche et al., 1993, Piazza et al., 
1993). This suggests that the mesocorticolimbic dopamine system and Cort 
signaling can interact to regulate motivated behavior. This interaction can 
become dysregulated as a result of extended-access cocaine self-administration. 
Rats that self-administer cocaine under LgA conditions display decreased 
corticosterone levels basally and in response to cocaine (Mantsch et al., 2003), 
augmented corticosterone levels in response to stress, and impaired negative 
feedback of the HPA axis (Mantsch et al., 2007). These changes may contribute 
to the augmented ability for footshock stress to induce reinstatement of 
extinguished LgA cocaine seeking (Mantsch et al., 2004). 
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Increased corticosterone (Cort) signaling has been implicated in both 
cocaine self-administration and footshock-induced reinstatement of cocaine-
seeking behavior. Early reports suggested that blockade of corticosterone 
synthesis and/or activation of type II glucocorticoid receptors attenuates cocaine 
self-administration and blocks footshock-induced reinstatement of extinguished 
cocaine seeking behavior (Sonino, 1987, Goeders et al., 1998, Mantsch and 
Goeders, 1999). These findings suggested that increased corticosterone 
signaling is necessary for both stable cocaine self-administration and later 
footshock stress-induced reinstatement of cocaine-seeking behavior (Goeders et 
al., 1998, Mantsch and Goeders, 1999). A more recent study found that 
corticosterone is not necessary for cocaine self-administration (Graf et al., 2011). 
However, Cort signaling appears to be necessary for the drug-induced 
neuroplasticity that is put in place at the time of LgA cocaine self-administration 
that contributes to escalation and augmented reinstatement (Mantsch et al., 
2008b), but is not necessary at the time of later footshock exposure for stress-
induced reinstatement (Graf et al., 2011). This suggests that the neuroplastic 
effects we see in the LgA model are dependent on glucocorticoid signaling during 
self-administration, and that another stress signal is acutely regulating later 
footshock-induced reinstatement. The key candidate for this is the corticotropin 
releasing factor (CRF) signaling system. 
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CORTICOTROPIN-RELEASING FACTOR SYSTEM SIGNALING 
 Corticotropin releasing factor (CRF) is an important regulator of the stress 
response and plays a central role in stress-induced reinstatement of drug-
seeking behavior (Shaham et al., 1997, Erb et al., 1998, Stewart, 2003, 
Spealman et al., 2004). Initial studies found CRF to have many different roles, 
but most were implicated in adapting the body’s behavioral, autonomic, and 
immune responses to stress (Beyermann, 1997). CRF system signaling is not 
only an integral regulator of hypothalamic-pituitary-adrenal (HPA) axis activity but 
there are numerous CRF pathways outside of the hypothalamus (Lymangrover 
and Brodish, 1973) where CRF acts as a central neuromodulator (Swanson et 
al., 1983, Nemeroff, 1997). The CRF signaling system is comprised of 4 ligands, 
a binding protein, and two receptors (Vale et al., 1981, Behan et al., 1995, 
Steckler and Holsboer, 1999, Ryabinin et al., 2002, Fekete and Zorrilla, 2007). 
Corticotropin releasing factor (CRF) is a 41-amino acid neuropeptide 
involved in hypothalamic-pituitary release of ACTH from the pituitary gland (Vale 
et al., 1981) and stress related neurotransmission throughout the brain (Swanson 
et al., 1983). CRF was first characterized in 1981 (Vale et al., 1981, Beyermann, 
1997) and shown to stimulate the secretion of ACTH-like and β-endorphin-like 
immunoreactivities in vitro and in vivo (Vale et al., 1981, Beyermann, 1997). In 
1983 CRF was successfully cloned and sequenced from the human CRF gene 
from which the human precursor was characterized (Shibahara et al., 1983, 
Beyermann, 1997). Isolation and sequence analysis of rat CRF was found to be 
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identical to the human peptide (Rivier et al., 1983). CRF is released at synaptic 
terminals due to depolarization (Smith et al., 1986) and is characterized by 
saturable, reversible, specific binding to its receptors (De Souza et al., 1985). 
The distribution of CRF neurons in the brain is consistent with its role in 
endocrine, physiological, and behavioral responses to stress. Although CRF is 
widely expressed throughout the brain, the highest concentrations of CRF 
containing cell bodies are found in the paraventricular nucleus of the 
hypothalamus (PVN), bed nucleus of the stria terminalis (BNST), and the central 
nucleus of the amygdala (CeA) (Merchenthaler et al., 1982, Olschowka et al., 
1982, Swanson et al., 1983, Petrusz, 1992).  
The largest concentration of CRF cell bodies outside of the PVN is in the 
BNST, followed by the CeA (Figure 7) (Swanson et al., 1983). The BNST, in 
addition to having influences on HPA axis function (Herman et al., 1994), plays a 
critical role in anxiety involving interpretation of threatening or aversive stimuli 
(Walker et al., 2003). The central nucleus of the amygdala (CeA) plays a critical 
role in anxiety and conditioned fear (Davis, 1992b, a). The BNST and CeA may 
communicate with one another through reciprocal CRF inputs. Moreover, a CRF 
projection from the CeA to the BNST has been identified (Sakanaka et al., 1986) 
suggesting that increases in CRF found in the BNST following stress exposure 
(Lee and Davis, 1997) can be regulated by CeA activation (Erb and Stewart, 
1999). The BNST and CeA send CRF projections throughout the brain allowing 
for complex integration of stress specific CRF signaling. 
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CORTICOTROPIN RELEASING FACTOR 
 Corticotropin releasing factor (CRF) signaling is activated during times of 
stress and found to have many different roles. These roles include the integration 
of endocrine, autonomic, emotional, and behavioral responses of the organism 
(Brown et al., 1982b, Bilezikjian and Vale, 1987, Baldwin, 1990, Dunn and 
Berridge, 1990, Beyermann, 1997, Moreau, 1997). Central administration of 
corticotropin releasing factor (CRF) produces increases in: 1) ACTH release from 
the pituitary (Rivier et al., 1984), 2) glucocorticoid secretion (Rivest et al., 1989, 
Korte et al., 1993, Linthorst et al., 1997), 3) epinephrine and norepinephrine 
release (Brown et al., 1982a), 4) glucagon levels (Brown et al., 1982a), 5) and 
even dopamine and norepinephrine turnover rates in discrete brain regions 
(Matsuzaki et al., 1989). In summary, central CRF signaling is specifically 
involved in increases in both the physiological and the behavioral manifestation 
of a state of stress.  
CRF-induced stress-related behavior includes increased locomotion 
(Sutton et al., 1982, Veldhuis and De Wied, 1984, Eaves et al., 1985, Sherman 
and Kalin, 1986, Ehlers and Chaplin, 1987, Sherman and Kalin, 1987), 
hypophagia (Britton et al., 1982, Gosnell et al., 1983, Britton et al., 1986a, 
Ruckebusch and Malbert, 1986), and anxiogenic behavior (Britton et al., 1982). 
Anxiogenic behavior consists of decreased rearing, food pellet approaches, and 
exploratory behavior (Berridge and Dunn, 1986, 1987) along with increased 
grooming and freezing behavior (Britton et al., 1982, Berridge and Dunn, 1986, 
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1987). Ventricular CRF administration also augments the acoustic startle reflex, 
(Swerdlow et al., 1989) and diminishes social interaction (Dunn and File, 1987).  
In addition to producing pro-stress effects by itself, CRF can also 
exacerbate behavior in the presence of stress. In support, ventricular CRF 
administration augments freezing (Sherman and Kalin, 1988) and fighting (Tazi 
et al., 1987) behavior induced by inescapable footshock. On the other hand, 
ventricular administration CRF receptor antagonists block these effects of stress 
(Heinrichs et al., 1994, Menzaghi et al., 1994, Spina et al., 2000). In summary, 
global CRF administration to the brain of rodents mimics the behavioral response 
during stress (Dunn and Berridge, 1990) while global antagonism of CRF 
receptor signaling blocks stress-related behavioral responses (Heinrichs et al., 
1994, Menzaghi et al., 1994, Spina et al., 2000).   
UROCORTINS 
 Importantly CRF is not the only stress-related neuropeptide in the brain. 
Additional members of the CRF peptide family have been identified, including 
urocortins1-3 (Figure 6), which differ in their tissue distribution and receptor 
pharmacology (Vaughan et al., 1995, Hsu and Hsueh, 2001, Lewis et al., 2001, 
Reyes et al., 2001). The identification of CRF receptor agonists found in fish 
(urotensin), frog skin (sauvagine), and additional non-mammalian members 
(teleosts and amphibians) led to the discovery of additional mammalian CRF-
related peptides (Beyermann, 1997). The first stress related neuropeptide other 
than CRF to be discovered was a novel 40-amino acid peptide termed urocortin 
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one (Ucn1) (Beyermann, 1997). Ucn1 was named after its sequence similarity to 
both carp urotensin (63%, “uro”) and mammalian CRF (45% “cort”) (Koob, 2010). 
Ucn1 projection distribution both overlaps and has differential distribution with 
CRF throughout the brain (Zorrilla, 2005).  
Ucn1 is most heavily expressed in the edinger westphal nucleus (Vaughan 
et al., 1995). Two additional urocortin cloned ligand family members were 
discovered, termed Urocortin two (Ucn2) and Urocortin three (Ucn3). Ucn2, also 
called stresscopin-related peptide, is expressed in the hypothalamus, brain stem, 
and spinal cord (Hsu and Hsueh, 2001, Reyes et al., 2001, Yamauchi et al., 
2005, Fekete and Zorrilla, 2007). Ucn3, also called stresscopin, is expressed in 
the hypothalamus and amygdala (Hsu and Hsueh, 2001, Lewis et al., 2001, Li et 
al., 2002, Fekete and Zorrilla, 2007).  
Although, urocortins (1-3) share 20-45% sequence homology with CRF 
(Vaughan et al., 1995), the physiological functions of these stress related 
neuropeptides vary significantly. In contrast to CRF, urocortins do not regulate 
activation of the HPA-axis (Kageyama et al., 2003, Nemoto et al., 2009). 
Moreover, urocortin signaling has been shown to produce both a reduction in 
anxiety-related behavior and recovery from the effects of stress (Coste et al., 
2000, Valdez et al., 2003, Todorovic et al., 2007, Tanaka and Telegdy, 2008). 
These effects have been compared and found to be the exact opposite to those 
of CRF signaling (Schank et al., 2012). Paradoxically, urocortin signaling has 
additionally been reported to also produce pro-stress-like effects (Henry et al., 
2006, Land et al., 2008, Fekete et al., 2009, Pastor et al., 2011). With this in 
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mind, it is important to note that the most consistent finding when comparing 
CRF function to urocortin function is that CRF appears to regulate the initial 
reactions to stress while urocortin appears to regulate later stress adaptation 
(Weninger et al., 2000, Kozicz et al., 2001, Gaszner et al., 2004, Kozicz, 2007, 
2009, Neufeld-Cohen et al., 2010a, Neufeld-Cohen et al., 2010b, Kozicz et al., 
2011). 
 
Figure 6: Corticotropin releasing factor peptide family ligand amino acid 
sequences. CRF-R1 binds CRF and Ucn1 but not Ucn2 and Ucn3. CRF-R2 
binds all urocortins with higher affinity that CRF. Red are proline residues at 
position 11 and alanine residues at position 35 and 39 that are specific to CRF-
R2 specific ligands Ucn2 and Ucn3.  Blue are nonspecific CRF receptor invariant 
arginine at position 35 and 39 (Grammatopoulos, 2012).  
 
 
 
NEUROPEPTIDES ARE NEUROMODULATORS 
 Neuropeptides, such as CRF and Urocortins, are characterized by volume 
neurotransmission. Volume neurotransmission is distinct from other forms of 
neurotransmission because the transmitter can diffuse outside of the synaptic 
cleft at biologically relevant concentrations (Garris et al., 1994, Zoli and Agnati, 
1996, Barbour and Hausser, 1997, Gonon, 1997) a mode of signaling referred to 
as an ‘open’ synapse (Fuxe, 1991, Agnati et al., 1995, Zoli and Agnati, 1996).  
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Neuropeptides can act at longer distances from their release sites than classical 
neurotransmitters. The large dense core peptide-containing vesicles can be close 
to the neuropeptide receptors (Herkenham, 1987, Nusbaum, 2002) but most of 
these receptors are extrasynaptic (Zoli et al., 1999).  Peptide release occurs in 
the general vicinity of axon terminals (Lysakowski et al., 1999, Karhunen et al., 
2001, Nusbaum, 2002, Salio et al., 2006). Neuropeptides lack reuptake 
mechanisms (Zoli and Agnati, 1996) and the regulators of extracellular 
neuropeptide concentrations are enzymes which either degrade or convert the 
neuropeptide. These enzymes are located in the extracellular space or on 
nonsynaptic cell membranes (Burbach, 1993, Davis and Konings, 1993, Konkoy 
and Davis, 1996). Therefore the distance of neuropeptide action in the brain is 
determined by membrane bound peptidases (Nassel, 2009). 
Neuropeptides and classical neurotransmitters are often produced by the 
same neurons (Jan and Jan, 1983, Chan-Palay, 1984, Hokfelt et al., 1987, 
Zupanc, 1996, Merighi, 2002, Salio et al., 2006). Neuropeptides such as CRF 
can also be co-packaged and co-released with classical neurotransmitters 
(Waselus and Van Bockstaele, 2007, Reyes et al., 2011). However, 
neuropeptides are often released only at higher stimulus frequencies than 
classical neurotransmitters (Nassel, 2009). Therefore, neuropeptides such as 
CRF and Ucns are released in a less precise manner than their co-released 
classical neurotransmitter counterpart (Nusbaum, 2002). 
Peptidergic receptors, usually G-protein-coupled receptors (GPCRs), are 
commonly located perisynaptically on post- and pre-synaptic neurons. 
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Neuropeptides can activate their GPCR receptor presynaptically resulting in 
autoregulation, postsynaptically on the same target neuron, or even different 
target neurons than their co-packaged, co-released classical neurotransmitter 
partners (Nassel, 2009). In this way, the GPCR signaling cascades of 
neuropeptide receptor activation modulate the response to classical 
neurotransmitters (Nassel, 2009). For these reasons neuropeptides, such as 
CRF and Ucns, are considered neuromodulators of classical neurotransmitters. 
CORTICOTROPIN RELEASING FACTOR RECEPTORS 
 CRF and Ucns produce their effect through the coordinated action of two 
CRF receptor subtypes (Dautzenberg and Hauger, 2002). CRF receptors belong 
to the class B subtype of G protein-coupled receptors (GPCR) (Kehne and De 
Lombaert, 2002, Hartz et al., 2004). Class B receptors bind moderate-sized 
peptides involved in both endocrine and neuroendocrine functions (Ulrich et al., 
1998, Harmar, 2001). The extracellular domain of CRF receptors primarily 
interacts with C-terminal residues of CRF (Rijkers et al., 2004, Yamada et al., 
2004, Grace et al., 2007b). The N-terminal residues of CRF are required for both 
activation and the conformational changes of the receptors enabling their 
activation (Grace et al., 2004). Binding of a CRF receptor ligand agonist induces 
a conformational change and receptor activation where the G-protein (Gα-
subunit) undergoes an exchange of GDP (inactive state) for GTP (active state) 
(Hamm and Gilchrist, 1996, Bohm et al., 1997). Once GTP is bound to the Gα-
subunit, it dissociates from the Gβγ dimer, allowing for a variety of downstream 
signaling (Hillhouse and Grammatopoulos, 2006).  
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CRF receptors are seven transmembrane, G protein-coupled, and 
predominantly link to adenylate cyclase activation through Gαs. However, CRF 
receptors are highly promiscuous, having the ability to activate multiple Gα 
subunits, including Gαs, Gαo, Gαq/11, Gαi1/2, and Gαz (Grammatopoulos et al., 
1999, Grammatopoulos et al., 2001, Blank et al., 2003). The ability of GPCRs, 
such as CRF receptors, to couple to multiple G protein heterotrimers with 
different Gα-subunits results in diverse downstream signaling cascades and 
cellular responses (Hillhouse and Grammatopoulos, 2006). However, most 
physiological functions of CRF in the CNS involve the coupling of CRF to Gαs-
proteins (Grammatopoulos, 2012).  
Figure 7: Anatomical expression of CRF-R1, CRF-R2, CRF binding protein, and 
CRF throughout the rat brain (Behan et al., 1996a). 
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The Gαs pathway initiates intracellular events both in the cytoplasm, 
resulting in acute post-translational modification of target proteins by protein 
kinase A (PKA), and in the nucleus at the level of gene transcription regulation by 
cyclic adenosine monophosphate (cAMP) response element-binding proteins 
(Shaywitz and Greenberg, 1999, Tasken and Aandahl, 2004). CRF-induced 
phosphorylation/activation of CREB leads to downstream regulation of genes 
containing the Ca2+/cAMP response element (Rossant et al., 1999) such as c-fos 
(Boutillier et al., 1991).  Interestingly, which Gα subunit is activated also depends 
on the ligand that is binding to that receptor (CRF vs. Ucns) (Grammatopoulos et 
al., 2000).  
CORTICOTROPIN RELEASING FACTOR RECEPTOR 1 
 The first CRF receptor identified encoded a 415-amino acid comprised of 
seven putative membrane-spanning domains characteristic of Gs-coupled 
receptors, and was designated CRF receptor 1 (CRF-R1) (Chen et al., 1993). 
Species homologs for CRF-R1 have been isolated from the brains of both rat 
(Chang et al., 1993, Perrin et al., 1993) and mouse (Vita et al., 1993) which are 
98% identical over their full length of 415 amino acids (De Souza, 1997). CRF-R1 
shows reversible, saturable, high-affinity binding to CRF (KD ~ 150 pM) (De 
Souza, 1997). CRF-R1 is coupled to a G-protein and when incubated in the 
presence of CRF, stimulates the production of cAMP with an EC50 of ~ 1 nM (De 
Souza, 1997). The CRF-R1 driven cAMP/PKA pathway can diverge and activate 
multiple downstream signaling molecules (Grammatopoulos, 2012).  
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Desensitization occurs through Gαs/PKA induced phosphorylation of the 
CRF-R1 receptor, selectively impairing CRF-R1/Gαq coupling (Papadopoulou et 
al., 2004) and, indicative of yet even another level of complexity to CRF-R1 
signaling. CRF-R1 has α and β isoforms in addition to subtypes designated c-h, 
which have been detected in both human and rodent tissue (Bale and Vale, 
2004). However, many of these isoforms have been found to be nonfunctional 
(Chen et al., 1993, Ross et al., 1994, Grammatopoulos et al., 1999, Pisarchik 
and Slominski, 2001). cAMP produced by CRF activation of CRF-R1 receptor is 
competitively inhibited by CRF-R1 antagonists antalarmin and CP-376395 
(Webster et al., 1996, De Souza, 1997, Chen et al., 2004, Guo et al., 2005, Di 
Fabio et al., 2008). 
CRF-R1 is widely expressed throughout the brain with very high 
expression in the neocortex, cerebellum, and sensory relay structures (Figure 7) 
(Chalmers et al., 1995, Primus et al., 1997, Van Pett et al., 2000) such as the 
cortex, cerebellum, hippocampus, amygdala, olfactory bulb, lateral septum, 
thalamus, basal ganglia, the raphe nuclei, pituitary, brain stem, and spinal cord 
(De Souza, 1997, Van Pett et al., 2000, Korosi et al., 2006, Korosi et al., 2007, 
Justice et al., 2008). Expression of the CRF-R1 overlaps with the distribution of 
CRF and Ucn 1 (Behan et al., 1996a, Skelton et al., 2000, Koob, 2010).  
CRF and urocortin release can also regulate CRF-R1 gene expression 
through changes in transcription activity (Luo et al., 1995, Mansi et al., 1996, 
Brunson et al., 2002, Kasagi et al., 2002, Parham et al., 2004, Herringa et al., 
2006). CRF-R1 mRNA expression has been well characterized in the rodent 
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brain (Van Pett et al., 2000), however, due to insufficient commercially available 
CRF receptor antibodies (Refojo et al., 2011) CRF-R1 protein expression in 
specific brain regions have not been accurately assessed. This is also true for 
the CRF-R2 receptor. 
CORTICOTROPIN RELEASING FACTOR RECEPTOR 2 
 A second CRF receptor exists and is referred to as CRF-R2 (Lovenberg et 
al., 1995b). CRF-R2 is a 397-437 amino acid protein also expressed in the brain 
(Kishimoto et al., 1995, Lovenberg et al., 1995b, Kostich et al., 1998, 
Palchaudhuri et al., 1999, Van Pett et al., 2000, Korosi et al., 2007). CRF-R2 
activation in the presence of CRF stimulates the production of cAMP with an 
EC50 of 20 nM (Liaw et al., 1996). cAMP produced by CRF activation of CRF-R2 
receptors is competitively inhibited by CRF-R2 antagonists (Ruhmann et al., 
2002). However, CRF-R2 abundance is not as dense as that of CRF-R1 (Figure 
7) (Van Pett et al., 2000). CRF-R2 is confined to subcortical structures, showing 
relative high expression levels in the pituitary, lateral septum, hypothalamus, 
dorsal and median raphe, extended amygdala, and spinal cord (Chalmers et al., 
1995, Primus et al., 1997, Palchaudhuri et al., 1999, Bittencourt and Sawchenko, 
2000, Van Pett et al., 2000, Korosi et al., 2006, Korosi et al., 2007, Lukkes et al., 
2011). CRF-R2 has three functional isoforms α, β, and γ (Dautzenberg and 
Hauger, 2002) produced through alternative splicing of a single gene, resulting in 
different N-terminal domains (De Souza, 1997). 
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CRF-R2 isoforms differ in their N-terminal sequence and their distribution in 
different tissues and species. CRF-R2α and CRF-R2β are present in humans 
and rodents (Lovenberg et al., 1995a, Liaw et al., 1996). In contrast, CRF-R2γ 
has only been reported in humans (Kostich et al., 1998) and is predominantly 
expressed in the brain (Kostich et al., 1998). CRF-2α and CRF-2β are both 
expressed in the rodent brain (Lovenberg et al., 1995a, Kostich et al., 1998). 
However, CRF-2α is the predominant isoform in the brain (Kostich et al., 1998) 
and is potently and selectively antagonized by astressin-2B and antisauvagine-
30 (Ruhmann et al., 1998, Rivier et al., 2002).  
DIFFERENCES BETWEEN CRF-R1 AND CRF-R2 
 The different CRF receptors are produced from distinct genes with several 
splice variants (Bale and Vale, 2004). Different CRF receptor subtypes exhibit 
varying degrees of ligand affinities and sensitivity to G-protein coupling. There is 
70% sequence homology between CRF-R1 and CRF-R2 at the amino acid level 
(Lovenberg et al., 1995b) with greater than 80% homology at the transmembrane 
and intracellular domains (Lovenberg et al., 1995b). The third intracellular loop is 
the receptor region that interacts with G proteins and is identical between both 
CRF receptors (Perrin and Vale, 1999, Arai et al., 2001). However, these 
receptors exhibit considerable differences at the N-terminal extracellular domain 
(~ 47%) (Dautzenberg and Hauger, 2002, Grammatopoulos, 2012). The 
juxtamembrane region of the N-terminus and the second and third extracellular 
domains are important ligand action sites that determine ligand binding and 
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receptor specificity (Assil et al., 2001, Hofmann et al., 2001, Perrin et al., 2001, 
Dautzenberg et al., 2002, Perrin et al., 2003). 
CRF has at least tenfold higher affinity for CRF-R1 over CRF-R2 (cAMP EC50 
= 3 nM over 20 nM; Ki = 2 nM over 30 nM) (Chen et al., 1993, Lovenberg et al., 
1995b, Behan et al., 1996a), while Ucn1 has equal affinities for both receptors 
(cAMP EC50 = 0.3 nM-R1 and .2 nM-R2; Ki = 0.3 nM-R1 and 0.6 nM-R2) (Perrin 
et al., 1995, Reyes et al., 2001). Ucn 2 and 3 bind and activate CRF-R1 and 
CRF-R2 receptors with varying affinities (Bale and Vale, 2004, Boorse et al., 
2005, Fekete and Zorrilla, 2007). Although, Ucn1 binds to both CRF receptors 
with equal affinities (Reyes et al., 2001) Ucn2 and Ucn3 bind only to the CRF-R2 
receptor at physiological levels (cAMP EC50 = 0.1 nM-Ucn2 and 0.07 nM-Ucn3; 
Ki = 2 nM-Ucn2 and 5 nM-Ucn3) (Lewis et al., 2001, Zorrilla et al., 2003).  
In summary, CRF-R1 binds CRF as well as urocortin 1 with high affinity, but 
binds Ucn2 and Ucn3 with significantly lower affinity (Reyes et al., 2001). CRF-
R2 binds all urocortins with significantly higher affinity that CRF (Chen et al., 
1993, Lovenberg et al., 1995b, Vaughan et al., 1995, Hsu and Hsueh, 2001, 
Lewis et al., 2001, Reyes et al., 2001). In contrast to CRF-R1, CRF-R2 has 
higher affinity for urocortins 2 and 3 than for CRF suggesting that these 
urocortins and not CRF may be the endogenous ligand for the CRF-R2 receptor 
(De Souza, 1997).  
Ucn2 and Ucn3 are endogenous CRF-R2 specific agonists while both 
CRF and Ucn1 are nonspecific agonists (Figure 8). Recently, cortagine, a CRF-
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R1 agonist, was generated by the synthesis of chimeric peptides derived from 
human/rat CRF, ovine CRF, and sauvagine (Tezval et al., 2004). This chimeric 
peptide allows for further pharmacological characterization of CRF-R1 versus 
CRF-R2 function.  
 
Figure 8: CRF ligand and receptor specificity with their physiological and 
behavioral affects. CRF increases stress responsiveness through activation of 
CRF-R1, while activation of CRF-R2 has been hypothesized to be involved in 
coping with stress. (Bale and Vale, 2004).  
 
CORTICOTROPIN RELEASING FACTOR BINDING PROTEIN 
 CRF not only has high affinity for the CRF-R1 receptor but also for the 
corticotropin releasing factor-binding protein (CRF-BP). CRF-BP is a 37 kDa N-
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linked secreted glycoprotein that binds extracellular CRF. CRF-BP prevents CRF 
from activating its receptors (Suda et al., 1988, Woods et al., 1994, Herringa et 
al., 2004) while also promoting CRF clearance and degradation (Burrows et al., 
1998, Karolyi et al., 1999). CRF-BP is found throughout the rodent and primate 
brain, including in the hypothalamus, cortical regions, amygdala, bed nucleus of 
the stria terminalis (BNST), and raphe nuclei (Potter et al., 1991, Potter et al., 
1992, Chen et al., 1993, Potter et al., 1994, Behan et al., 1995, Cortright et al., 
1995). CRF-BP binds both CRF and urocortin 1 (Potter et al., 1991, Behan et al., 
1996b) and is highly conserved between humans and rats (Denver, 2009).  
CRF-BP binds both CRF and Ucn1 with high affinity (Ki = 0.2 nM-CRF and 
0.9 nM-Ucn1) (Orth and Mount, 1987, Boorse et al., 2005), and Ucn2 with lower 
affinity (Ki = 12 nM-Ucn2), but does not bind Ucn3 (Huising et al., 2008). CRF-BP 
affinity for both CRF and Ucn1 is several-fold higher than that of either CRF 
receptor (Huising et al., 2008). When CRF-BP binds CRF or Ucn1, a functional 
dimer complex is formed which is hypothesized to have multiple functions 
including uptake and degradation of the CRF-BP/CRF complex (Potter et al., 
1991, Behan et al., 1996b, Kemp et al., 1998, Sajdyk et al., 1999, Chan et al., 
2000, Roseboom et al., 2007). CRF-BP is often considered a functional CRF 
receptor antagonist due to its ability to sequester ligands and prevent CRF 
receptors from becoming activated (Huising et al., 2008).  
CRF-BP levels are ~ 10-fold higher than CRF levels in most brain regions and 
CRF-BP binds between 40-90% of endogenous CRF (Suda et al., 1988, Behan 
et al., 1996a). In this way, CRF-BP limits the concentrations of CRF and Ucn1 
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available to activate receptors by acting as a buffer for CRF system signaling 
(Behan et al., 1996b, Chan et al., 2000). Stress-induced CRF release can 
increase CRF-BP mRNA levels independently of corticosterone or CRF receptor 
function (Herringa et al., 2004, Herringa et al., 2006). Acute stress and ICV CRF 
administration both increase CRF-BP mRNA levels (Herringa et al., 2004, 
Herringa et al., 2006). This increased CRF-BP mRNA expression is not blocked 
by CRF receptor antagonists nor mimicked by administration of corticosterone 
(Herringa et al., 2006). These findings support the notion that when CRF is 
bound by CRF-BP there is an increase in CRF-BP transcription (Lombardo et al., 
2001, Roseboom et al., 2007). This increased CRF-BP transcription likely 
represents an acute compensatory homeostatic mechanism in response to 
increased CRF levels. 
In summary, CRF was originally discovered to have a central role in initiating 
the hypothalamic-pituitary-adrenal (HPA) axis response to stress, yet its role 
throughout the rest of the brain is very complex involving: CRF, Ucn1, Ucn2, 
Ucn3, CRF-BP, CRF-R1 and CRF-R2 (Vale et al., 1981, Behan et al., 1995, 
Steckler and Holsboer, 1999, Ryabinin et al., 2002, Fekete and Zorrilla, 2007). 
CORTICOTROPIN RELEASING FACTOR RECEPTOR FUNCTION 
 CRF receptors participate in the regulation and maintenance of 
homeostasis in response to stress (Preil et al., 2001, Bale et al., 2002, Bale and 
Vale, 2004, Janssen and Kozicz, 2013). Ventricular administration of CRF-R1 
antagonists inhibit stress-induced behaviors and decrease both basal and stress-
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induced HPA axis activation (Swerdlow et al., 1989, Heinrichs et al., 1992, Kalin, 
1998, Habib et al., 2000). Generally administration of CRF-R1 antagonists 
produces anxiolytic effects (Schulz et al., 1996, Deak et al., 1999, Okuyama et 
al., 1999, Risbrough et al., 2004). In contrast, CRF-R2 activation has been 
associated with an increase and a decrease in both stress responsiveness and 
stress-related behavior (Radulovic et al., 1999, Bale et al., 2000, Kishimoto et al., 
2000, Pelleymounter et al., 2000, Cullen et al., 2001, Takahashi et al., 2001, 
Bakshi et al., 2002, Valdez et al., 2002, Risbrough et al., 2004, Kehne and Cain, 
2010, Neufeld-Cohen et al., 2012).  
A coordinated functional dualism, where each receptor regulates different 
aspects of the stress response has been proposed. Specifically, it has been 
suggested that CRF-R1 activation results in the initiation of a physiological stress 
response, while activation of the CRF-R2 receptor facilitates recovery from stress 
(Janssen and Kozicz, 2013). However, this simple dualism of CRF receptor 
subtype function is likely too simplistic (Janssen and Kozicz, 2013). The 
coordinated action of these receptors along with their differential anatomical 
distribution (Chalmers et al., 1995, Van Pett et al., 2000) suggests more 
complexity than a simple functional dualism.  
Although there is conflicting evidence as to the role for CRF-R2 activation 
in the physiological and behavioral response to stress, there remains little 
question as to the function of the CRF-R1 receptor. CRF-R1 activation produces 
effects that cause and resemble the stress response (Koob and Thatcher-Britton, 
1985, Britton et al., 1986b, Rassnick et al., 1993, Menzaghi et al., 1994, 
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Rodriguez de Fonseca et al., 1996, Koob and Heinrichs, 1999, Cullen et al., 
2001, Spina et al., 2002).  
CRF AND COCAINE-SEEKING BEHAVIOR 
 The effects of CRF system signaling has been implicated in cocaine-
seeking behavior. Cocaine-intake dependent increases in CRF signaling have 
been reported in the extended amygdala (Sarnyai et al., 1995, Zhou et al., 1996, 
Gardi et al., 1997). The extended amygdala consists of basal forebrain regions 
that share cytoarchitecture and circuitry involved in feeding, reproduction, 
learning, cognition, punishment, and reward (Alheid, 2003).  The extended 
amygdala is made up of the central nucleus of the amygdala (CeA), bed nucleus 
of the stria terminalis (BNST), and the shell of the nucleus accumbens (Heimer 
and Alheid, 1991). These areas that make up the extended amygdala share 
similarities in immunohistochemistry, morphology, and connectivity (Alheid and 
Heimer, 1988). The extended amygdala plays a pivotal role in the behavioral, 
emotional, and physiological response of an organism to fear and anxiety 
(Duvarci et al., 2009, Regev et al., 2011, Park et al., 2012). 
Following drug exposure the extended amygdala regulates dysphoria during 
both withdrawal and protracted abstinence (Koob, 1999a). This dysphoria is 
regulated by norepinephrine and CRF signaling throughout the extended 
amygdala and can be exacerbated with exposure to acute stress (Rassnick et al., 
1993, Koob, 1994, Heinrichs et al., 1995, Rodriguez de Fonseca et al., 1997, 
Shaham et al., 1997, Erb et al., 1998, Shaham et al., 1998, Erb and Stewart, 
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1999, Richter and Weiss, 1999, Sinha et al., 1999, Erb et al., 2000, Stine et al., 
2002, Sinha et al., 2003, McFarland et al., 2004, Feltenstein and See, 2006, 
Smith and Aston-Jones, 2008, Brown et al., 2009, Mantsch et al., 2010, Brown et 
al., 2011, Graf et al., 2011, Jobes et al., 2011, Vranjkovic et al., 2012). 
LgA self-administration appears to recruit the CRF system. CRF 
immunoreactivity is increased in the extended amygdala following daily long-
access to cocaine for self-administration (Zorrilla et al., 2012). Moreover, 
ventricular administration of a CRF-R1 antagonist only attenuates cocaine self-
administration in rats tested under LgA conditions (Specio et al., 2008). This 
suggests that loss of control over drug intake is at least partly regulated by CRF 
signaling at the time of drug self-administration (Ahmed and Koob, 1998). In 
addition, withdrawal from cocaine produces increased CRF signaling and 
anxiogenic behavior which can be blocked by inhibiting CRF system signaling 
(Sarnyai et al., 1995). These findings suggest that recruitment of the CRF system 
plays an integral part in both escalating patterns of self-administration and 
withdrawal induced dysphoria. 
Increases in CRF function induced by high intake cocaine self-administration 
are not transient but persist throughout protracted abstinence (Koob and Le 
Moal, 2001). This may contribute to the augmented ability of footshock stress to 
induce reinstatement of extinguished cocaine seeking following LgA self-
administration (Mantsch et al., 2004, Blacktop et al., 2011, Graf et al., 2011). 
Thus, repeated cocaine self-administration changes CRF reactivity in the brain in 
a way that promotes later stress-induced reinstatement of extinguished cocaine 
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seeking (Erb et al., 1998, Shaham et al., 1998, Mantsch et al., 2008a, Blacktop et 
al., 2011, Graf et al., 2011). 
 Ventricular CRF administration is sufficient to reinstate extinguished cocaine 
seeking; an effect blocked by systemic CRF-R1 specific antagonists or central 
ICV CRF-R1/R2 nonspecific antagonists (Erb et al., 1998, Shaham et al., 1998, 
Erb et al., 2006b, Mantsch et al., 2008a, Graf et al., 2011, Buffalari et al., 2012). 
Notably, CRF-R1 antagonists attenuate footshock-induced reinstatement of not 
only cocaine- but also heroin-, alcohol, and nicotine-seeking (Erb et al., 1998, 
Shaham et al., 1998, Le et al., 2000, Bruijnzeel et al., 2009). Thus, the CRF 
system represents a common mechanism for stress-induced relapse to multiple 
common drugs of abuse. For these reasons, the CRF system has been 
hypothesized to represent a promising target for the development of medications 
that prevent stress from facilitating relapse in abstinent human drug addicts 
(Webster et al., 1996, Deak et al., 1999, Koob and Zorrilla, 2010). 
Stress-induced reinstatement of drug seeking can occur independently of 
acute stress-induced activation of the HPA axis at the time of reinstatement 
(Shaham et al., 1997, Erb et al., 1998, Le et al., 2000, Graf et al., 2011). 
Ventricular CRF administration is sufficient for reinstatement, while ICV delivery 
of a nonspecific CRF receptor antagonist blocks footshock-induced reinstatement 
of cocaine seeking. CRF- and stress-induced reinstatement is observed both in 
animals that have functioning or nonfunctioning corticosterone signaling (Erb et 
al., 1998, Lu et al., 2003b, Mantsch et al., 2008b, Graf et al., 2011). However, 
although glucocorticoids do not appear to be required for acute stress-induced 
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reinstatement, they are necessary for the neuroplastic changes to occur at the 
time of drug use (Mantsch et al., 2008b) hypothesized to gate the ability of later 
footshock stress to cause reinstatement (Graf et al., 2011). Corticosterone levels 
are increased as a result of cocaine self-administration (Goeders and Guerin, 
1996b, Deroche et al., 1997, Mantsch et al., 2000, Mantsch et al., 2003). This 
increase in corticosterone is hypothesized to induce neuroplastic changes in 
areas of convergence between stress and motivational neurocircuitry. This 
neuroplasticity may change brain function to where the circuitry of motivated 
behavior is more responsive to acute stress-induced CRF release. In summary, 
stress-induced reinstatement of extinguished cocaine seeking following LgA self-
administration is dependent on glucocorticoid secretion at the time of drug self-
administration, and CRF signaling by an acute stressor (footshock) at the time of 
reinstatement.  
CRF actions in both the central nucleus of the amygdala (CeA) and bed 
nucleus of the stria terminalis (BNST) are critical for footshock-induced 
reinstatement of extinguished cocaine seeking (Erb et al., 1996, Erb and Stewart, 
1999, Erb et al., 2001). As mentioned previously, the two brain regions outside of 
the paraventricular nucleus of the hypothalamus (PVN) that have the highest 
concentrations of CRF-containing cell bodies are the BNST and the CeA 
(Merchenthaler et al., 1982, Olschowka et al., 1982, Swanson et al., 1983, 
Petrusz, 1992). The BNST and CeA both send CRF-containing projections to the 
ventral tegmental area (VTA) (Beckstead et al., 1979, Phillipson, 1979a, Wallace 
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et al., 1989, Rodaros et al., 2007). We hypothesize that this circuitry enables 
CRF to regulate the effects of stress on the dopamine system. 
The VTA is the origin of midbrain dopamine neurons that make up the 
circuitry of motivated behavior.  In addition to CRF inputs, CRF-R1 and CRF-R2 
are also found in the VTA (De Souza, 1987, Perrin et al., 1993, Behan et al., 
1996a, Van Pett et al., 2000, Ungless et al., 2003, Korotkova et al., 2006, Wang 
et al., 2007, Wanat et al., 2008, Beckstead et al., 2009, Blacktop et al., 2011, 
Wanat et al., 2013). This positions the ventral tegmental area as a potential key 
neuroanatomical region involved in the complex integration of stress and reward 
related signaling.  
REINSTATEMENT NEUROCIRCUITRY 
 The mesocorticolimbic dopamine system consists of midbrain dopamine 
neurons in the ventral tegmental area (VTA; meso) and their terminal fields in the 
medial prefrontal cortex (mPFC; cortico), and nucleus accumbens (NA; limbic) 
(Figure 9) (Fields et al., 2007). The NA is involved in responding to rewarding 
and salient stimuli, while the PFC is involved in emotion, cognition, executive 
function, and inhibitory control processes (Everitt and Robbins, 2005). It is well 
established that central to addiction is neurotransmission within the 
mesocorticolimbic system (Di Chiara and Imperato, 1988, Wise and Rompre, 
1989). This includes the motivation processes that underlie the reinstatement of 
drug seeking.  
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 The upstream mechanisms of cocaine-, cue-, and stress-induced cocaine 
seeking can differ. For example, stress-induced reinstatement but not cocaine-
induced reinstatement is blocked by CRF receptor antagonists (Graf et al., 2011) 
suggesting distinct neuromechanisms (Capriles et al., 2003). In contrast, cue-
induced and stress-induced reinstatement are less easily differentiated because 
footshock stress-induced reinstatement only occurs when given in the drug-
taking context (Shalev et al., 2000). This is indicative that drug-related cues may 
be critically involved in CRF-dependent stress-induced relapse. However, 
cocaine-, cue-, and stress-induced reinstatement of cocaine seeking all have 
been suggested to share a common downstream neurocircuit (Figure 10). This 
putative circuit involves dopaminergic input from the VTA to the medial prefrontal 
cortex which in turn provides glutamate input to the nucleus accumbens core 
(McFarland and Kalivas, 2001, McFarland et al., 2004). 
 
Figure 9: Schematic illustrating simplified version of dopamine (blue), glutamate 
(red), and GABA (green) signaling in the mesocorticolimbic system. 
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Figure 10: Schematic illustrating that the PFC functions as a final relay station in 
the reinstatement of drug seeking (Kalivas and Volkow, 2005). The blue is 
illustrating the upstream extended amygdala component of stress-induced 
reinstatement (blue), the conversion of both cue (yellow) and stress triggers 
upon the VTA, and the final common pathway for all three stimuli (red) (drug, 
cue, and stress) in reinstatement. 
 
 
 
 
 
 
 
 
 
 
 
The medial prefrontal cortex (mPFC) functions as a main terminal field of the 
VTA as well as a final relay station in relapse evoked by drugs, cues, and stress 
(Kalivas et al., 2005, Kalivas and Volkow, 2005). In support, inactivation of this 
region blocks reinstatement of cocaine seeking by all three modalities 
(McFarland and Kalivas, 2001, McLaughlin and See, 2003, Fuchs et al., 2005). 
Drug seeking depends on activation (Ciccocioppo et al., 2001, Zavala et al., 
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2008) of a glutamate projection from the PFC to the nucleus accumbens core 
(Kalivas et al., 2005). This regulates the NA core output to the ventral pallidum 
which completes the pallido-thalamo-cortical circuit involved in motivated 
behavior (Kalivas et al., 1999). 
The nucleus accumbens (NA) is divided into two traditional subregions with 
differential functions. These regions are the nucleus accumbens (NA) core and 
the nucleus accumbens shell, which together form the ventral striatum. The NA 
core is often considered an extension of the dorsal striatum functioning in 
instrumental learning and cue-induced reinstatement (Ito et al., 2000, Cardinal 
and Everitt, 2004, Ito et al., 2004).The NA shell is characterized as a transitional 
zone between the striatum and the extended amygdala functioning in the 
reinforcing effects of drugs of abuse (Kalivas et al., 2005, Pierce and Kumaresan, 
2006). The NA core receives glutamate inputs from the dorsomedial prefrontal 
cortex (Gabbott et al., 2005, Reynolds and Zahm, 2005) while NA shell receives 
glutamate input from the ventromedial PFC (Gabbott et al., 2005, Reynolds and 
Zahm, 2005).  
The dmPFC is comprised of the anterior cingulate (AC) and dorsal prelimbic 
(dPL) cortices while the vmPFC is comprised of the ventral prelimbic (vPL) and 
infralimbic cortices (Van den Oever et al., 2010). In summary, the projections 
from mPFC to the NA are organized into a dorsal-ventral pattern, where the 
dorsal mPFC projects predominantly to the NA core while the vmPFC projects 
predominantly to the NA shell (Figure 11) (Heidbreder and Groenewegen, 2003, 
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Voorn et al., 2004). These two circuits have differential role in regulating drug-
seeking behavior. 
 
Figure 11: Schematic illustrating the mPFC subregions and their inputs to NA 
subregions producing the ‘Go, No Go’ circuit (Van den Oever et al.) involved in 
footshock-induced reinstatement (Capriles et al., 2003, Sanchez et al., 2003, 
McFarland et al., 2004). Glutamate inputs from the dorsal medial PFC (anterior 
cingulate [AC] + dorsal prelimbic cortex [PLd]; green) to the NA core is thought to 
be a final relay to induce drug seeking (McFarland et al., 2003). In contrast, 
glutamate projections from the ventral medial PFC (ventral prelimbic cortex [PLv], 
infralimbic cortex [IL]; red) to the NA shell are thought to suppress drug seeking 
(Peters et al., 2008). Together, these circuits make the “Go No Go” circuit 
involved in drug-seeking behavior (LaLumiere et al., 2012), both regulated 
through dopaminergic inputs from the VTA 
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The glutamate input from the dmPFC to the nucleus accumbens core has 
been proposed to be a final downstream circuit involved in the renewal of 
extinguished drug seeking induced by drugs, cues, and footshock stress (Cornish 
et al., 1999, Capriles et al., 2003, McFarland et al., 2003, McFarland et al., 2004, 
LaLumiere and Kalivas, 2008). A parallel circuit involves the glutamatergic input 
from the vmPFC to nucleus accumbens shell which suppresses drug seeking 
(LaLumiere et al., 2010, LaLumiere et al., 2012). This circuit appears to be 
involved in the extinction process. 
Extinction is a form of learning (Bouton, 2002). It has been proposed that the 
ventral medial prefrontal cortex and its glutamate input into the nucleus 
accumbens shell regulates suppression of drug seeking (Peters et al., 2008) 
through the formation of new extinction memories (LaLumiere et al., 2010). This 
is further supported by the findings that inactivation of either the infralimbic cortex 
or the nucleus accumbens shell reinstates drug seeking without drug, cue, or 
stress triggers (Peters et al., 2008).  
Following extinction of drug-seeking behavior, the glutamatergic neurons in 
the dorsal medial PFC that project to the NA core are highly responsive to 
reinstating stimuli (Van den Oever et al., 2010). This produces opposing 
regulation of drug seeking through two different circuits involving different 
subregions of the medial prefrontal cortex and nucleus accumbens (Cornish et 
al., 1999, McFarland and Kalivas, 2001, McFarland et al., 2003, McFarland et al., 
2004, Fuchs et al., 2008, Peters et al., 2008, Van den Oever et al., 2010, 
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LaLumiere et al., 2012). Notably, stress-induced reinstatement of cocaine 
seeking requires the activity of the ventral tegmental area, dorsal medial 
prefrontal cortex, and the nucleus accumbens core (Di Ciano and Everitt, 2001, 
McFarland and Kalivas, 2001, McLaughlin and See, 2003). Therefore, footshock 
stress-induced reinstatement of extinguished LgA cocaine seeking likely involves 
activation of the prelimbic nucleus accumbens core pathway, inhibition of the 
infralimbic nucleus accumbens shell pathway, or both. Since the VTA projects to 
both these circuits and receives CRF input from the extended amygdala, it is 
ideally positioned to regulate drug seeking in response to stress. 
 
THE VENTRAL TEGMENTAL AREA: CONVERGENCE OF STRESS AND 
MOTIVATIONAL NEUROCIRCUITRY 
 
 
 The VTA represents a convergence point where dopamine (Wise and 
Rompre, 1989, Kalivas, 1993, Wise et al., 1995), glutamate (Stuber et al., 2010, 
Tecuapetla et al., 2010), and GABA (Van Bockstaele and Pickel, 1995, Ikemoto 
et al., 1997a, Steffensen et al., 1998, Xi and Stein, 1998, Carr and Sesack, 
2000a, Doherty and Gratton, 2007) neurons interact to control motivated 
behavior. VTA dopamine, CRF, GABA, and glutamate neurotransmission have 
all been implicated in drug addiction and drug seeking (Brebner et al., 2002, 
Wang et al., 2005, Wang et al., 2007, Koob and Volkow, 2010). This implication 
includes stress-induced reinstatement of cocaine seeking. Points of convergence 
between reward- and stress-related circuitry, as seen in the VTA, provide 
potential neurobiological substrates for the therapeutic intervention in stress-
induced relapse.  
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VTA dopamine neurons have an integral role in reward- and 
motivationally-relevant behaviors (Wise and Rompre, 1989, Bjorklund and 
Dunnett, 2007, Schultz, 2007b, Matsumoto and Hikosaka, 2009b, Tsai et al., 
2009, Bromberg-Martin et al., 2010, Cohen et al., 2012, Kim et al., 2012). To this 
end, VTA dopamine neuron firing conveys rewarding and motivationally relevant 
information (White, 1996)- initiating, promoting, maintaining, and driving reward-
seeking behavior (Fields et al., 2007, Sun, 2011). In order to characterize the 
effects of intra-VTA drug-induced neuroplasticity on stress-induced relapse, it is 
important to first acknowledge the complexities of VTA neurocircuitry. 
The ventral tegmental area (VTA) is synonymous with area A10 of 
grouped dopamine neurons (Dahlstrom, 1964, Fallon and Moore, 1978, Moore 
and Bloom, 1979). The VTA/A10 region is comprised of three major nuclei: (1) 
the parabrachial pigmented (PBP), (2) parainterfascicular (PIF), and (3) 
paranigral (PN) nuclei (Figure 12) (Swanson, 1982). These nuclei are particularly 
rich in dopaminergic cell body concentrations (Dahlstrom, 1964, Fallon et al., 
1978, Moore and Bloom, 1978, Phillipson, 1979b, Halliday and Tork, 1986, 
Paxinos, 2007). The VTA is a midbrain structure that consists of approximately 
14,000 neurons comprised of a mixture of dopamine neurons (~65%) and GABA 
neurons (~35%) (Swanson, 1982, Oades and Halliday, 1987, Johnson and North, 
1992b). Subpopulations of these VTA dopamine and GABA neurons can 
subserve different functions (Guarraci and Kapp, 1999, Bjorklund and Dunnett, 
2007, Lammel et al., 2008, Margolis et al., 2008, Berridge et al., 2009, 
Matsumoto and Hikosaka, 2009b, Bromberg-Martin et al., 2010, Sesack and 
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Grace, 2010, Lammel et al., 2011, Cohen et al., 2012, Kim et al., 2012, Tan et 
al., 2012, van Zessen et al., 2012). 
VENTRAL TEGMENTAL AREA NEUROCIRCUITRY IS NOT HOMOGENOUS 
 The ventral tegmental area (VTA) should not be viewed as a homogenous 
structure in function, anatomy, or physiology. VTA dopamine neurons have 
unique subpopulations with different inputs, axonal projections, and unique 
neurochemical and electrophysiological properties (Bannon and Roth, 1983, 
White, 1996, Tzschentke, 2001, Margolis et al., 2006, Ikemoto, 2007, Lammel et 
al., 2008, Margolis et al., 2008, Lammel et al., 2011, Lammel et al., 2012). The 
heterogeneous nature of the VTA provides different neuronal populations that are 
essential for the expression of motivated behaviors and actions related to 
addiction (Wise, 2004, Fields et al., 2007, Ikemoto, 2007, Lammel et al., 2008, 
Lammel et al., 2011, Luscher and Malenka, 2011, Lammel et al., 2012). The 
functional heterogeneity of the VTA was first demonstrated along its rostral 
caudal axis in behavioral studies via local intracranial self-administration 
procedures (Carlezon et al., 2000, Rodd-Henricks et al., 2000, Ikemoto and 
Wise, 2002, Zangen et al., 2002, Bolanos et al., 2003, Olson et al., 2005, Rodd 
et al., 2005a, Rodd et al., 2005b, Ikemoto et al., 2006).  
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Figure 12: Schematic illustrating the area of interest for this dissertation, the 
posterior VTA. 12A & 12B are illustrating sagittal and coronal views of the VTA, 
respectively, with a close up illustrating PBP, PIF, and PN nuclei. 12C-E are 
illustrating high dopamine neuron expression in the area of interest using (12C) 
immunohistochemistry (IHC) for tyrosine hydroxylase (TH; marker for dopamine 
neurons in the VTA) in low mag (12D) high mag, and (12E) high mag using 
immunofluorescence for TH (Paxinos, 2004, Brischoux et al., 2009).  
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The VTA can be divided into rostral and caudal subregions constituting 
functionally distinct areas in their ability to regulate rewarding effects of drugs of 
abuse (Ikemoto et al., 1997a, Ikemoto et al., 1997b, 1998, Carlezon et al., 2000, 
Ikemoto and Wise, 2002, Zangen et al., 2002, Bolanos et al., 2003, Ikemoto et 
al., 2003, Olson et al., 2005, Rodd et al., 2005a). These distinct subregions are 
referred to as anterior, posterior, and tail regions of the VTA (Ikemoto et al., 
1998, Zangen et al., 2002, Olson et al., 2005, Perrotti et al., 2005, Ikemoto, 2007, 
Shabat-Simon et al., 2008, Kaufling et al., 2009). 
The anterior VTA (aVTA) is the region dorsal to the medial mamillary 
nucleus and medial to the substantia nigra pars compacta (SNC) (Zhao-Shea et 
al., 2011). The aVTA contains the ventral tegmental area rostral (VTAR) and the 
parabrachial pigmented area (PBP), but not midline nuclei (interfascicular 
nucleus [IF], rostral linear [RLi] nucleus) or the A10 dopamine neurons of 
supramamillary nucleus (Hokfelt et al., 1984a, Hokfelt et al., 1984b, Zhao-Shea 
et al., 2011). The posterior VTA (pVTA) is dorsal to the interpeduncular nucleus, 
medial to the SNC, and ventral to the red nucleus (Zhao-Shea et al., 2011). The 
pVTA is comprised of the parabrachial pigmented nucleus (PBP), 
parainterfascicular (PIF), and the paranigral nucleus (PN) (Fig. 12). The pVTA 
does not include the midline nuclei (IF, RLi), the caudal linear nucleus (CLi), or 
A10 dopamine neurons of the dorsal raphe nucleus (Hokfelt et al., 1984a, Hokfelt 
et al., 1984b, Zhao-Shea et al., 2011). The pVTA is the area of interest for this 
dissertation. The pVTA has a higher percentage of dopamine neurons than both 
the aVTA or tail of the VTA (tVTA) (Zhao-Shea et al., 2011). Moreover, the aVTA 
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and pVTA subregions respond differently to drugs of abuse (Boehm et al., 2002, 
Rodd et al., 2004, Rodd et al., 2005b, Ericson et al., 2008, Shabat-Simon et al., 
2008). Dopamine neurons of the pVTA are more responsive and critical for 
reinforcement as compared to the aVTA (Zhao-Shea et al., 2011). 
The tail of the VTA (tVTA), also called the rostromedial tegmental nucleus 
(RMTn), is the most caudal extent of the VTA limited to a subregion posterior to 
the paranigral nucleus and dorsolateral to the interpeduncular nucleus. The tVTA 
shifts dorsally and slightly laterally more caudally to become embedded within 
the superior cerebellar peduncle decussation (SCP) (Zhao-Shea et al., 2011). 
The tVTA has a low density of dopamine neurons, a high density of GABAergic 
neurons, and does not include the midline nuclei (Zhao-Shea et al., 2011). The 
tail of VTA has GABAergic output to the anterior and posterior VTA (Kaufling et 
al., 2010). This produces a microcircuit whereby GABAergic projections of the 
tVTA contact and inhibit a/pVTA dopamine neurons (Kaufling et al., 2010).  
VTA AFFERENTS 
 The VTA is a hub of converging inputs allowing for the integration of 
diverse stimuli. Strong inputs to the VTA come from the prefrontal cortex, lateral 
septum, medial septum diagonal-band complex, accumbens shell, ventral 
pallidum, medial and lateral preoptic areas, paraventricular nucleus of the 
hypothalamus, medial and lateral hypothalamus, lateral habenula, laterodorsal 
tegmentum, pedunculopontine tegmental nucleus, dorsal raphe, periaqueductal 
gray, and mesencephalic and pontine reticular formation (Geisler and Zahm, 
2005). With regard to stress and addiction, the confluence of the 
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mesocorticolimbic dopamine system and the extended amygdala have been best 
characterized. The VTA receives both excitatory and inhibitory input from 
numerous areas (Geisler et al., 2007, Bromberg-Martin et al., 2010, Sesack and 
Grace, 2010, Jennings et al., 2013). 
GLUTAMATERGIC VTA AFFERENTS 
 Glutamatergic inputs onto VTA dopaminergic neurons regulate their firing 
and the release of dopamine in VTA targets (Overton and Clark, 1997). The VTA 
receives excitatory glutamate inputs from numerous areas such as the 
ventromedial prefrontal cortex, ventral subiculum, subthalamic nucleus, 
parabrachial nucleus from the nucleus of the solitary tract (NTS), 
pedunculopontine tegmental nucleus, laterodorsal tegmental nucleus, and the 
bed nucleus of the stria terminalis (Kalivas, 1993, Georges and Aston-Jones, 
2001, 2002, Stuber et al., 2008). 
One of the main glutamatergic afferent projections to the VTA is the 
prefrontal cortex (Christie et al., 1985, Sesack et al., 1989, Hurley et al., 1991, 
Sesack and Pickel, 1992, Lu et al., 1997). This glutamate input comes mainly 
from the infralimbic and prelimbic regions (Beckstead et al., 1979, Phillipson, 
1979a, Sesack et al., 1989, Sesack and Pickel, 1992, Geisler and Zahm, 2005, 
Frankle et al., 2006). Furthermore, excitation and inhibition of the PFC results in 
increased and decreased activity of the VTA, respectively (Gariano and Groves, 
1988, Svensson and Tung, 1989, Murase et al., 1993a, Tong et al., 1996). VTA 
PFC glutamate inputs selectively activate dopamine mesocortical neurons and 
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GABA-containing mesolimbic (accumbens) neurons (Sesack and Pickel, 1992, 
Carr and Sesack, 2000b). This is one mesocorticolimbic dopamine circuit that 
may become aberrant with drug-induced neuroplasticity. At least two different 
glutamate inputs into the VTA can signal reward or aversion (Figure 13). The 
laterodorsal tegmentum (LDT) and lateral habenula (LHb) have VTA afferents 
that preferentially project to different VTA dopamine neuron subpopulations. 
These dopamine populations then project to different target structures (nucleus 
accumbens lateral shell versus medial PFC) (Margolis et al., 2008, Lammel et al., 
2011, Lammel et al., 2012) eliciting reward and aversion, respectively (Lammel et 
al., 2012).  
 
Figure 13: Summary of circuitry proposed from Lammel et al., 2011. Rewarding 
versus aversive stimuli provide differential input upon midbrain dopamine 
neurons which in turn have different terminal field projections. 
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Reward involves excitation of VTA dopamine neurons that project to the 
nucleus accumbens shell (Lammel et al., 2011). Aversion involves excitation of 
the GABAergic tVTA neurons which then project to the a/pVTA signaling 
aversion by activating mesocortical dopamine projections through an unknown 
mechanism (Lammel et al., 2012). The tVTA also receives inputs from brain 
regions involved in aversive stimuli processing including the cingulate cortex 
(Devinsky et al., 1995, Vogt, 2005), septum (Sheehan et al., 2004), lateral 
habenula (Matsumoto and Hikosaka, 2009a, Sartorius et al., 2010, Winter et al., 
2011), periaqueductal gray (Jhou, 2005, Berton et al., 2007, McNally et al., 
2011), and extended amygdala (Davis et al., 2010). 
GABAERGIC VTA AFFERENTS 
 The VTA receives substantial inhibitory GABAergic inputs from areas such 
as the pedunculopontine tegmental nucleus (PPTg), laterodorsal tegmentum 
(LDT), lateral hypothalamus, diagonal band, lateral septum, periaqueductal gray, 
dorsal raphe nuclei, parabrachial nucleus (PB) from the nucleus of the solitary 
tract (NTS), nucleus accumbens shell, ventral pallidum, lateral habenula, 
rostromedial tegmental nucleus, and the bed nucleus of the stria terminalis 
(Oades and Halliday, 1987, Floresco et al., 2003, Geisler and Zahm, 2005, 
Grace et al., 2007a, Matsumoto and Hikosaka, 2007, 2009b, Smith et al., 2009, 
Bourdy and Barrot, 2012, Kudo et al., 2012, Jennings et al., 2013). The VTA 
receives extensive inhibitory feedback from the extended amygdala and basal 
ganglia which originating from the nucleus accumbens shell and the ventral 
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pallidum, respectively (Zahm and Heimer, 1990, Heimer et al., 1991, Zahm et al., 
1996, Usuda et al., 1998, Geisler and Zahm, 2005). 
VTA GABA neurons provide local inhibition of dopamine neurons (Grace and 
Bunney, 1985, Johnson and North, 1992b, Tan et al., 2010) where local contacts 
between these neuronal phenotypes have been reported (Omelchenko and 
Sesack, 2009). In addition to local GABAergic interneurons, there are GABA 
neurons of the tail of the VTA (rostromedial tegmental nucleus) which inhibit DA 
neurons in the more rostral VTA (Johnson and North, 1992b, Olson and Nestler, 
2007, Jhou et al., 2009, Kaufling et al., 2010). GABAergic local interneurons and 
projection neurons in the VTA not only regulate the excitatory state VTA 
dopamine and GABA neurons (Klitenick et al., 1992, Marinelli et al., 2006, Dobi 
et al., 2010) but also the excitatory state of VTA terminal fields including the PFC 
and NA (Pirot et al., 1992, Van Bockstaele and Pickel, 1995, Steffensen et al., 
1998, Carr and Sesack, 2000a).  
VTA AFFERENTS FROM THE BNST 
 One brain region upstream of the VTA that has received considerable 
attention is the bed nucleus of the stria-terminalis (BNST). The BNST sends both 
glutamatergic and GABAergic inputs into the VTA (Georges and Aston-Jones, 
2002, Kudo et al., 2012, Jennings et al., 2013). The BNST also has aversive and 
reward specific inputs into the VTA, similar to the LDT and LH glutamate inputs, 
but through different mechanisms (Figure 14). Specifically, two differential BNST 
afferents into the VTA have been characterized. GABAergic BNST inputs onto 
VTA GABA neurons produces anxiolytic/rewarding behavioral responses, while 
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glutamatergic BNST inputs onto VTA GABA neurons produces 
anxiogenic/aversive behavioral responses (Jennings et al., 2013).  
 
Figure 14: Summary of circuitry proposed from Jennings et al., 2013. Inhibition 
of VTA dopamine neurons by GABA input is aversive and anxiogenic while 
disinhibition is rewarding and anxiolytic. 
 
 
 
 
 
 
 
 
 
 
 
The hypothesis that decreasing GABA neuron activity in the VTA is rewarding 
is supported by the finding that anxiolytic/rewarding behavioral responses can be 
induced by directly inhibiting intra-VTA GABA neurons (Jennings et al., 2013). 
Importantly, it has been reported that footshock stress selectively activates BNST 
glutamate projection neurons that increase intra-VTA GABA neuron activity 
(Jennings et al., 2013). These findings suggest that footshock stress increases 
GABA neuron firing in the VTA through excitatory drive from the BNST. 
Furthermore, footshock-induced increases in VTA GABA neuron activation 
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signals aversion and anxiogenesis. In summary, the findings from Lammel et al., 
(2012) and Jennings et al., (2013) suggest that increasing GABA input or intra-
VTA GABA neuron activity produces aversive/anxiogenic behavioral responses. 
Alternatively, increasing glutamatergic input or disinhibiting VTA dopamine 
neurons both produce rewarding/anxiolytic behavioral responses (Lammel et al., 
2012, Jennings et al., 2013). 
VTA EFFERENTS 
 Neuroanatomical studies have characterized VTA projections using 
different criteria. One criteria used is medial/lateral topography of the mesolimbic 
projections to produce two different pathways (Fallon and Moore, 1978, 
Beckstead et al., 1979). These two pathways are: (1) the medial striatal 
projections to the medial nucleus accumbens shell, and (2) the lateral striatal 
projections to the lateral nucleus accumbens core and shell (Ikemoto, 2007). 
Another criteria used is dorsal/ventral topography to produce two distinct efferent 
pathways. These two pathways are:  (1) the dorsal dopamine neurons that 
express lower levels of the dopamine active transporter (DAT) and high levels of 
calbindin calcium binding protein, and (2) the ventral dopamine neurons that 
project primarily to the striatum and have high levels of DAT and low levels of 
calbindin (Gerfen, 1992, Haber et al., 1995, Bjorklund and Dunnett, 2007). The 
latest criteria characterizing VTA efferents uses the forebrain targets, physical 
characteristics, and firing patterns of VTA dopamine neurons to produce distinct 
efferent pathways. These two pathways are: (1) the slow firing dopamine 
neurons that project to the lateral nucleus accumbens shell and dorsolateral 
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striatum, and (2) fast firing dopamine neurons that express lower levels of DAT 
and project to the PFC, nucleus accumbens core, and the medial nucleus 
accumbens shell (Lammel et al., 2008). 
The majority of VTA dopamine neuron projections do not have overlapping 
target areas. This suggests that different VTA projections are separate and 
independent, but parallel (Fallon, 1981, Albanese and Minciacchi, 1983, Loughlin 
and Fallon, 1984, Lammel et al., 2008). For example, dopamine neurons of the 
medial posterior VTA project selectively to the nucleus accumbens core, medial 
nucleus accumbens shell, and to the medial prefrontal cortex. In contrast, 
dopamine neurons in the lateral posterior and anterior VTA project primarily to 
the nucleus accumbens lateral shell (Lammel et al., 2008). For these reasons, 
dopamine neurons that project to the medial prefrontal cortex and nucleus 
accumbens can be functionally distinct from one another, adding to the 
complexity of behavior that is preferentially regulated either by mesocortical or 
mesolimbic dopamine input.  
Heterogeneous groups of VTA neurons which project to different terminal 
fields can be further divided into dopaminergic and non-dopaminergic (GABA) 
populations (Swanson, 1982). VTA GABA neurons are not only local inhibitory 
interneurons that regulate the excitatory state of VTA DA neurons (Klitenick et 
al., 1992, Marinelli et al., 2006) but also projection neurons that have terminal 
fields in the medial prefrontal cortex and nucleus accumbens (Pirot et al., 1992, 
Van Bockstaele and Pickel, 1995, Steffensen et al., 1998, Carr and Sesack, 
2000a, Dobi et al., 2010). This makes GABA neurotransmission an essential 
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component to the mesocorticolimbic system and likely motivated behavior. In 
summary, the converging functional afferents, diverging efferents, and 
heterogeneous neuron populations of the VTA produces very complex 
neurocircuitry involved in motivated behavior. Although, the full complexity of 
VTA neurocircuitry is beyond the scope of this dissertation, there exists 
heterogenous circuits that control the differential response of the 
mesocorticolimbic system to different stimuli, including stress and reward. 
STRESS REGULATION OF MESOCORTICOLIMBIC DOPAMINE SIGNALING 
 Distinct subpopulations of VTA dopamine neurons respond differently to 
aversive stimuli.  Stressful stimuli can increase VTA dopamine neuron excitation 
and terminal field release of dopamine (Abercrombie et al., 1989, Mantz et al., 
1989, Guarraci and Kapp, 1999, Bassareo et al., 2002, Joseph et al., 2003, 
Young, 2004, Anstrom and Woodward, 2005, Brischoux et al., 2009, Matsumoto 
and Hikosaka, 2009b, Bromberg-Martin et al., 2010, Cohen et al., 2012). 
Paradoxically, others have reported that the majority of VTA DA neurons are in 
fact inhibited by aversive stimuli (Ungless et al., 2004, Roitman et al., 2008, 
Badrinarayan et al., 2012, Oleson et al., 2012). These findings suggest that VTA 
dopamine neurons can both be excited and inhibited by stressful stimuli. In 
support, it has been reported that whether a VTA dopamine neuron is excited or 
inhibited by footshock depends on their ventral versus dorsal location in VTA sub 
nuclei (Brischoux et al., 2009). 
Ventral VTA DA neurons have been reported to be preferentially excited 
by footshock stress while dorsal VTA DA neurons are inhibited (Brischoux et al., 
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2009). This roughly translates to the dorsal parabrachial (PBP) and the more 
ventral parainterfascicular (PIF) and paranigral (PN) nuclei, respectively. The 
functional heterogeneity in VTA DA neurons in response to stress has not only 
been reported in the ventral dorsal topography but also in the rostral caudal 
topography (Ikemoto et al., 1997a, Ikemoto et al., 1998, Carlezon et al., 2000, 
Bolanos et al., 2003, Olson et al., 2005). These different regions also have 
specific connectivity within the mesocorticolimbic system (Ikemoto, 2007).  
  Dopamine neurons projecting to the medial prefrontal cortex (mPFC) are 
hypothesized to be preferentially activated by aversive stimuli, while dopamine 
neurons that project to the nucleus accumbens shell are hypothesized to signal 
reward and salience (Lammel et al., 2011, Lammel et al., 2012). The first 
evidence supporting heterogeneous mesocortical versus mesolimbic VTA DA 
neuron function was provided by looking at the effects of footshock stress on this 
system (Thierry et al., 1976). Dopamine levels were found to be significantly 
increased in the prefrontal cortex, but only slightly in the nucleus accumbens of 
drug naïve rats that had undergone short periods of intermittent footshock stress 
(Thierry et al., 1976). These findings have been replicated using footshock and 
other stressors across a range of different techniques (Fadda, 1978, Lavielle, 
1978, Tassin et al., 1980, Herman et al., 1982, Bannon, 1983, Deutch et al., 
1985, Roth et al., 1988, Deutch et al., 1990, Deutch and Roth, 1990, Deutch et 
al., 1991, Lammel et al., 2011). Mesocortical VTA DA neurons possess distinct 
characteristics (Bannon et al., 1983, Roth, 1984) such the lack of autoreceptors 
to regulate neurotransmission (Chiodo et al., 1984). However, upon initial 
76 
 
investigation the absence of functional autoreceptors does not appear to be a 
critical determinant in the preferential responsiveness of mesocortical DA 
neurons to footshock stress (Roth et al., 1988). 
To summarize, there are conflicting results as to what stressful stimuli are 
doing to mesocorticolimbic dopamine neurotransmission in drug naïve animals, 
much less in cocaine experienced ones. These inconsistencies are likely the 
result of the complexity of the VTA neurocircuitry regulating both stress and 
reward. However, it is safe to say that we can no longer consider the VTA to be a 
homologous structure and its heterogeneity will need to be taken into 
consideration to fully characterize stress-induced reinstatement of drug seeking 
and other questions related to motivation and reward. Surely the complex 
circuitry of the VTA is converged upon by CRF release during stress in a way 
that regulates cocaine seeking. 
VENTRAL TEGMENTAL AREA AND CORTICOTROPIN RELEASING FACTOR  
 CRF inputs to the VTA arise from multiple sources including afferents from 
the paraventricular nucleus of the hypothalamus (PVN), bed nucleus of the stria 
terminals (BNST), central nucleus of the amygdala (CeA), and (Beckstead et al., 
1979, Phillipson, 1979a, Swanson et al., 1983, Wallace et al., 1989, Rodaros et 
al., 2007). CRF-containing axons and varicosities had been identified in the VTA 
(Swanson et al., 1983) and are co-expressed with classical neurotransmitters 
(Tagliaferro and Morales, 2008). There are two types of CRF-containing neurons 
that project to the VTA, these are CRF-asymmetric (assumed glutamatergic) and 
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CRF-symmetric (assumed GABAergic) (Tagliaferro and Morales, 2008). The 
majority of CRF terminals contacting dopamine neurons in the VTA are 
asymmetric (Tagliaferro and Morales, 2008). However, CRF containing terminals 
make contact onto the dendrites of both dopamine and GABA neurons 
(Tagliaferro and Morales, 2008). The exact origin of these two types of terminal 
inputs has not been determined. 
CRF and both its receptors appear to be functionally expressed within the 
VTA (Ungless et al., 2003, Korotkova et al., 2006, Wanat et al., 2008). CRF-R1 
mRNA has been found in both dopaminergic and GABAergic neurons of the VTA 
(Korotkova et al., 2006, Refojo et al., 2011). It should be noted that the VTA does 
express CRF-R1 but at significantly lower levels than other brain regions in the 
rat (Van Pett et al., 2000, Sauvage and Steckler, 2001). In contrast, in situ 
hybridization has failed to detect CRF-R2 mRNA in the VTA (Chalmers et al., 
1995, Van Pett et al., 2000). This does not rule out a presynaptic mechanism for 
CRF-R2 in the VTA. Moreover, CRF-R2 mRNA has been detected in the VTA 
using single cell RT-PCR (Korotkova et al., 2006). Surprisingly, CRF-R2 mRNA 
levels were reported to greatly exceed those of CRF-R1 in VTA dopamine 
neurons (Korotkova et al., 2006). It should be noted that this was the only report 
to show expression of CRF-R2 mRNA in the VTA.  
In contrast to in situ hybridization, immunohistochemical analysis of CRF 
receptor subtype specific expression has been met with significant skepticism 
because commercially available antibodies for the CRF receptors have failed 
sensitivity and specificity tests (Refojo et al., 2011). The inability to reliably detect 
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CRF receptor protein expression has greatly stymied the progress of the field. 
Pre- versus post-synaptic localization of both CRF receptor subtypes within the 
VTA has up to this point been ambiguous. Nevertheless, electrophysiological 
studies have implicated both CRF receptor subtype function in the regulation of 
VTA DA neuron activity (Ungless et al., 2003, Korotkova et al., 2006, Wanat et 
al., 2008, Beckstead et al., 2009). In summary, even without reliable protein 
detection, the field still supports the notion that both CRF-R1 and CRF-R2 are in 
fact expressed in the VTA (Van Pett et al., 2000, Ungless et al., 2003, Korotkova 
et al., 2006, Wang et al., 2007, Wanat et al., 2008, Beckstead et al., 2009, 
Blacktop et al., 2011, Wanat et al., 2013). CRF systems are in a good anatomical 
location to regulate dopaminergic neurotransmission of the mesocorticolimbic 
system and therefore motivated behavior.  
CRF RECEPTORS AND STRESS-INDUCED REINSTATEMENT  
 CRF was originally hypothesized to be important to addiction-related 
actions in the VTA because the mesocorticolimbic dopamine system is implicated 
in both responsiveness to stress (Thierry et al., 1976) and cocaine self-
administration (Roberts et al., 1977). A common theme to repeated cocaine 
administration is increased responsiveness throughout the brain to CRF (Sarnyai 
et al., 1992, Sarnyai et al., 1993, 1995, Erb et al., 1996, 1998, Shaham et al., 
1998, Basso et al., 1999, Erb and Stewart, 1999, Koob, 1999b, Shaham et al., 
2000, Shalev et al., 2000, Erb et al., 2001, Sarnyai et al., 2001, Erb et al., 2003, 
Erb et al., 2006a, Pollandt et al., 2006, Fu et al., 2007, Koob and Kreek, 2007, 
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Koob, 2008, Mantsch et al., 2008a, Specio et al., 2008, Shalev et al., 2010, Graf 
et al., 2011). One very important area in which this is occurring is the VTA 
(Kalivas et al., 1987, Goeders et al., 1990, Wang et al., 2007, Blacktop et al., 
2011). Footshock stress which causes reinstatement of extinguished cocaine-
seeking (Erb et al., 1996, Shaham et al., 1998, Mantsch et al., 2008a) also 
causes CRF release in the VTA in both drug-naïve and drug-experienced 
animals (Wang et al., 2005, Wang et al., 2007). Cocaine exposure alters the 
function of CRF in the VTA in such a way that it facilitates drug seeking (Wang et 
al., 2005, Wang et al., 2007, Blacktop et al., 2011).  
GLUTAMATE AND VTA DOPAMINE NEURONS 
 The VTA receives both excitatory and inhibitory inputs (Watabe-Uchida et 
al., Geisler et al., 2007, Bromberg-Martin et al., 2010, Sesack and Grace, 2010). 
Stress and psychostimulants produce similar adaptations of excitatory (Ungless 
et al., 2001, Saal et al., 2003, Hahn et al., 2009) and inhibitory (Beckstead et al., 
2009, Padgett et al., 2012) neurotransmission in the VTA. Several mechanisms 
have been postulated to explain how stress reinstates drug-seeking behavior. 
One hypothesis is that stressors activate the mesocorticolimbic DA system, in a 
similar way to both drugs and cues previously associated with use, resulting in 
craving and therefore relapse (Robinson and Berridge, 1993, Shaham and 
Stewart, 1995). Consistent with this, excitatory drive on this circuit through 
glutamate neurotransmission in the VTA is a leading hypothesis as to how 
stress-induced CRF release facilitates reinstatement.  Glutamatergic afferent 
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projectionss are important to drug seeking through regulation of VTA dopamine 
neuron firing and release of downstream dopamine (Overton and Clark, 1997).  
VTA DA neurons possess pacemaker like properties and fire in two 
distinct modes. These modes are tonic and phasic firing with phasic firing 
producing the highest DA levels (Grace and Bunney, 1984a, b, Cooper, 2002). 
Baseline dopamine neuron activity is regulated by pacemaker conductance 
bringing the membrane potential from a hyperpolarized state to a depolarized 
state, thereby decreasing the spike threshold and increasing burst firing (Grace 
and Bunney, 1983, 1984a, Grace and Onn, 1989). Phasic firing is a brief 
transient increase in dopamine cell firing that results in either episodic burst firing 
allowing for temporal summation (Gonon, 1988, Wightman and Zimmerman, 
1990, Suaud-Chagny et al., 1992) or simultaneous firing of multiple cells 
projecting to the same target neurons allowing for spatial summation (Grace and 
Bunney, 1984a, b). In contrast, tonic firing is a slow pattern of dopamine neuron 
excitation resulting in dopamine concentration increases that can last from tens 
of seconds to days or longer (Grace, 1995, Goto and Grace, 2005).  
Glutamatergic inputs stimulate midbrain dopamine neurons, promoting 
burst firing rather than single spike firing (Grace and Onn, 1989, Taber et al., 
1995, Grillner and Mercuri, 2002, Floresco et al., 2003). Burst firing patterns of 
VTA DA neurons produce optimally efficient dopamine release at both terminals 
and somatodendritic sites (Wightman and Zimmerman, 1990). This results in the 
facilitation of supra-additive release or summation of dopamine, which saturates 
dopamine transporters limiting uptake. This optimization of VTA DA neuron firing 
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is ultimately responsible for the downstream behavioral responses to dopamine 
(Chergui et al., 1994, Floresco et al., 2003, Phillips et al., 2003) including the 
perception of both reward (Overton and Clark, 1997) and reward-predicting 
salient stimuli (Schultz, 1998). Endogenous burst activity of dopamine neurons is 
regulated by glutamate activation of the NMDA receptor (Johnson and North, 
1992b, Overton and Clark, 1992, Chergui et al., 1993, Deister et al., 2009, 
Zweifel et al., 2009), which requires removal of its magnesium block by AMPA 
receptor activation (Calabresi et al., 1992). To the extent that increased levels of 
terminal field DA release are responsible for stress-induced cocaine seeking, 
glutamate inputs onto VTA dopamine neurons represent a possible mechanism.  
CRF can augment glutamate signaling in the VTA. CRF-containing and 
glutamatergic VTA afferents can converge independently (Georges and Aston-
Jones, 2001, Rodaros et al., 2007, Zahm et al., 2011, Jennings et al., 2013) or 
glutamate and CRF can be co-released (Rodaros et al., 2007, Tagliaferro and 
Morales, 2008). Intra-VTA CRF can increase dopamine and glutamate 
concentrations as measured by HPLC tissue or microdialysis sample analysis 
(Kalivas et al., 1987, Lavicky and Dunn, 1993, Wang et al., 2005). In slice 
preparations from drug-naïve rats, ex vivo electrophysiology studies have 
reported increased excitatory drive on VTA dopamine neurons by CRF through: 
(1) CRF-R2/CRF-BP/PKC-dependent increases in NMDA receptor conductance 
(Ungless et al., 2003),  (2) CRF-R1/PKC-dependent increases in 
hyperpolarization-activated cation current IH (Wanat et al., 2008), and (3) mGluR-
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dependent increases in potassium-sensitive calcium channel conductance 
(Riegel and Williams, 2008).  
Drug-induced neuroplasticity can augment glutamate-induced excitation of 
VTA dopamine neurons. A single exposure to cocaine, amphetamine, morphine, 
nicotine, ethanol, and notably, acute stress can enhance glutamate synaptic 
transmission upon midbrain dopamine neurons (Ungless et al., 2001, Saal et al., 
2003). Drugs of abuse have consistently been reported to augment the function 
of ionotropic glutamate receptors on VTA dopamine neurons (Ungless et al., 
2001, Saal et al., 2003, Bellone and Luscher, 2006, Argilli et al., 2008, Chen et 
al., 2008, Bowers et al., 2010, Luscher and Malenka, 2011, Mameli et al., 2011).  
Cocaine- and stress-exposure induced neuroplasticity appears to target 
the AMPA receptor which in turn potentiates NMDA-mediated synaptic 
transmission by removing magnesium block (Ungless et al., 2010). Cocaine 
exposure has been reported to recruit a CRF-R1/PKA dependent mechanism 
that enhances NMDA and AMPA receptor signaling on VTA DA neurons (Hahn 
et al., 2009). These findings suggest that, following drug or stress exposure, the 
ability of CRF to augment glutamatergic signaling in the VTA is enhanced. 
However, these studies used ex vivo electrophysiology with brain slice 
preparations from animals that had received noncontingent cocaine 
administration followed by, at most, acute withdrawal without extinction.  
STRESS-INDUCED RELAPSE CRF AND GLUTAMATE 
 In a set of experiments by Wise and colleagues, the role of glutamate and 
CRF in the VTA was characterized during footshock-induced reinstatement of 
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cocaine seeking. Footshock stress produced a significant increase in intra-VTA 
CRF release in both drug-naïve and drug-experienced animals (Wang et al., 
2005). The importance of this CRF was highlighted by the finding that both 
footshock stress and reverse dialysis of CRF into the VTA was sufficient to 
reinstate extinguished cocaine-seeking behavior (Wang et al., 2005). 
Reinstatement was further characterized by increases in VTA glutamate and 
somatodendritic dopamine release, which were both blocked by a nonspecific 
CRF receptor antagonist (Wang et al., 2005). Furthermore, administration of 
kynurenic acid, a nonspecific ionotropic glutamate receptor antagonist (Stone, 
1993), blocked footshock- and intra-CRF-induced reinstatement, along with the 
simultaneous increases in somatodendritic dopamine release but not the 
increases in extracellular glutamate (Wang et al., 2005). These data indicate that 
reinstatement involves excitatory drive on VTA dopamine neurons through CRF-
dependent regulation of presynaptic glutamate release and subsequent 
ionotropic glutamate receptor activation on dopamine neurons. It was later 
reported that footshock and intra-VTA CRF-induced reinstatement and 
concomitant increases in glutamate and dopamine can be blocked by 
administration of CRF-R2 but not CRF-R1 specific antagonists (Wang et al., 
2007). These findings were unexpected for reasons outlined below.  
CRF has 10-fold higher affinity for the CRF-R1 than the CRF-R2 receptor 
(Perrin et al., 1995). CRF-R1 is much more widely distributed throughout the 
rodent brain than CRF-R2 (Van Pett et al., 2000). Moreover, the majority of 
experiments using ventricular administration of antagonists support the 
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conclusion that CRF-R1 and not CRF-R2 activation is necessary for footshock-
induced reinstatement of not only cocaine- but also heroin-, alcohol-, and 
nicotine-seeking (Erb et al., 1998, Shaham et al., 1998, Le et al., 2000, Bruijnzeel 
et al., 2009). Although, there is a well-established role for CRF-R1 function in 
footshock-induced reinstatement of drug seeking, Wise and colleagues defined a 
clear role for the CRF-R2 receptor. Importantly, site-specific versus global 
ventricular administration of drugs targeting CRF receptors could help explain 
these disparate findings. 
CRF receptor subtype-specific ligands (urocortins) that were sufficient to 
reinstate drug-seeking were also reported. Ligands sufficient to reinstate (CRF, 
Ucn1, and Ucn2) were not specific for a CRF-R receptor subtype but all bound to 
the CRF-BP (Wang et al., 2007).  Paradoxically, when CRF-R2 specific ligands 
prevented binding to the CRF-BP, they also prevented the sufficiency of these 
ligands to reinstate cocaine seeking (Wang et al., 2007). CRF-BP is considered 
to be a functional CRF receptor antagonist due to its ability to sequester ligands 
(e.g., CRF) and prevent them from activating CRF receptors (Huising et al., 
2008). Prevention of CRF binding to CRF-BP should increase the amount of free 
CRF available to activate endogenous CRF receptors. This would be 
hypothesized augment reinstatement and not block it.  
Wang et al., (2007) suggested that in order for intra-VTA CRF to reinstate 
cocaine seeking it needs to bind to the CRF-BP and activate CRF-R2.  Although 
these findings do not fit with the traditional role of CRF-BP they do support the 
hypothesis that a functional dimer with unique functions forms when CRF-BP 
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binds CRF (Potter et al., 1991, Behan et al., 1996b, Kemp et al., 1998, Sajdyk et 
al., 1999, Chan et al., 2000, Roseboom et al., 2007). Moreover, they are in 
congruence with a report by Ungless et al., (2003) of a CRF-R2/CRF-BP/PKC-
dependent enhancement of NMDAR signaling on VTA dopamine neurons. 
However, both CRF-R1 and CRF-R2 have both been implicated in facilitating 
glutamate neurotransmission in the VTA through NMDA and AMPA receptors on 
dopamine neurons (Ungless et al., 2003, Pollandt et al., 2006, Wang et al., 2007, 
Wanat et al., 2008, Hahn et al., 2009). Therefore, there still remains conflicting 
evidence as to which CRF receptor subtype provides excitatory drive of VTA 
dopamine neurons through increased ionotropic glutamate receptor 
conductance.  
In summary, there is strong evidence that CRF regulates VTA dopamine 
cellular activity in response to stress by facilitating glutamate signaling through 
ionotropic glutamate receptors on VTA dopamine neurons; an effect that appears 
to be enhanced following cocaine exposure (Ungless et al., 2003, Hahn et al., 
2009). This enhancement of excitatory signaling through ionotropic glutamate 
receptors is one mechanism that could be involved in footshock stress-induced 
reinstatement of extinguished cocaine seeking. The specific role of both CRF and 
ionotropic glutamate receptor subtypes in the VTA has not been sufficiently 
characterized in stress-induced reinstatement of extinguished cocaine seeking, 
particularly following LgA self-administration. The LgA self-administration model 
of stress-induced relapse involves intake-dependent neuroplastic changes that 
regulate escalation of drug intake and the emergent ability of footshock stress to 
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cause relapse. Characterizing the interactions between drug-induced 
neuroplasticity and stress signaling in the VTA under conditions that reinstate 
extinguished cocaine seeking under these conditions will contribute to the field 
substantially.However, it is likely that the processes responsible for stress-
induced relapse are more complex than simply increased excitatory drive on VTA 
DA neurons in response to a stressful stimulus.  
GABA AND VTA DOPAMINE NEURONS  
 Footshock stress also results in increased activity of GABAergic inputs 
into the VTA as well as increased activity of VTA GABA neurons (Lammel et al., 
2012, Tan et al., 2012). This increase in VTA GABA signaling may decrease the 
activity of neighboring dopamine neurons contributing to behaviors associated 
with aversion (Cohen et al., 2012, Kim et al., 2012, Tan et al., 2012, van Zessen 
et al., 2012). GABA inhibits neurons by activating two receptors, the ionotropic 
GABAA receptor and the metabotropic GABAB receptor. Fast inhibitory 
postsynaptic currents (IPSCs) are induced by GABAA receptor activation via 
intrinsic chloride channel influx (Rudolph et al., 2001),  while slower inhibitory 
outward currents are induced by GABAB receptor activation (Otis and Mody, 
1992). GABA exerts a direct GABAB receptor-mediated inhibitory influence by 
activation Gi/o protein-coupled receptors and hyperpolarization of neuronal 
membrane potentials through increases in inwardly rectifying potassium channel 
conductance (Lacey et al., 1988). 
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GABAA and GABAB receptors are both expressed in the VTA (Kalivas, 1993, 
Westerink et al., 1996, Westerink et al., 1998). In the VTA GABAA receptors are 
located predominantly, but not exclusively, on GABA neurons while GABAB 
receptors are predominantly (but not exclusively) located on dopamine neurons 
(Churchill et al., 1992, Klitenick et al., 1992, Xi and Stein, 1998, Magreta-Mitrovic, 
1999, Laviolette and van der Kooy, 2001, Laviolette et al., 2004). Therefore, 
GABAergic interneuron inhibition of VTA DA neurons is largely regulated by 
ionotropic GABAA receptors (Sugita et al., 1992, Kalivas, 1993) while direct 
GABA inhibition of dopamine neurons is largely regulated by metabotropic 
GABAB receptors (Xi and Stein, 1998, Margeta-Mitrovic et al., 1999). In the VTA, 
GABA can also act presynaptically via GABAB receptor activation on both GABA 
and glutamate terminals (Bonci and Williams, 1997, Manzoni and Williams, 1999, 
Wu et al., 1999, Giorgetti et al., 2002, Michaeli and Yaka, 2010) and 
postsynaptically upon dopamine and GABA neurons (Georges and Aston-Jones, 
2002, Giorgetti et al., 2002, Beckstead et al., 2009, Cohen et al., 2012, Tan et al., 
2012).  
Altogether, phasic firing of DA neurons can be induced by glutamate input 
and NMDA receptor activation, and inhibited by GABA inputs and activation of 
both GABAA and GABAB receptors. NMDA receptor activation facilitates phasic 
firing of VTA dopamine neurons (Johnson and North, 1992b, Overton and Clark, 
1992, Chergui et al., 1993, Deister et al., 2009, Zweifel et al., 2009) while both 
GABAA and GABAB receptor activation inhibits it (Lacey et al., 1988, Engberg et 
al., 1993, Seutin et al., 1994, Erhardt et al., 1998, Paladini et al., 1999a, Paladini 
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et al., 1999b, Paladini and Tepper, 1999, Wu et al., 1999, Erhardt et al., 2002). In 
addition to regulation of phasic firing GABAA and GABAB receptors provide tonic 
inhibition (Yim and Mogenson, 1980, Johnson and North, 1992b, a, Suaud-
Chagny et al., 1992, Laviolette and van der Kooy, 2001, Erhardt et al., 2002, 
Giorgetti et al., 2002, Chen et al., 2005). Therefore, there is an important balance 
between excitatory and inhibitory effects on phasic and tonic firing of VTA DA 
neurons determined by activity of NMDA, GABAA, and GABAB receptors.  
GABA AND DRUGS OF ABUSE 
 Many drugs of abuse can directly inhibit VTA GABA neurons, thereby 
increasing VTA dopamine neuronal activity and facilitating the reinforcing effects 
of these drugs which includes: opioids, benzodiazepines, nicotine, cannabinoids, 
and cocaine (Johnson and North, 1992a, Mansvelder et al., 2002, Szabo et al., 
2002, Steffensen et al., 2008, Bocklisch et al., 2013). This disinhibition can be 
mediated by increased GABA input on VTA GABA neurons and decreased 
responsiveness of VTA dopamine neurons to GABA (Johnson and North, 1992a, 
Beckstead et al., 2009, Arora et al., 2011, Bocklisch et al., 2013). Cocaine, on 
the other hand, provides excitatory drive on VTA dopamine neurons through both 
glutamatergic and, potentially, GABAergic mechanisms. These mechanisms 
include increased ionotropic glutamate receptor signaling on VTA DA neurons, 
increased GABA input on VTA GABA neurons, and decreased GABAB-receptor 
mediated inhibition of dopamine neurons (Sun, 2005, Beckstead and Williams, 
2007, Beckstead et al., 2009, Hahn et al., 2009, Arora et al., 2011, Bocklisch et 
al., 2013). GABAB-receptor inhibition of VTA DA neurons occurs primarily 
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through Gi protein-gated inwardly rectifying potassium (GIRK) channels that 
actually results in potassium ion efflux (Johnson and North, 1992b, Cruz et al., 
2004, Labouebe et al., 2007, Beckstead et al., 2009).  
In the case of repeated cocaine, both increased ionotropic glutamate 
receptor conductance (Ungless et al., 2001, Hahn et al., 2009, Ungless et al., 
2010) and decreased GABAA- and GABAB-induced inhibition of VTA dopamine 
neurons (Klitenick et al., 1992, Cameron and Williams, 1994, Kushner, 2001, 
Beckstead et al., 2009, Arora et al., 2011, Padgett et al., 2012, Graziane et al., 
2013) have been reported. Notably, it has been reported that cocaine self-
administration and increases in dopamine as a result of cocaine self-
administration are both significantly inhibited by activation of the GABAB receptor 
following systemic administration of GABAB receptor agonists (Brebner et al., 
2000, Fadda, 2003). Together, these mechanisms may facilitate a net shift in 
excitation of VTA dopamine neurons upon cocaine exposure. However, it is 
important to note that this shift is acute and does not extend into protracted 
abstinence, when reinstatement is typically assessed. 
GABA AND CRF INTERACTIONS IN THE VTA 
 Although much research has focused on effects of CRF on excitatory 
synaptic transmission in the VTA, footshock-induced reinstatement of cocaine 
seeking may be regulated by intra-VTA CRF in such a way that reflects inhibition 
of VTA dopamine neurons. Intra-VTA CRF administration can decrease the 
motivation to work for food rewards; an effect that occurs through CRF-induced 
inhibition of reward-evoked dopamine release (Wanat et al., 2013). This suggests 
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that in the VTA CRF can exert inhibitory effects upon dopamine signaling in a 
way that can affect operant behavior. Intra-VTA CRF has been shown to exert 
inhibitory effects via enhancement of GABAB-receptor regulated GIRK channel 
conductance on dopamine neurons (Beckstead et al., 2009). Specifically, 
activation of CRF-R1 receptors is necessary for CRF administration to augment 
this GABAB/GIRK-induced inhibition (Beckstead et al., 2009). Notably, CRF-
dependent enhancement of GABAB/GIRK-induced inhibition of VTA dopamine 
neurons is acutely diminished by drug exposure (Beckstead et al., 2009). 
Rewarding and aversive stressful stimuli can both reinstate extinguished 
cocaine seeking and by themselves have opposing effects on GABA regulation 
of VTA dopamine neuron activity. For example, cocaine increases VTA 
dopamine activity in part by decreasing GABAergic signaling in the VTA 
(Bocklisch et al., 2013) and induces conditioned place preference (Mueller and 
Stewart, 2000), while footshock stress decreases VTA dopamine activity by 
increasing GABAergic signaling in the VTA and induces conditioned place 
aversion (Tan et al., 2012). Both cocaine and footshock reinstate extinguished 
cocaine-seeking behavior (McFarland and Kalivas, 2001, McFarland et al., 
2004). Moreover, prior history of exposure to drugs of abuse can change VTA 
GABAergic neurotransmission substantially (Johnson and North, 1992a, Bonci 
and Williams, 1997, Nugent et al., 2007, Madhavan et al., 2010). The role of 
GABA in footshock-induced reinstatement of extinguished LgA cocaine seeking 
has not been investigated despite its clear involvement with both CRF and 
dopamine neuron signaling in the VTA. 
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BACKGROUND AND SIGNIFICANCE SUMMARY 
 The high propensity for relapse in drug-abstinent addicts has made 
relapse prevention a key target for pre-clinical research aimed at improving 
approaches for the long-term management of drug addiction. Further, 
understanding of the neurobiological processes that contribute to relapse is 
needed for the development of new and/or more effective treatment for drug 
addiction. Primary questions being asked about addiction are: 1) what are the 
primary triggers for relapse, 2) what brain systems regulate these triggers of 
relapse, and 3) what maintains the vulnerability for these triggers to cause 
relapse even following periods of prolonged drug abstinence? One unpredictable 
and unavoidable cause of relapse in human addicts is the occurrence of a 
stressful life event. Importantly, stress-induced relapse can be modeled using the 
long-access self-administration/reinstatement model in rodents. Specific 
questions being asked in this dissertation are: 1) what are the primary 
mechanisms of stress-induced reinstatement, 2) what part of the brain regulates 
stress-induced reinstatement, and 3) what maintains the vulnerability for stress to 
trigger reinstatement even after extinction of drug seeking? 
Very little is known about the neuromechanisms through which stress 
contributes to the relapse process. Previous work from our laboratory has 
demonstrated that intake-dependent neuroplasticity and its interactions with the 
stress-related neuropeptide, corticotropin-releasing factor, determines the ability 
of stress to facilitate reinstatement (Mantsch et al., 2008a, Graf et al., 2011). 
However, the exact brain region where CRF is interacting with this neuroplasticity 
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is unknown. Areas of convergence between motivational and reward 
neurocircuitry represent likely neurobiological substrates through which stress 
can facilitate relapse. A major area of convergence between motivational- and 
stress-related neurocircuitry is the ventral tegmental area (VTA). This area 
involves the convergence of resident dopamine neurons and inputs that release 
the stress-related neuropeptide corticotropin releasing factor (CRF). This 
dissertation will primarily characterize CRF-related neurobiological mechanisms 
within the VTA that contribute to stressor-induced reinstatement to cocaine use 
using the long-access (LgA) self-administration/reinstatement model of relapse in 
rats.  
Chapter two characterizes whether CRF actions in the VTA represent a 
primary mechanism of stress-induced reinstatement, and, if so, which CRF 
receptor CRF is acting through. This is accomplished using site specific 
pharmacological manipulations within the ventral tegmental area and the 
reinstatement approach in rats. The hypotheses of chapter two are that intra-VTA 
CRF administration is sufficient to reinstate drug seeking in high- (long-access) 
but not moderate intake (short-access) animals and that, CRF-R1, but not CRF-
R2, activation in the VTA is necessary and sufficient for this reinstatement.  
Chapter three examines whether stressor-induced reinstatement of long-
access (LgA) cocaine seeking involves an increase or a decrease in VTA 
dopamine neuron activation. This is done using dual immunohistochemistry to 
characterize stress-induced expression of an indicator of neuronal activation, c-
Fos (Sagar et al., 1988), with tyrosine hydroxylase a known marker for dopamine 
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neurons in the VTA (Hokfelt, 1984). It is hypothesized that a significant increase 
in dopamine neuronal activation will only be observed under conditions in which 
footshock stress reinstates cocaine seeking. Therefore, it is hypothesized that 
there will be a significant increase in intra-VTA dopamine neurons that co-
express c-Fos in response to footshock stress in long-access (which show 
stress-induced cocaine seeking) -but not short-access animals (which do not).  
Lastly, chapter 4 determines whether both stress- and intra-VTA CRF-
induced reinstatement is dependent on excitatory or inhibitory receptor activation 
in the VTA. More specifically, the necessity of VTA AMPA, NMDA, GABAA, and 
GABAB receptor activation in reinstatement of extinguished cocaine seeking will 
be tested. This is also accomplished using site-specific pharmacological 
manipulations within the VTA using the long-access reinstatement rodent model 
of relapse. It is hypothesized that both stress- and intra-VTA CRF-induced 
reinstatement of extinguished long-access cocaine-seeking behavior is 
dependent on excitatory and not inhibitory receptor activation within the VTA. 
Therefore, it is more specifically hypothesized that both NMDA and AMPA 
antagonists will block while both GABAA and GABAB antagonists will augment 
both stress- and intra-VTA CRF-induced reinstatement following LgA self-
administration. 
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CHAPTER 2 
 
 
AUGMENTED COCAINE SEEKING IN RESPONSE TO STRESS OR CRF 
DELIVERED INTO THE VENTRAL TEGMENTAL AREA FOLLOWING LONG-
ACCESS SELF-ADMINISTRATION IS MEDIATED BY CRF-R1 BUT NOT CRF-
R2 RECEPTORS 
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ABSTRACT 
Excessive cocaine use may increase susceptibility to stressor-induced relapse 
through alterations in brain corticotropin releasing factor (CRF) regulation of 
neurocircuitry involved in drug seeking. Reinstatement of cocaine seeking by a 
stressor (footshock) is CRF-dependent and is augmented in rats that self-
administered cocaine under long-access (LgA; 6 hrs daily) conditions for 14 days 
when compared to rats provided shorter daily cocaine access (ShA rats; 2 hrs 
daily).  Further, reinstatement in response to ventricular CRF administration is 
heightened in LgA rats.  This study examined the role of altered ventral 
tegmental area (VTA) responsiveness to CRF in intake-dependent increases in 
CRF- and stress-induced cocaine seeking.   Bilateral intra-VTA administration of 
CRF (250 or 500 ng/side) produced reinstatement in LgA but not ShA rats.   In 
LgA rats, intra-VTA CRF-induced reinstatement was blocked by administration of 
the CRF-R1 receptor antagonists antalarmin (500 ng/side) or CP-376395 (500 
ng/side) but not the CRF-R2 receptor antagonists astressin-2B (500 ng or 1 
µg/side) or ASV-30 (500 ng/side) into the VTA.  Likewise, intra-VTA antalarmin, 
but not astressin-2B, blocked footshock-induced reinstatement in LgA rats.  By 
contrast, neither intra-VTA antalarmin nor CP-376395 altered food-reinforced 
lever pressing.  Intra-VTA injection of the CRF-R1 receptor-selective agonist, 
cortagine (100 ng/side) but not the CRF-R2 receptor-selective agonist rat 
urocortin 2 (250 ng/side) produced reinstatement.  Excessive cocaine use 
increases susceptibility to stressor-induced relapse in part by augmenting CRF-
R1 receptor dependent regulation of addiction-related neurocircuitry in the VTA. 
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INTRODUCTION 
 Cocaine addiction is associated with a persistent susceptibility to drug 
relapse that emerges in an intake-dependent manner with repeated use.  
Understanding the neurobiological mechanisms that underlie drug relapse in 
cocaine addicts is critical to the development of effective treatment.  Much 
evidence suggests that stress contributes to relapse.  Stress promotes craving in 
abstinent human cocaine addicts (Sinha et al., 1999) and precipitates 
reinstatement in rodent relapse models (Erb et al., 1996, Ahmed and Koob, 
1997). The preclinical study of addiction-related drug-induced neuroplasticity has 
involved the use of the long-access self-administration approach (Ahmed and 
Koob, 1998) in which rats provided repeated daily long access to cocaine for self-
administration (6-10 hrs/daily; LgA rats) are compared to rats provided shorter 
daily drug access (1-2 hrs/daily; ShA rats).  We have reported that, compared to 
ShA rats, LgA rats are more susceptible to reinstatement by a stressor, 
footshock, suggesting that repeated cocaine use can produce intake-dependent 
alterations in how stress regulates neurocircuitry subserving motivation and 
relapse susceptibility (Mantsch et al., 2008a).  Our findings are consistent with 
reports that the magnitude of stress-induced craving is influenced by the amount 
of prior use in human addicts (Fox et al., 2005). 
The neuropeptide, corticotropin releasing factor (CRF), is a key mediator 
of stress-induced cocaine seeking (Shalev et al., 2010).  CRF receptor 
antagonists block stress-induced reinstatement (Erb et al., 1998, Shaham et al., 
1998, Graf et al., 2011) while delivery of CRF directly into the brain reinstates 
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cocaine seeking (Erb et al., 2006b, Mantsch et al., 2008a).  One key site at which 
CRF promotes reinstatement is the ventral tegmental area (VTA) (Wise and 
Morales, 2010) where CRF delivery precipitates reinstatement following self-
administration (Wang et al., 2005, Wang et al., 2007).  The VTA receives CRF-
containing projections from a number of brain regions (Rodaros et al., 2007), and 
in vivo microdialysis studies have found that, during footshock-induced 
reinstatement, VTA extracellular CRF levels are elevated (Wang et al., 2005). 
Both CRF-R1 and CRF-R2 receptor subtypes have been reported to be 
expressed in the VTA (Korotkova et al., 2006), but the receptor mechanism 
through which CRF regulates cocaine seeking remains unclear.  Wang et al., 
(2005; 2007) have reported that reinstatement by intra-VTA CRF involves an 
activation of CRF-R2 receptors that relies on an interaction with CRF binding 
protein, consistent with the mechanism through which CRF acutely enhances 
NMDA receptor-mediated currents in the VTA (Ungless et al., 2003).  However, 
others have found that stress-induced reinstatement and evoked increases in 
VTA and nucleus accumbens dopamine rely on CRF-R1 and not CRF-R2 
receptors (Shaham et al., 1998, Lu et al., 2001, Lu et al., 2003a). 
We have reported that reinstatement by centrally administered CRF is 
also augmented following LgA self-administration, suggesting that enhanced 
CRF responsiveness contributes to heightened stress-induced relapse (Mantsch 
et al., 2008a).  It has been shown that repeated cocaine administration recruits 
CRF-R1 receptor regulation of excitatory signaling in the VTA (Hahn et al., 2009).  
In this study, we examine intake-dependent augmentation of intra-VTA CRF-
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induced reinstatement and role of VTA CRF-R1 versus CRF-R2 receptors in 
reinstatement in response to intra-VTA CRF and stress. 
MATERIALS AND METHODS 
 Adult male Sprague–Dawley rats (Harlan Laboratories, St. Louis, MO) 
were housed individually under a 12 h/12 h reversed light/dark cycle (lights on at 
7:00 PM) in a temperature and humidity controlled AAALAC-accredited animal 
facility. All procedures were approved by the Marquette University IACUC and 
carried out in accordance with the NIH Guide for the Care and Use of Laboratory 
Animals. 
Catheter and cannula implantation  
 For the reinstatement studies, rats were implanted with chronic indwelling 
jugular catheters under ketamine HCl (100 mg/kg, ip) and xylazine (2 mg/kg, ip) 
anesthesia as previously described (Mantsch et al., 2008a, Graf et al., 2011) and 
with bilateral 2.1-cm 23 gauge guide cannulae aimed at the VTA for intracranial 
injections. The tips of the guide cannulae were aimed 0.5 mm above the target 
injection site using the following coordinates determined from Paxinos and 
Watson (2000): 12˚ angle away from midline; A/P − 5.6 mm from bregma; M/L ± 
2.2 mm from midline; and D/V − 6.7 mm from the skull surface.  Placements for 
cannula targeting the VTA for rats from each of the experiments are depicted in 
Figure 15 (Paxinos, 2000). 
Self-Administration Training  
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 After recovery from surgery, rats were trained to self-administer cocaine 
(1.0 mg/kg/inf, iv; NIDA Drug Supply Program) by pressing a lever under a FR1 
schedule during daily 2-h sessions, within which the active (i.e., front) lever was 
extended into the chamber and the corresponding stimulus light was illuminated. 
Pressing the lever resulted in an iv infusion of drug or saline solution (200 μl over 
5 s) followed by a 25-s time-out period during which the stimulus light was 
extinguished but the lever remained extended. Responding on a second, inactive 
(i.e., back) lever was recorded but had no programmed consequences.  
Response requirements were gradually increased until rats displayed stable 
responding (within 10% of the 3-session mean) under an FR4 schedule at which 
time they entered into a 14-day period of self-administration testing. 
Effects of LgA Self-Administration on intra-VTA CRF-induced reinstatement  
 
 To examine intake-dependent effects of cocaine self-administration on 
later reinstatement by intra-VTA CRF, rats were assigned to ShA or LgA groups 
after self-administration training according to their access conditions for cocaine 
self-administration for the next 14 days.  ShA rats (n=6) continued to have 
access to cocaine for two hrs daily as described above.  LgA rats (n=8) had 
access to the same cocaine dose for six hrs daily.   Additionally a third group of 
rats with no prior history of cocaine self-administration had access to infusions of 
saline during 14 daily 2-h sessions and served as a control to examine non-
specific effects of intra-VTA CRF on lever pressing (n=6).  Following 14 days of 
self-administration, rats underwent extinction during ten consecutive 2-h sessions 
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within which the cocaine solution was replaced by saline.  After extinction, rats 
received a bilateral sham intra-VTA injection prior to testing for reinstatement in 
response to bilateral intra-VTA delivery of CRF (250 or 500 ng/side; 210 or 420 
µM; Sigma-Aldrich) or vehicle (0.9% NaCl) delivered in a volume of 0.25 µl/side 
over a 1-min period ten minutes prior to the reinstatement session.  Responding 
on both the cocaine and inactive levers were recorded during the 2-h 
reinstatement sessions which were otherwise identical to extinction conditions.  
The order of testing with the two CRF doses and vehicle varied across rats in 
each group to avoid potential sequence effects.  Rats underwent additional 
extinction sessions between reinstatement test sessions and were required to 
display less than 20 cocaine lever responses during an intervening extinction 
session in order to be tested again for reinstatement. 
Effects of CRF Receptor Antagonists on Intra-VTA CRF-Induced Reinstatement  
 To examine the role of CRF-R1 and CRF-R2 receptors in reinstatement by 
intra-VTA administration of CRF, the ability of CRF (500 ng/side) to reinstate 
cocaine seeking following a 15-min bilateral intra-VTA pretreatment (0.25 µl/side 
over 1 min) with the CRF-R1 receptor selective antagonists antalarmin (500 
ng/side; 4.8 mM; Sigma Aldrich; n=7) or CP-376395 (500 ng/side; 5.5 mM; Tocris 
Biosciences; n=6) or the CRF-R2 receptor-selective antagonists astressin-2B 
(500 ng and 1 µg/side; 495 and 990 µM; Sigma-Aldrich; n=6) or anti-sauvagine 
30 (ASV-30; 500 ng/side; 548 µM; Sigma-Aldrich; n=6) was determined in 
separate groups of LgA rats.  The astressin-2B and ASV-30 doses that were 
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used were based on those previously used for intracranial injections (Henry et 
al., 2006, Forster et al., 2008).  After 14 days of LgA self-administration and 
extinction, rats were tested twice for CRF-induced reinstatement in 
counterbalanced sequence: once following intra-VTA pretreatment with CRF 
receptor antagonist and once following pretreatment with vehicle.  In the case of 
the CRF-R2 receptor antagonist astressin-2B, rats were also treated with a 
second, higher antagonist dose (1 µg/side). 
Effects of CRF Receptor Antagonists on Stress-Induced Reinstatement 
 To examine the role of CRF-R1 and CRF-R2 receptor activation in the 
VTA in stress-induced reinstatement, separate groups of rats were tested for the 
ability of electric footshock, delivered though the stainless steel grid floors of the 
self-administration chambers, to reinstate cocaine seeking following bilateral 
intra-VTA delivery of the CRF-R1 receptor-selective antagonist antalarmin (500 
ng/side; n=7) or the CRF-R2 receptor-selective antagonist astressin-2B  (500 
ng/side; n=8).  During the 15-min footshock period, the houselight was 
illuminated and the levers were retracted and stimulus lights extinguished.  
Shocks (0.5 mA, 0.5” duration) were delivered an average of every 40 sec (range 
10-70 sec).  We have reported that these parameters produce robust 
reinstatement after long-access, but not short-access, self-administration 
(Mantsch et al., 2008a).  As was the case with intra-VTA CRF, rats were tested 
twice for footshock-induced reinstatement in counterbalanced fashion: once 
following intra-VTA pretreatment with CRF receptor antagonist and once 
following pretreatment with vehicle. 
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Food Self-Administration 
 In order to confirm that the effects of intra-VTA antalarmin and CP-376395 
on reinstatement were not attributable to non-specific motor impairments, rats 
were tested for effects on sucrose pellet-reinforced lever pressing (data not 
shown).  These rats were maintained at 90% of their free-feeding body weights 
and trained to self-administer 45 mg sucrose-sweetened food pellets (BioServ) 
by pressing a response lever under a FR4 schedule of reinforcement during 30-
min sessions.  Once stable response patterns were observed (responding within 
10% of the mean over 3 sessions), separate groups of rats were tested for the 
effects of intra-VTA delivery of antalarmin (500 ng/side; n=10) or CP-376395 
(500 ng/side; n=6), as described above, on responding.  Each rat was tested 
twice with intra-VTA treatment in counterbalanced sequence: once with the CRF-
R1 receptor antagonist and once with vehicle. 
Reinstatement by Intra-VTA Administration of CRF Receptor Agonist Drugs 
To further examine the role of CRF-R1 and CRF-R2 receptors in 
reinstatement, a separate group of LgA rats (n=5) was tested for reinstatement 
following bilateral intra-VTA administration of the CRF-R1 receptor-selective 
agonist, cortagine (100 ng/side; 90 µM; Phoenix Pharmaceuticals) (Tezval et al., 
2004), the CRF-R2 receptor-selective agonist rat Urocortin 2 (rUcn2; 250 
ng/side; 212.5 µM; Phoenix Pharmaceuticals) (Reyes et al., 2001), or vehicle (5 
mM acetic acid in sterile saline).  Following self-administration and extinction, 
each rat was tested with each intra-VTA treatment in counterbalanced sequence.  
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After the first test, rats were only tested again for reinstatement if they emitted 
less than 20 responses during an intervening extinction session. 
Histological Confirmation of Injection Sites  
 The accuracy of cannula implantation was confirmed postmortem in each 
rat after cardiac perfusion with 60-ml NaCl followed by 60-ml 2.5% buffered 
neutral formalin under sodium barbital anesthesia (55 mg/kg). Brains were 
removed and stored in 2.5% buffered formalin for at least one day. 200-µm 
sections were cut using a vibrotome, slide-mounted, and stained with cresyl 
violet for placement confirmation using a light microscope. Rats with injection 
sites outside of the VTA were excluded from data analysis. 
 
Statistical Analyses  
 Statistical analyses were conducted using Predictive Analytics SoftWare 
statistics software (SPSS, Inc.). Statistical significance was determined using 
ANOVA or Student’s t-tests followed, when appropriate, by further analyses of 
main effects using ANOVA and/or post-hoc testing using Bonferroni-corrected t-
tests. 
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Figure 15: Injection sites within the VTA  for: A) LgA rats (triangles), ShA rats 
(squares) and Sal rats (circles); B) LgA rats tested for CRF-induced 
reinstatement following CP-376395 (triangles), ASV-30 (circles), antalarmin 
(diamonds), and astressin-2B (squares) or LgA rats tested for EFS-induced 
reinstatement (stars); and  C) rats tested for effects on food-reinforced 
responding (open circles) and LgA rats tested for reinstatement by CRF receptor 
agonists (closed circles). 
 
 
 
RESULTS 
Effects of Self-Administration Access Condition on Reinstatement by Intra-
VTA CRF Self-Administration 
 As expected, escalated self-administration was observed in rats 
provided daily long access (6 hrs, LgA, n=8) but not short access (2 hrs, 
ShA, n=6) to cocaine for self-administration and was not observed in rats 
provided access to saline (n=6, Sal).  For analysis, the mean daily hourly 
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self-administration (infusions/hr) was compared across groups over the 14-
day time period (Figure 16A).  Two-way ANOVA examining effects of self-
administration condition (ShA, LgA, and Sal) and day (1-14, repeated 
measure) on the hourly number of self-administered infusions showed a 
significant overall main effect of self-administration condition (F2,16=23.561; 
P<0.001) but not day and a significant condition x day interaction 
(F26,208=2.708; P<0.01).  The daily number of self-administered infusions 
increased across the 14 days of self-administration in LgA but not ShA or Sal 
rats (one-way ANOVA: F13,78=2.520; P<0.01).  Post-hoc testing showed that 
self-administration was increased in LgA rats on days 5 and 9-14 compared 
to short-access rats (Bonferroni-corrected t-test; P<0.05 for each 
comparison).  The mean net cocaine intake over the 14 sessions was 
marked higher in LgA rats compared to ShA rats (t11=5.889; P<0.001) and is 
shown in the insert for Figure 16A. 
Extinction and Intra-VTA CRF-Induced Reinstatement 
 Responding did not differ between ShA and LgA rats during the ten 
extinction sessions prior to reinstatement testing (Fig 16B).  However, differences 
in reinstatement in response to intra-VTA CRF (250 or 500 ng/side) were 
observed (Figure 16C).  Reinstatement by intra-VTA CRF was only observed in 
rats with a history of LgA self-administration.  Two-way self-administration group 
(ShA, LgA, Sal) x reinstatement condition (Veh, 250 ng/side CRF, 500 ng/side 
CRF; repeated measure) ANOVA showed significant main effects of self-
administration group (F2,17=16.774; P<0.001) and reinstatement condition 
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(F2,34=7.934; P=0.001), and a significant group x reinstatement condition 
interaction (F4,34=5.969; P=0.001).    
CRF-induced increases in responding were only found in rats with a prior 
history of LgA self-administration (one-way repeated measures ANOVA; 
F2,14=10.639; P<0.01).  Post-hoc testing showed that responding following intra-
VTA administration of the 500 ng/side CRF dose was significantly increased 
compared to vehicle (P<0.05).   Additionally, responding on the previously active 
lever was significantly increased in LgA rats compared to ShA and Saline rats 
following intra-VTA delivery of either 250 ng/side CRF (one-way ANOVA, 
F2,19=4.179, P<0.05; significant increase in LgA vs. either ShA or Sal, P<0.05, 
Bonferroni-corrected t-test) or 500 ng/side CRF (one-way ANOVA,  F2,19=23.103, 
P<0.001; significant increase in LgA vs. either ShA or Sal, P<0.05).  By contrast, 
we failed to find reinstatement effects or self-administration group effects on 
responding on the previously inactive lever or a reinstatement x group interaction 
(Figure 16D). 
 
 
Figure 16:  Self-administration, extinction, and reinstatement of cocaine seeking 
by intra-VTA injections of CRF in rats that self-administered cocaine under short-
access (ShA; 14 x 2 h/day) and long-access (LgA; 14 x 6h/day) conditions and in 
saline self-administration control rats.  Data in Figure 16A represent the daily 
mean hourly numbers of self-administered infusions (±S.E.) in ShA, LgA, and Sal 
rats across the 14-day test period.  Escalation was observed in LgA, but not ShA 
or Sal rats (**P<0.05 overall effect) and self-administration was increased in LgA 
rats compared to ShA (and Sal) rats on days 5 and 9-14 of self-administration 
(*P<0.05).  The cumulative total cocaine intake (mg/kg ± S.E.) in ShA and LgA 
rats is shown in the insert for Figure 16A.  Intake was markedly and significantly 
increased in LgA rats (**P<0.001 vs. ShA rats).  Responding (± S.E.) during the 
final self-administration session (represented as the 2-h mean in LgA rats) and 
the ten consecutive 2h extinctions sessions is shown in Figure 16B. Significant 
differences in extinction responding between ShA and LgA rats were not found. 
Significant intra-VTA CRF-induced reinstatement was observed in LgA but not 
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ShA rats, and CRF-induced responding was significantly higher in LgA rats 
compared to ShA rats and Sal controls at both doses tested (*P<0.05; 16C) and 
increased compared to vehicle at the 500 (but not 250) ng/side CRF dose 
(#P<0.05).  Effects on responding on the previously inactive lever during 
reinstatement testing were not found (16D). 
 
 
 
Effects of Intra-VTA CRF-R1 Receptor Antagonists on CRF-Induced 
Reinstatement  
 
 
 Bilateral intra-VTA pretreatment with the CRF-R1 receptor-selective 
antagonist antalarmin or CP-376395 blocked reinstatement by intra-VTA CRF 
(500 ng/side) in LgA rats (Figure 17).  The effect of antalarmin on CRF-induced 
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reinstatement (n=7) is shown in Figure 17A and the effect of CP-376395 on CRF-
induced reinstatement (n=6) is shown in Figure 17B.  In both cases, 2-way 
repeated measures (CRF vs. extinction; antagonist vs. vehicle) ANOVA showed 
significant main effects of CRF delivery (F1,6=12.603, P<0.05 for antalarmin; 
F1,5=6.920, P<0.05 for CP-376395), but not antagonist treatment, and significant 
interactions between CRF-R1 antagonist pretreatment and CRF-induced 
reinstatement (F1,6=5.696, P=0.05 for antalarmin; F1,5=9.120, P<0.05 for CP-
376395).  Intra-VTA CRF produced significant reinstatement following 
pretreatment with vehicle (P<0.01 for each experiment), but not antalarmin or 
CP-376395, and responding following intra-VTA CRF administration was 
significantly lower following antalarmin or CP-376395 pretreatment compared to 
vehicle pretreatment (P<0.01). 
 
Figure 17: Effects of intra-VTA injections of CRF-R1 receptor antagonists on 
reinstatement by intra-VTA CRF delivery and footshock stress in LgA rats.  Data 
represent the effects of bilateral injections of antalarmin (500 ng/side; 17A; n=7) 
or CP-376395 (500 ng/side; 17B; n=6) or vehicle on reinstatement by bilateral 
intra-VTA delivery of CRF (500 ng/side) and the effects of bilateral injections of 
antalarmin (500 ng/side) on reinstatement (responses/2-h session ± S.E.) by 
electric footshock (EFS; 17C; n=6).  In all cases, significant reinstatement was 
observed in rats pretreated with vehicle (*P<0.05 vs. Ext) but not CRF-R1 
receptor antagonists and responding during reinstatement was significantly lower 
following CRF-R1 receptor antagonists compared to vehicle (#P<0.05 vs. Veh). 
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Effects of Intra-VTA CRF-R1 Receptor Antagonism on Stress-Induced 
Reinstatement 
 
 
Antagonism of CRF-R1 receptors in the VTA also blocked footshock-
induced reinstatement in LgA rats (n=6; Figure 17C).  Two-way (footshock vs. 
extinction; antalarmin vs. vehicle) repeated measures ANOVA showed a 
significant overall effect of footshock (F1,5=28.817, P<0.01), but not antalarmin 
pretreatment, and a significant antalarmin x footshock interaction (F1,5=6.294, 
P=0.05).  Footshock stress produced significant reinstatement following 
pretreatment with vehicle (P<0.01), but not antalarmin, and responding following 
EFS was significantly lower following antalarmin pretreatment compared to 
vehicle pretreatment (P<0.01). 
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Effects of Intra-VTA CRF-R1 Receptor Antagonists on Food-Reinforced Lever 
Pressing 
 
In order to confirm that the effects of intra-VTA antalarmin and CP-376395 
on reinstatement were not attributable to non-specific motor impairments, effects 
on sucrose pellet-reinforced lever pressing were examined.  Neither intra-VTA 
antalarmin (185.83 ± 28.86 resp/30-min session vs. 211.80 ± 13.41 resp/session 
for vehicle) nor intra-VTA CP-376395 (192.67 ± 23.73 resp/30-min session vs. 
203.10 ± 13.17 resp/session for vehicle) significantly decreased food-reinforced 
responding at doses that blocked CRF- or footshock-induced reinstatement.  
When interpreting these findings, it is important to note that in contrast to our 
self-administration rats, these rats had no history of cocaine intake and were 
food-restricted, possibly altering their sensitivity to CRF-R1 receptor antagonism. 
Effects of Intra-VTA CRF-R2 Receptor Antagonists on CRF- and Stress-Induced 
Reinstatement 
 
 The effects of bilateral intra-VTA pretreatment with CRF-R2 receptor-
selective antagonists astressin-2B or ASV-30 on reinstatement by intra-VTA CRF 
(500 ng/side) are shown in Figures 18A and 18B.   The effects of the astressin-
2B on CRF-induced reinstatement (n=6) are shown in Figure 18A. 
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Figure 18: Effects of intra-VTA injections of CRF-R2 receptor antagonists on 
reinstatement by intra-VTA CRF delivery and footshock stress in LgA rats.  Data 
represent the effects of bilateral injections of astressin-2B (500 ng and 1 µg/side; 
18A; n=6) or ASV-30 (500 ng/side; 18B; n=6) or vehicle on reinstatement by 
bilateral intra-VTA delivery of CRF (500 ng/side) and the effects of bilateral 
injections of astressin-2B (500 ng/side) on reinstatement (responses/2-h session 
± S.E.) by electric footshock (EFS; 18C; n=8).  In all cases, significant 
reinstatement was observed in rats pretreated with vehicle or CRF-R2 receptor 
antagonists (*P<0.05 vs. Ext), while CRF-R2 receptor antagonist pretreatments 
failed to attenuate reinstatement by intra-VTA CRF or shock. 
 
We initially tested rats for the effect of astressin-2B at the 250 ng/side 
dose.  However, since this dose of astressin-2B did not attenuate reinstatement, 
we also tested rats with a 2-fold higher dose of astressin-2B (500 ng/side; 18A).  
Two-way repeated measures ANOVA examining the effects of both astressin-2B 
doses on reinstatement showed a significant overall effect of CRF-induced 
reinstatement (F1,5=52.077, P=0.001), but not astressin-2B pretreatment, and no 
significant astressin-2B x CRF reinstatement interaction.  Significant intra-VTA 
CRF-induced reinstatement was observed in rats pretreated with vehicle or either 
astressin-2B dose (P<0.01 for each comparison) and reinstatement was not 
significantly different following astressin-2B delivery when compared to vehicle 
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administration.  Likewise, intra-VTA pretreatment with ASV-30 failed to alter 
reinstatement by intra-VTA CRF (n=6; Figure 18B).  Two-way repeated 
measures ANOVA showed a significant overall effect of CRF-induced 
reinstatement (F1,5=8.462, P<0.05), but not ASV-30 pretreatment, and no 
significant ASV-30 x CRF reinstatement interaction.  Significant intra-VTA CRF-
induced reinstatement was observed in rats pretreated with vehicle or ASV-30 
(P<0.01) and reinstatement was not different following ASV-30 delivery when 
compared to vehicle administration. 
Effects of Intra-VTA CRF-R2 Receptor Antagonism on Stress-Induced 
Reinstatement 
 
Intra-VTA pretreatment with the CRF-R2 receptor-selective antagonist 
astressin-2B also failed to alter footshock-induced reinstatement (n=8; Fig 18C).  
As was the case with CRF-induced reinstatement, ANOVA showed a significant 
overall effect of footshock reinstatement (F1,7=20.587, P<0.01), but not astressin-
2B pretreatment, and no significant interaction.  Significant footshock-induced 
reinstatement was observed in rats pretreated with vehicle or astressin-2B 
(P<0.01) and reinstatement was not different following astressin-2B delivery 
when compared to vehicle. 
Reinstatement by Intra-VTA Administration of the CRF Receptor Agonists 
To further examine the role of VTA CRF-R1 and CRF-R2 receptors in 
reinstatement, the ability of bilateral intra-VTA injection of the selective CRF-R1 
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receptor agonist, cortagine (100 ng/side) or the selective CRF-R2 receptor 
agonist, rat Urocortin 2 (rUCN2; 250 ng/side), to reinstate cocaine seeking was 
examined in a separate group of LgA rats (n=5). Reinstatement was observed 
following intra-VTA delivery of cortagine but not rUCN2 (Figure 19).   
Figure 19:  Reinstatement by intra-VTA administration of the CRF-R1 receptor-
selective agonist, cortagine, and the CRF-R2 receptor-selective agonist, rUcn2, 
in LgA rats (n=5).  Cortagine (100 ng/side), but not rUcn2 (250 ng/side) or vehicle 
reinstated extinguished cocaine seeking (*P<0.05 vs. vehicle and the preceding 
extinction session).  Data represent responding on the cocaine lever 
(responses/2-h session ± S.E.) during extinction (ext) or following bilateral intra-
VTA cortagine or vehicle (Veh). 
 
 
 
 
 
 
A 2-way repeated measure ANOVA with reinstatement condition 
(extinction vs. intra-VTA treatment) and drug treatment (cortagine vs. vehicle) as 
factors showed a significant overall main effect of reinstatement (F1,4=17.316, 
P<0.05), but not cortagine treatment, and a significant reinstatement x cortagine 
treatment interaction (F1,4=7.626, P=0.05).  By contrast, an identical analysis 
examining rUCN2-induced reinstatement failed to show effects of rUcn2 
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treatment or reinstatement testing or a rUcn2 x reinstatement testing interaction. 
Intra-VTA cortagine treatment increased responding compared to the preceding 
extinction session (P<0.05) and compared to vehicle-treated rats (P<0.05). 
DISCUSSION  
 We have reported that self-administration under LgA/high-intake 
conditions augments later reinstatement by footshock stress and ventricular 
CRF (Mantsch et al., 2008a) and that footshock-induced reinstatement 
following LgA self-administration is CRF-dependent (Graf et al., 2011).  
These findings are consistent with prior reports that stress-induced 
reinstatement of drug seeking following self-administration of cocaine (Erb et 
al., 1998), heroin (Shaham et al., 1997), alcohol (Le et al., 2000) or nicotine 
(Bruijnzeel et al., 2009) involves CRF, as does stress-induced reinstatement 
of palatable food-seeking behavior (Ghitza et al., 2006).  
Our current findings demonstrate that heightened CRF responsiveness in 
the VTA likely contributes to intake dependent increases in vulnerability to stress-
induced relapse that emerge with repeated drug use.  Previous studies have 
reported that VTA CRF levels are increased during stress-induced reinstatement 
and that stress-induced cocaine seeking involves CRF actions in the VTA (Wang 
et al., 2005, Wang et al., 2007). Here we report that, similar to stress-induced 
reinstatement, reinstatement by intra-VTA CRF was augmented and, in fact was 
only observed, in rats with a history of self-administration under long-
access/high-intake conditions.  Further, we find that cocaine seeking induced by 
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CRF delivery into the VTA or by footshock is mediated by VTA CRF-R1 and not 
CRF-R2 receptors, a finding that contrasts with previous reports implicating CRF-
R2 receptors in the VTA in stress-induced reinstatement (Wang et al., 2005, 
Wang et al., 2007). 
A circuit involving the regulation of VTA dopaminergic neurons that project 
to the dorsal medial prefrontal cortex has been implicated in stress-induced 
relapse (McFarland et al., 2004).  According to this model, inputs from several 
regions, including the bed nucleus of the stria terminalis (BNST), the central 
nucleus of the amygdala (CeA), and the nucleus accumbens (NA) shell positively 
regulate mesocortical dopamine neurons in the VTA, thereby promoting cocaine 
seeking through activation of corticostriatal glutamatergic inputs into the NA core.   
It has been reported that the VTA receives CRF-containing afferents from two of 
these regions, the CeA and BNST (Rodaros et al., 2007) and dual 
immunolabeling studies indicate that these CRF-containing projections are 
primarily glutamatergic (Tagliaferro and Morales, 2008).  CRF containing 
afferents form synapses on dopaminergic and GABAergic cells in the VTA 
(Tagliaferro and Morales, 2008) and the activity of both cell types is altered upon 
local CRF application (Korotkova et al., 2006).  In the case of dopaminergic cells, 
CRF-positive synapses on are primarily asymmetric (Tagliaferro and Morales, 
2008), suggesting that CRF-releasing glutamatergic projections into the VTA, 
likely originating in the BNST and CeA, positively regulate the activity of 
dopaminergic cells.  Accordingly, delivery of CRF into the VTA stimulates local 
and terminal field dopamine release (Kalivas et al., 1987, Wang et al., 2005).  
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Although CRF-R1 receptors are abundant in the VTA, their expression on 
dopaminergic cells has been reported to be limited (Korotkova et al., 2006). 
However, preliminary findings from the Seasholtz laboratory reports more CRF-
R1 expression in dopamine than GABA neurons. This suggests that actions of 
CRF on dopaminergic cells may contribute to its effects on cocaine seeking.  
GABAergic and dopaminergic cells in the VTA likely express CRF-R1 receptors 
(Korotkova et al., 2006), however, the picture is less clear for CRF-R2 receptors.  
Despite pharmacological evidence for CRF-R2 receptor expression in the VTA 
(Wang et al., 2007), examination of the VTA using in situ hybridization suggests 
that there is little or no cell body expression (Van Pett et al., 2000).  However, 
CRF-R2 receptor expression has been reported as determined by reverse 
transcription-PCR (Korotkova et al., 2006).  The purported ability of CRF-R2 
receptors to locally regulate glutamate release suggests a potential presynaptic 
localization of CRF-R2 receptors on glutamate terminals (Wang et al., 2007).  A 
clear understanding of the localization of CRF-R2 receptors in the VTA awaits 
the availability of better antibodies for immunohistochemical characterization. 
The precise mechanism of CRF regulation of dopaminergic cells in the VTA is 
also unclear and has been reported to involve both CRF-R1 receptor-mediated 
activation of protein kinase C (Wanat et al., 2008) and possibly protein kinase A 
(PKA) (Riegel and Williams, 2008) signaling and/or CRF-R2 facilitation of NMDA 
receptor function (Ungless et al., 2003).  The CRF-R2 receptor effects on 
signaling also appear to require CRF interaction with CRF binding protein 
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(Ungless et al., 2003, Wang et al., 2007) and may also involve presynaptic 
enhancement of glutamate release (Wang et al., 2005, Wang et al., 2007). 
While our data implicate CRF actions in the VTA in stress-induced 
reinstatement, others have reported that CRF can act elsewhere within this 
circuit, including at sites upstream from the VTA, to regulate cocaine seeking, 
most notably in the BNST, where CRF receptor antagonism blocks stress-
induced cocaine seeking (Erb and Stewart, 1999).  As the CRF actions in the 
BNST involve projections from the CeA (Erb et al., 2001) and both regions send 
CRF containing efferents to the VTA (Rodaros et al., 2007), it is likely that CRF 
exerts actions at multiple sites in the circuit that contribute to stress-induced 
cocaine seeking. 
Similar to what we previously reported with stress-induced reinstatement 
(Mantsch et al., 2008a), reinstatement by intra-VTA CRF appeared to represent 
an emergent phenomenon in that it was only observed following LgA self-
administration.  This finding is consistent with a report by Wang et al. (2005), who 
found that while footshock-induced increases in VTA CRF were observed in the 
VTA, the ability of CRF to regulate dopamine and glutamate levels in the VTA 
required a history of cocaine self-administration.  The apparent augmentation of 
CRF responsiveness is also consistent with reports that CRF responsiveness in 
a number of brain regions is heightened following repeated cocaine 
administration (Erb et al., 2005, Liu et al., 2005, Pollandt et al., 2006, Orozco-
Cabal et al., 2008, Francesconi et al., 2009, Guan et al., 2009). Although the 
effects of LgA cocaine self-administration on CRF-R1 receptor-mediated actions 
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in the VTA have not been examined, some insight into potential mechanisms 
underlying heightened CRF regulation of cocaine seeking can be provided by 
studies involving repeated experimenter-delivered cocaine.  In the VTA, CRF-R1 
receptor activation has been reported to produce both excitatory effects on 
dopamine neurons via potentiation of NMDA and AMPA receptor-mediated 
neurotransmission (Hahn et al., 2009), and inhibitory effects via enhancement D2 
dopamine- and GABAB-receptor mediated regulation of G-protein activated 
inwardly rectifying potassium channels (Beckstead et al., 2009).  With repeated 
cocaine exposure, the excitatory effects of CRF-R1 activation are augmented 
(Hahn et al., 2009), while the inhibitory effects diminish (Beckstead et al., 2009), 
likely resulting in a net shift towards positive CRF-R1 receptor regulation of 
dopaminergic cells in the VTA.  Further, CRF binding in the VTA, as measured 
using autoradiography, is increased with repeated cocaine delivery (Goeders et 
al., 1990). 
Our findings that VTA CRF-R1 receptors mediate CRF- and stress-
induced cocaine seeking are inconsistent with previous reports suggesting 
involvement of CRF-R2 receptors in the VTA, apparently through a mechanism 
that also involves CRF binding protein (Wang et al., 2005, Wang et al., 2007).  
However, others have reported that stress-induced reinstatement is inhibited by 
systemic or ventricular delivery CRF-R1, but not CRF-R2, receptor antagonists 
(Shaham et al., 1998, Lu et al., 2001) and that CRF-R1 but not -R2 receptor 
antagonism can reduce evoked increases in VTA and NAc dopamine (Lu et al., 
2003a, Lodge and Grace, 2005).  The reason for the discrepancy between our 
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findings and those of Wang et al. is unclear but may involve different modes of 
CRF and receptor antagonist delivery (microinjection vs. reverse dialysis), 
different CRF receptor antagonist and agonist doses, different rat strains, and 
differential experimental histories.  Most importantly, it may be that the regulation 
of cocaine seeking by CRF-R1 receptors in VTA requires a prior history of very 
high levels of cocaine intake (daily cocaine intake reported by Wang et al. was 
approximately 33 mg/kg compared to more than 70 mg/kg in our LgA rats), 
consistent with reports that the selective CRF-R1 antagonists only reduce 
cocaine self-administration following escalation in LgA rats (Specio et al., 2008). 
The ability of stressful life events to precipitate drug use through actions 
involving CRF-R1 receptors in the VTA may represent an emergent 
consequence of excessive cocaine use.  Identification of the precise mechanisms 
through which VTA CRF-R1 receptor activation produces cocaine seeking and 
the neuroadaptations that contribute to heightened susceptibility to CRF-
dependent reinstatement should provide important insight into how stressor 
responsiveness changes in cocaine addicts in a way that promotes further use. 
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CHAPTER 3 
 
EFFECTS OF COCAINE SELF-ADMINISTRATION ON BASAL AND STRESS-
INDUCED ACTIVATION OF DOPAMINE CELLS IN THE VTA IN RATS: 
RELATIONSHIP TO STRESS-INDUCED COCAINE SEEKING 
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ABSTRACT 
The ventral tegmental area (VTA) is a key site for stress-induced regulation of 
illicit drug use.  Here we investigate the relationship between stress-induced 
cocaine seeking, measured using the self-administration (SA)/reinstatement 
approach in rats, and activation of VTA dopamine (DA) cells.  Previous work has 
demonstrated that footshock-induced reinstatement is more pronounced and DA 
alterations are more evident in rats that have a history of cocaine SA under daily 
long-access (LgA) conditions.  We examined basal and stress-induced Fos 
expression in DA (tyrosine hydroxylase/TH-positive) cells in the VTA using dual 
immunohistochemistry following testing for footshock-induced reinstatement or 
under basal conditions in rats with a history of LgA (14 x 6 hrs/day), short-access 
(ShA; 14 x 2 hrs/day) and saline (Sal) SA.  Despite overall differences in TH-
positive cell Fos expression across groups (ShA, but not LgA rats had more Fos-
expressing TH-positive cells vs. saline controls), significant stress-induced 
increases in DA cellular Fos reactivity were not observed in any SA access 
group.  However, when examined across groups, the percentage of TH-positive 
cells expressing Fos following stress-induced reinstatement was positively 
correlated with reinstatement magnitude.  Compared to non-stress and saline 
controls and non-reinstating rats, the number and percentage of VTA Fos-
expressing TH-positive cells were significantly increased in rats that displayed 
stress-induced reinstatement.  These data suggest that stress-induced cocaine 
use is associated with the activation of DA cells in the VTA and likely with 
elevated DA levels in target regions. 
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INTRODUCTION 
 It is well established that stress contributes to relapse to drug use in 
cocaine users (Marlatt, 1980). Reports that stressful life events promote relapse 
are paralleled by findings that, in a laboratory setting, audiotaped scripts 
describing past stressful events can elicit craving in cocaine-dependent 
individuals (Sinha et al., 1999). Notably, prior history of higher-frequency cocaine 
use is associated with augmented stress-induced craving (Fox et al., 2005), with 
measures of stress-induced craving positively correlated with higher relapse 
rates (Sinha et al., 2006). Thus, the ability of stress to regulate cocaine use may 
intensify with excessive use as a result of intake-dependent drug-induced 
neuroadaptations. 
In rats, stress-induced relapse can be examined by determining the 
ability of electric footshock to reinstate extinguished cocaine seeking following 
intravenous self-administration (SA) (Shaham et al., 2003).  As is the case with 
stress-induced craving in humans, the ability of footshock to reinstate cocaine 
seeking is dependent on use history.  We have reported that reliable footshock-
induced reinstatement is observed in rats with a history of daily long-access 
(LgA) SA (14 x 6 hrs daily), a condition that results in high levels of drug intake 
and escalating patterns of use, but not in rats that undergo daily testing under 
short-access (ShA) SA conditions (14 x 2 hrs daily) (Mantsch et al., 2008a).  
Understanding the mechanisms that underlie stress-induced reinstatement and 
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its intake-dependent augmentation in rats could guide the development of 
treatment aimed at relapse prevention. 
VTA dopamine (DA) cells have been implicated in stress-induced cocaine 
seeking.   Extracellular DA in the VTA, likely reflecting somatodendritic release, is 
elevated during footshock-induced reinstatement following SA in rats (Wang et 
al., 2005), while transient inhibition of the VTA prevents stress-induced cocaine 
seeking (McFarland et al., 2004).    In particular, DA projections to the medial 
prefrontal cortex (mPFC) appear to mediate stress-induced cocaine seeking, as 
administration of DA D1 receptor antagonists into the mPFC prevent 
reinstatement (Capriles et al., 2003, Sanchez et al., 2003, McFarland et al., 
2004).   Although these findings suggest that stressors activate DA cells in the 
VTA to promote drug use, studies examining the effects of stressors on VTA DA 
neuronal activity and mesocorticolimbic DA neurotransmission have produced 
mixed results, with reports of both increases and decreases in cellular activity 
(Ungless et al., 2004, Brischoux et al., 2009) and terminal field DA release 
(Deutch et al., 1985, Abercrombie et al., 1989, Kalivas and Duffy, 1995, Tidey 
and Miczek, 1996, Di Chiara et al., 1999, Roitman et al., 2008, Oleson et al., 
2012).   
One approach for studying neurocircuitry that contributes to cocaine 
seeking involves examination of the expression of the immediate early gene c-
Fos.  For example, cue-induced reinstatement of cocaine seeking is associated 
with increased Fos immunoreactivity in the VTA (Kufahl et al., 2009) and in 
regions from which it receives projections (Briand et al., 2010, Mahler and Aston-
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Jones, 2012).  Stressors also increase VTA Fos expression (Deutch et al., 1991), 
and augment the subsequent induction of VTA Fos expression by other stimuli, 
including abused drugs (Nikulina et al., 2004, Miczek et al., 2011).  However, the 
exact relationship between stress-evoked increases in Fos expression in VTA DA 
cells and stress-induced cocaine seeking is unclear. 
We have found that augmented stress-induced reinstatement in rats with a 
history of LgA cocaine SA involves increased VTA responsiveness to 
corticotropin releasing factor (CRF) (Blacktop et al., 2011), suggesting that 
heightened stressor-induced reactivity of the mesocorticolimbic DA system may 
determine relapse susceptibility.   In this study we investigate this possibility by 
examining stress-induced activation of VTA DA cells, defined by the 
number/percentage of Fos expressing tyrosine hydroxylase- (TH) positive cells, 
in rats with a history of ShA or LgA SA or control rats with a history of access to 
saline for SA.  We hypothesize that footshock-induced increases in the number 
of Fos-expressing TH-positive cells would be more pronounced after LgA SA and 
therefore would correspond to the magnitude of stress-induced reinstatement.   
MATERIALS AND METHODS 
Subjects 
 Adult male Sprague–Dawley rats (Harlan Laboratories, St. Louis) were 
housed individually under a 12-h/12-h reversed light/dark cycle (lights on at 7:00 
PM) in a temperature and humidity controlled AAALAC-accredited animal facility. 
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All procedures were carried out in accordance with the NIH Guide for the Care 
and Use of Laboratory Animals. 
Catheter Implantation and Self-Administration 
 Rats were implanted with jugular catheters under ketamine HCl (100 
mg/kg, ip) and xylazine (2 mg/kg, ip) anesthesia (Mantsch et al., 2008a, Blacktop 
et al., 2011, Graf et al., 2011). After recovery, rats were assigned to a cocaine 
SA or saline control (Sal) group.  Rats in the SA groups were trained to self-
administer cocaine (1.0 mg/kg/inf, iv; NIDA) by pressing a lever under a FR1 
schedule during daily 2-h sessions, within which the active lever was extended 
into the chamber and the corresponding stimulus light was illuminated.  Rats in 
the Sal group were tested under identical conditions except that saline was 
available.  Lever pressing resulted in an iv infusion of drug or saline solution (200 
μl over 5 s) followed by a 25-s time-out period during which the stimulus light was 
extinguished but the lever remained extended. Response requirements were 
increased until rats displayed stable responding (within 10% of the 3-session 
mean) under an FR4 schedule was observed, at which time rats were assigned 
to groups according to their SA conditions for the next 14 days: ShA rats (n=20) 
continued to have access to cocaine for two hours daily; LgA rats (n=20) were 
provided access to the same cocaine dose for six hours daily.  Sal rats (n=20) 
continued to have access to saline for SA.  
 
126 
 
Stress-Induced Reinstatement 
 Following SA testing, ShA and LgA rats underwent extinction training for 
ten consecutive 2-h sessions during which the cocaine solution was replaced by 
saline. Sal rats continued to have saline access over this 10-day period.  After 
extinction, ShA, LgA and Sal rats were further divided into subgroups according 
to their test conditions prior to sacrifice.  Half of the rats in each group 
(n=10/subgroup) were placed in the chambers and underwent testing for 
footshock-induced reinstatement.  Over a 15-min period prior to the 
reinstatement session, intermittent shocks (0.5 mA, 0.5” duration, average every 
40 sec; range 10-70 sec) were delivered through the grid floors of the chambers.  
During the shock period, the houselight was illuminated, the levers were 
retracted, and stimulus lights were extinguished.  After the shock period, the 
response levers were extended into the chamber, the houselight was 
extinguished and the stimulus light above the previously active lever was 
illuminated.  Reinstatement was defined as responding on the lever previously 
reinforced by cocaine during the 2-h session, which was otherwise identical to 
extinction sessions.  We have reported that these shock parameters produce 
robust reinstatement after LgA, but not ShA, SA and do not increase responding 
in Sal rats (Mantsch et al., 2008a, Blacktop et al., 2011, Graf et al., 2011)).  Non-
shocked control rats (n=10/ subgroup) were placed into the chambers for fifteen 
minutes with no shock exposure prior to undergoing an additional extinction 
session.   
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Tissue Processing 
 Immediately following the 2-h reinstatement/control session, rats were 
perfused transcardially with 300 ml of 0.5 M potassium phosphate buffered saline 
(KPBS) followed immediately by 300 ml of 4% paraformaldehyde in potassium 
phosphate buffer pH 6.8. Brains were removed and post-fixed in 4% 
paraformaldehyde overnight at 4°C, then stored in 30% sucrose until they sank, 
which occurred within 48 hours. Brains were then cut into a series of 40-µm 
sections with a sliding microtome and placed immediately into cryoprotectant at -
20°C to prevent freezing during storage.  
Immunohistochemistry 
 Fos is an indicator of neuronal activation (Sagar et al., 1988) and TH is a 
marker for DA neurons (Hokfelt, 1984). Therefore, co-localization of nuclear Fos 
and cytoplasmic TH is indicative of a recently activated DA neuron. In order to 
detect co-labeling, contrasting compartmentalized labeling of Fos and TH is 
necessary.  The immunohistochemical approach described was optimized for this 
purpose in preliminary experiments using acute ip treatment of 5 mg/kg D-
amphetamine, a treatment shown to significantly induce Fos in VTA neurons 
(Rotllant et al., 2010). 
Sequential identification of co-labeled Fos and TH positive neurons via 
color immunoperoxidase staining was conducted using a protocol modified from 
Hoffman et al., (2008). Four consecutive sections containing the VTA (~ -5.52 to -
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5.76 mm A/P from bregma) were collected from each rat in each treatment 
condition. Free floating sections were washed in 0.5 M KPBS and incubated in 
1% hydrogen peroxide in KPBS for 15 min to block endogenous peroxidase 
activity. Sections were washed again and incubated in primary polyclonal rabbit 
anti-Fos antibody (sc-52, Santa Cruz Biotechnology; 1:10,000) in KPBS 
containing 0.4% triton X-100 first for one hr at room temperature then 24 hr at 
4°C. The next day sections were washed again then incubated for one hour in 
biotinylated goat anti-rabbit IgG secondary antibody (Vector Laboratories; 1:600) 
in KPBS containing 0.4% triton X-100. Sections were washed once again then 
incubated for one hr in A/B solution (Vectastain Elite ABC kit; Vector 
Laboratories). After another series of washes, sections were incubated in 0.175 
M sodium acetate (pH 7.0). Activity was visualized with nickel diaminobenzidine 
(DAB substrate kit; Vector Laboratories) and the reaction was terminated after 20 
min by washing first in 0.175 M sodium acetate then KPBS (Hoffman et al., 
2008). 
After Fos processing, sections were treated with blocking solutions to 
block nonspecific avidin and biotin binding sites (Avidin/Biotin Blocking Kit; 
Vector Laboratories). Sections were incubated in avidin blocking solution for 15 
min, washed, incubated in biotin blocking solution for 15 min, and then washed. 
This step is critical for specific biotinylated goat anti-mouse antibody binding to 
the mouse anti-TH primary antibody. Following the avidin biotin blocking step, 
sections were incubated in primary monoclonal mouse anti-TH antibody (MAB-
318, Chemicon; 1:300,000) in KPBS containing 0.4% triton X-100 first for 1 hr at 
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room temperature, then 24 hr at 4°C. Sections were washed then incubated for 
one hour in biotinylated goat anti-mouse IgG secondary antibody (Vector 
Laboratories; 1:600) in KPBS containing 0.4% triton X-100. Sections were 
washed again then incubated in for one hour in A/B solution (Vectastain Elite 
ABC kit; Vector Laboratories). After another series of washes, sections were 
incubated in 0.1 M Tris buffer (pH 7.5). Activity was visualized with DAB (DAB 
substrate kit; Vector Laboratories) as described for Fos. Following termination of 
the last reaction after 4 mins with 0.1 M Tris buffer (PH 7.5), sections were 
mounted onto superfrost plus glass slides (VWR International) and allowed to air 
dry overnight, dehydrated, xylene cleared and coverslipped. 
Counting of labeled cells 
 Bilateral photomicrographs of four consecutive 40-µm sections VTA 
sections (~ -5.52 to -5.76 A/P coordinates; (Paxinos, 2004)) containing the 
parabrachial (PBP), parainterfascicular (PIF), and paranigral nuclei (PN) of the 
VTA were acquired at 20X using a Zeiss Axioscop microscope (Axioscop-2; 
Zeiss, Thornwood, NY) and Axiovision software (Zeiss) by an experimenter blind 
to treatment condition.  Selection of this area was based on earlier findings that 
CRF-R1 receptor antagonist administration into this region prevents footshock-
induced reinstatement while CRF delivery into this region reinstates (Paxinos, 
2004, Blacktop et al., 2011). The DA neurons in this VTA subregion are most 
responsive (Fos) to rewarding stimuli and have the highest percent of DA 
neurons (Zhao-Shea et al., 2011). 
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Fos immunoreactive (ir) neurons were identified by a dark purple/black 
oval-shaped immunoprecipitate in the nucleus. TH-ir neurons were identified by 
light brown cytoplasmic staining. This allowed for the identification of TH-ir cells 
with or without Fos-ir. TH-ir/Fos-ir neurons were identified as cells with dark 
purple/black nuclear Ni-DAB staining surrounded by light brown cytoplasmic DAB 
staining. The numbers of TH-ir, Fos-ir, and TH/Fos-ir neurons in the VTA were 
counted in each series of sections by an experimenter blind to the treatment 
condition.  In addition to the number, the percentage of TH-ir cells that co-
expressed Fos was calculated.  
Data Analysis 
 In order to ensure similar withdrawal periods across conditions, all rats 
were perfused no more than two weeks after the last SA session.  As a result, 
cocaine seeking was not fully extinguished in some rats at the time of testing.   
SA rats displaying more than 25 responses during the final extinction session 
prior to sacrifice (i.e., non-extinguished rats) were removed from the analyses.  A 
total of ten rats (five ShA and five LgA) were excluded based on this criterion (60-
10 = n of 50).  Statistical analyses were conducted using Predictive Analytics 
SoftWare statistics software (SPSS).  Differences in SA among Sal, ShA and 
LgA rats were assessed using 2-way SA condition x test day (repeated measure) 
ANOVA.  Reinstatement in each group was defined as a significant increase in 
responding relative to the prior extinction session using paired Student’s t-tests.  
Differences in the numbers of Fos-ir, TH-ir, and TH-ir/Fos-ir cells and percentage 
131 
 
of TH-ir cells expressing Fos across SA groups and in response to footshock 
were determined using 2-way SA condition x stress condition ANOVA followed 
by post-hoc testing using Bonferroni-corrected t-tests.  The relationship between 
reinstatement and Fos reactivity was assessed using linear regression analysis.  
Since, in contrast to earlier finding (Mantsch et al 2008), about 30% of ShA rats 
showed footshock-induced reinstatement while about 40% of LgA rats did not, 
we examined differences in Fos reactivity between rats that reinstated, rats that 
did not reinstate, and rats not exposed to shock, as well as Sal controls, using 
one-way ANOVA followed by post-hoc testing using Bonferroni-corrected t-tests.  
For this analysis, reinstatement was defined as an increase in responding by at 
least ten responses relative to the prior extinction session.  For all analyses, 
significance was defined as P<0.05. 
RESULTS 
Cocaine SA and Extinction 
 SA on days one and 14 of testing in rats provided 14 days of ShA (2 hrs) 
or LgA (6 hrs) to cocaine or Sal access is shown in Figure 20A.   To permit 
comparison across groups, hourly SA was assessed and is shown in Figure 20B.  
Two-way SA group x day ANOVA comparing day one and 14 infusions in ShA, 
LgA and Sal rats, showed a significant SA group x test day interaction 
(F2,47=3.67; P<0.05).  Post-hoc testing showed that the number of hourly 
infusions was significantly increased in LgA, but not ShA or Sal, rats on day 14 
vs. day one (P<0.05) and that on day 14, but not day one, SA was greater in LgA 
132 
 
vs. ShA rats (P<0.05).  Thus, as has been reported (Ahmed and Koob, 1998, 
Mantsch et al., 2004), escalated SA was observed in LgA, but not ShA rats.  ShA 
and LgA rats did not significantly differ in extinction responding (Figure 20C). 
 
Figure 20: Self-administration and extinction responding in ShA, LgA, and Sal 
control rats.  Data represent A) the mean total (infusions/session) and B) hourly 
(infusions/hr) self-administration (SA) on days 1 and 14 of daily SA and C) 
extinction (responses/2 hrs) of cocaine seeking in rats tested under short-access 
(ShA; 14 x 2 hrs/day) or long-access (LgA; 14 x 6 hrs/day) conditions or under 
saline control (Sal) conditions.  Escalation of SA was determined based on 
differences in hourly SA.  Two-way ANOVA followed by post-hoc testing showed 
that escalation was observed in LgA (P<0.05 day 14 vs. day) but not ShA and Sal 
rats and that SA on day 14 was increased in LgA rats compared to ShA rats 
(P<0.05).  Differences between ShA and LgA rats in extinction responding were 
not observed. 
 
Footshock-Induced Reinstatement of Cocaine Seeking 
 Footshock-induced reinstatement in ShA, LgA and Sal rats is shown in 
Figure 21.   Responding on the active lever on the final day of extinction and 
following footshock is shown in Fig. 21A.  Significant reinstatement was observed 
in LgA (increased responding vs. extinction; paired 2-tailed t8=3.126; P<0.05) but 
not ShA rats.  However, in contrast to previous findings that footshock-induced 
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reinstatement was observed in virtually all LgA rats and no ShA rats (Mantsch et 
al., 2008a), in this study, reinstatement was observed in 30% of ShA rats and 
only 60% of LgA animals.  The mean change in lever pressing in each group 
relative to the previous extinction session is shown in Figure 21B.  One-way 
ANOVA failed to show an overall effect of SA group on footshock-induced 
reinstatement. 
 
Figure 21: Footshock-induced reinstatement of cocaine seeking in ShA and LgA 
rats.    Data represent A) responding on the active lever on the final day of 
extinction (Fig. 21A; white bar) and following footshock, prior to Fos 
measurement, in ShA (grey bar) and LgA (black bar) rats and B) Footshock-
induced increases in active lever presses in ShA and LgA animals as compared 
to saline controls.  Although significant reinstatement was observed in LgA, but 
not ShA, rats (*P<0.05 vs. extinction), significant differences in the magnitude of 
reinstatement were not observed across SA groups and individual variability in 
reinstatement was observed in each group. 
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Effects of SA Condition on Fos Expression in VTA DA Cells 
 Table 1 shows the numbers of TH- and Fos-ir cells in the VTA following 
footshock or under control conditions in ShA, LgA and Sal rats.  Two-way 
ANOVA failed to show significant main effects of SA condition or footshock on 
the numbers of TH- or Fos-ir VTA cells or significant group x footshock 
interactions.  However, although no differences were observed, there was much 
within-group variability.  For this reason, when examining Fos reactivity, both the 
total number of Fos-/TH-ir and percentage of TH-ir cells showing Fos-ir were 
assessed. 
 
Table 1: Total numbers of TH-positive (TH+) and Fos-positive (Fos+) cells in the 
VTA (±S.E.) following footshock (Shock) or under control (No Shock) conditions 
in rats with a history of Saline, ShA or LgA SA. 
 
 
 
The number and percentage of TH-ir cells co-expressing Fos under 
footshock reinstatement or control conditions following Sal, ShA or LgA SA are 
shown in Figures 22A (number of cells) and 22C (percentage of cells).  Two-way 
ANOVA revealed a significant overall effect of SA condition on both the number 
(F
2,43
=3.612;P<0.05) and percentage (F
2,43
=4.591;P<0.05) of TH-ir cells that 
SA CONDITION:            Saline       ShA          LgA 
 Ctrl EFS Ctrl EFS Ctrl EFS 
TOTAL TH+  
VTA CELLS 
367.33 
±64.74 
280.90 
±61.42 
316.00 
±79.29 
465.44 
±64.74 
234.00 
±79.29 
255.89 
±64.74 
 
TOTAL FOS+  
VTA CELLS 
310.78 
±130.59 
354.3 
±104.45 
504.00 
±159.94 
573.56 
±130.59 
282.00 
±159.94 
451.78 
±130.59 
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were also Fos-ir. However significant overall effects of footshock or SA condition 
x footshock interactions were not observed.  Figures 22B (number of Fos-ir DA 
cells) and 22D (percentage of Fos-ir DA cells) represent the data collapsed 
across shock conditions.  Post-hoc analyses showed that, overall, both the 
number and percentage of Fos-ir VTA DA cells were increased in ShA, but not 
LgA rats, compared to Sal controls (P<0.05), suggesting that 1) DA cells are 
activated in rats with a history of ShA SA, regardless of whether or not rats are 
exposed to shock and 2) the activation of DA cells is blunted or absent in LgA 
rats. 
 
Figure 22:  Fos-expressing DA cells in the VTA following footshock in ShA, LgA, 
and Sal rats.  Data represent the number (A and B) and percentage (C and D) of 
TH-positive cells co-expressing Fos in the VTA of Sal, ShA, and LgA rats.  
Panels A and C depict Fos expression in DA cells in rats tested under extinction 
conditions (Ext) and in rats that underwent testing for footshock-induced 
reinstatement of cocaine seeking (Shock).  Two-way ANOVA showed significant 
main effects of SA condition (P<0.05) but not footshock on both the numbers and 
percentages of Fos-expressing DA cells and failed to show a significant 
interaction between SA condition and footshock.  Overall differences across 
treatment conditions are shown in panels B and D.  Post-hoc testing showed that 
overall increases in both the number (B) and percentage (D) of Fos-expressing 
DA cells were increased in ShA, but not LgA, rats compared to Sal controls 
(P<0.05). 
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Representative photomicrographs showing immunoperoxidase staining for 
nuclear Fos and cytoplasmic TH in Sal (23A/D.), ShA (23B/E), and LgA (23C/F) 
rats are presented in Figure 23. Figures 23D, 23E, and 23F are higher 
magnification photomicrographs of the area within the black perimeter in 23A, 
23B, and 23C, respectively. Figure 23G illustrates the area of interest in the VTA 
used for analysis, which includes the PBP, PIF, and PN of the VTA. 
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Figure 23: Photomicrographs showing Fos-, TH-, and combined Fos-/TH- 
immunoreactive cells in the VTA from representative sections from ShA, LgA, 
and Sal rats.  The photomicrographs display the midbrain magnified at 20X from 
sections labeled using anti-Fos and anti-TH antibodies from a Sal control rat (A) 
or rats that underwent ShA (B) or LgA (C) SA testing. D, E, and F are higher 
magnification photomicrographs of the area within the black perimeter in A, B, 
and C, respectively. TH-positive only cells are indicated by white arrows, and TH-
positive cells with Fos-positive nuclei are indicated by black arrows.   Panel G 
shows the target area (box) including the parabrachial (PBP), parainterfascicular 
(PIF), and paranigral nuclei (PN) of the VTA at -5.76 mm posterior to bregma 
using the RMC (magnocellular part of the red nucleus) as an anatomic reference 
(Paxinos and Watson, 2004).  The reticule in panel A represents 100 µm.  
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Relationship between Fos Expression in VTA DA Cells and Shock-Induced 
Reinstatement 
 
 
Since there was variability in footshock-induced reinstatement in both ShA 
and LgA rats, we conducted linear regression to examine the relationship 
between the magnitude of cocaine seeking following footshock and the number 
of VTA Fos-ir DA cells (Figure 24).  A significant positive correlation was 
observed between the number of TH-ir/c-fos-ir cells and EFS-induced 
reinstatement defined as either the total number of responses during testing 
(R2=0.279; F1,19= 6.976; P<0.05; Figure 24) or the increase relative to the prior 
extinction session (R2=0.245; F1,19= 5.854; P<0.05; not shown).  The relationship 
between VTA DA cell Fos expression and footshock-induced cocaine seeking 
was stronger in ShA rats (R2=0.449; P<0.05), but was also present, although not 
statistically significant, in LgA rats (R2=0.314; P=0.09).  By contrast, no significant 
correlations between TH-ir/Fos-ir cell numbers in the VTA and cocaine seeking in 
the absence of footshock were observed.  
 
 
Figure 24: Scatter plot with regression line depicting the relationship between 
stress-induced cocaine seeking and the activation of DA cells in the VTA.   When 
rats with a history of ShA and LgA SA were combined, a significant positive 
correlation was observed between the total number of Fos-labeled TH-positive 
cells in the VTA and active lever responding during testing for footshock-induced 
reinstatement (R2=0.279; P<0.05).  Closed circles represent LgA rats.  Open 
circle represent ShA rats. 
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To further the examine the relationship between the activation of DA cells 
in the VTA and stress-induced cocaine seeking, we compared Fos-ir in TH-
positive cells among rats that 1) demonstrated footshock-induced reinstatement 
(increase ≥ 10 responses vs. extinction), 2) failed to demonstrate reinstatement, 
and 3) were not exposed to footshock - in each case regardless of if they had 
undergone ShA or LgA SA.  Immunoreactivity in these rats was also compared to 
shocked and non-shocked Sal rats.  Differences in footshock-induced cocaine 
seeking between “reinstated” and “non-reinstated” rats are shown in Figure 25.   
Due to an imbalanced design, differences in the numbers and percentages of 
Fos-ir and/or TH-ir cells in the VTA were analyzed using one-way ANOVA 
comparing the following groups: 1) rats with a history of SA (ShA or LgA) but not 
exposed to footshock; 2) rats with a history of SA (ShA or LgA) that displayed 
footshock-induced reinstatement; 3) rats with a history of SA (ShA or LgA) that 
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did not display footshock-induced reinstatement; 4) Sal control rats the received 
footshock; and 5) Sal control rats that did not receive footshock. 
 
Figure 25:  Footshock-induced cocaine seeking in rats classified according to 
footshock-induced reinstatement.   Rats were classified as reinstated and non-
reinstated according to whether or not they displayed footshock-induced 
reinstatement (see Materials and Methods).  Active lever presses (± S.E.) under 
extinction conditions and during testing for footshock-induced reinstatement in 
responders and non-responders is shown in panel A (*P<0.001 vs. extinction).  
The magnitude of reinstatement defined as the mean increase in responding 
relative to the prior reinstatement session (± S.E.) is shown in panel B. 
 
 
 
  
 
 
 
 
 
 
 
 
 Table 2 shows the numbers of TH-ir and Fos-ir cells in the VTA in each of 
the groups.  One-way ANOVA failed to show differences across conditions in TH-
positive or Fos-positive cell numbers.  However, since there was much within-
group variability, when examining Fos reactivity, both the total number of Fos-
/TH-ir and percentage of TH-ir cells showing Fos-ir were assessed. 
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Table 2: Total numbers of TH-positive (TH+) and Fos-positive (Fos+) cells in the 
VTA (±S.E.) following footshock (Shock) in saline control rats (Sal SA), cocaine 
self-administering rats that displayed footshock-induced reinstatement (Coc 
SA/Resp), and self-administering rats that did not reinstate (Coc SA/Non-Resp) 
and in cocaine self-administering rats (Coc SA) and saline controls (Sal SA) that 
did not receive footshock (No Shock). 
 
SA CONDITION:     SHOCK               NO SHOCK 
 Sal SA Coc SA/ 
Resp 
Coc SA/ 
Non-Resp 
Sal SA Coc SA 
TOTAL 
TH+ 
VTA 
CELLS 
280.90 
±43.63 
476.56 
±97.74 
307.90 
±62.14 
367.33 
±63.44 
275.00 
±59.03 
TOTAL 
FOS+ 
VTA 
CELLS 
354.3 
±110.32 
620.56 
±138.06 
414.70 
±140.49 
310.78 
±87.26 
393.00 
±117.47 
 
 
The number and percentage of VTA DA cells expressing Fos under each 
condition are depicted in Figure 26.  One-way ANOVA showed significant group 
effects on both the number of Fos-expressing TH-positive cells (F2,28=5.346; 
P<0.05; 26A) and the percentage of TH-positive cells expressing Fos 
(F2,28=6.690; P<0.01; 26B).  Post-hoc testing showed that both the number and 
percentage of VTA cells that displayed dual TH-/Fos-ir were significantly 
increased in rats in which reinstatement was observed, but not in non-reinstating 
rats or rats not exposed to footshock, compared to Sal controls (P<0.05).  Thus, 
DA cells in the VTA were only activated when footshock produced cocaine 
seeking. 
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Figure 26:  Fos-expressing DA cells in the VTA following footshock in rats 
classified based on the expression of footshock-induced cocaine seeking.  Data 
represent the number (panel A) and percentage (panel B) of TH-positive cells co-
expressing Fos in the VTA following footshock (Shock) in saline control rats 
(Sal), cocaine self-administering rats that displayed footshock-induced 
reinstatement (Coc/Reinst), and self-administering rats that did not reinstate 
(Coc/Non-Reinst) and cocaine self-administering rats (Coc) and saline controls 
(Sal) that did not receive footshock (No Shock).  Shock only increased the 
number of Fos-expressing DA cells in the VTA in rats that expressed footshock-
induced cocaine seeking (Coc/Resp rats; P<0.05 vs. Sal rats). 
 
 
Representative photomicrographs showing staining for VTA nuclear Fos 
and cytoplasmic TH in cocaine experienced animals that did not receive 
footshock (Fig. 27A/D), cocaine experienced that received footshock and 
reinstated (Fig. 27B/E), and experienced animals that received footshock and did 
not reinstate (Fig. 27C/F) are shown in Figure 27. Figures 27D, 27E, and 27F are 
higher magnification photomicrographs of the area within the black perimeter in 
27A, 27B, and 27C, respectively. 
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Figure 27: Photomicrographs showing footshock-induced increases Fos-, TH-, 
and dual Fos-/TH- immunoreactive cells in the VTA in reinstating but not non-
reinstating rats.  The photomicrographs display the VTA magnified at 20X from 
sections labeled using anti-Fos and anti-TH antibodies from a representative rat 
that self-administered but did not receive footshock (A), a rat that displayed 
footshock-induced reinstatement (B) and a rat that did not engage in cocaine 
seeking following footshock exposure (C).  D, E, and F are higher magnification 
photomicrographs of the area within the black perimeter in A, B, and C, 
respectively. TH-positive only cells are indicated by white arrows, and TH-
positive cells with Fos-positive nuclei are indicated by black arrows. 
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DISCUSSION 
 Evidence suggests that activation of the VTA is involved in stress-induced 
relapse to cocaine use.  However, the exact relationship between stress-induced 
cocaine seeking and the activity of DA cells in the VTA is not well understood.  
Here we demonstrate that stress-induced reinstatement following cocaine SA 
and extinction in rats is associated with the recruitment of VTA DA cells VTA, as 
defined by Fos expression in TH-positive cells.   In rats with a history of cocaine 
SA, regardless of whether it was ShA or LgA, footshock stress only increased the 
number of Fos-expressing DA cells in the VTA when it reinstated cocaine 
seeking.  Furthermore, the magnitude of footshock-induced reinstatement was 
positively correlated with both the number and percentage of Fos-expressing DA 
cells.  The association between stress-induced cocaine seeking and activation of 
DA cells is consistent with reports that extracellular VTA DA levels are increased 
during footshock-induced cocaine seeking following SA (Wang et al., 2005). 
Furthermore, it has been reported that 1) pharmacological manipulations of the 
VTA disrupt stress-induced reinstatement of cocaine seeking (McFarland et al., 
2004, Blacktop et al., 2011); and 2) DA D1 receptor antagonist administration into 
the mPFC prevents stress-induced reinstatement (Capriles et al., 2003, Sanchez 
et al., 2003, McFarland et al., 2004), suggesting that there is a causal 
relationship between stress-induced activation of DA cells in the VTA, particularly 
those that project to the mPFC, and stress-induced cocaine seeking. 
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 Since we previously reported that footshock reinstates cocaine seeking in 
LgA but not ShA rats (Mantsch et al., 2008a), the initial objective of this study 
was to compare stress-induced activation of DA cells between rats with a history 
of ShA and LgA cocaine SA and saline controls.  Not only were there no 
differences in the numbers or percentages of Fos-expressing TH-positive cells in 
the VTA  following footshock across ShA, LgA, and Sal rats, but footshock-
induced increases in DA cell activation were not observed in any SA group.  The 
lack of differences was likely attributable in part to a greater variability in 
footshock effects than was previously reported.  In contrast our prior findings, 
30% of the ShA rats tested and only 60% of LgA rats tested displayed footshock-
induced reinstatement and the overall magnitude of reinstatement did not differ 
between ShA and LgA rats.  These differences were not the result of altered 
intake, as regression analyses found that cocaine intake over the 14-day SA 
period failed to predict Fos reactivity (data not shown).  It is not clear why we 
failed to observe the clear differences in drug seeking between ShA and LgA rats 
that we previously found.  Nonetheless, these findings indicate that while prior 
intake is one predictor of stress-induced cocaine seeking, other factors (e.g., pre-
existing individual differences) that dictate the ability of stress to engage VTA DA 
cells are also important determinants. 
While stress-induced activation of DA cells in the VTA did not differ with SA 
history, overall Fos expression in DA cells did.   In ShA rats, the number of Fos-
expressing TH-positive cells was higher than in Sal controls.  Since these rats 
were re-introduced into an environment in which they previously self-
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administered cocaine prior to Fos measurement, it is likely that the exposure to 
the SA context accounted for the overall increase in DA cell activation.  
Consistent with this interpretation, it has been reported that Fos expression in the 
VTA (Kufahl et al., 2009) and in regions that project to the VTA (Mahler and 
Aston-Jones, 2012) is increased by exposure to cocaine-conditioned stimuli that 
reinstate drug seeking.  Alternatively, simply having a history of prior drug 
exposure may produce long-term basal increases in Fos expression in TH-
positive cells.   
In contrast to ShA rats, the overall number of Fos-positive DA cells in the VTA 
in LgA rats was no different than Sal controls.  One interpretation of this finding is 
that, with repeated LgA SA, overall deficits in DA cell function emerge and mask 
the processes that elevate DA activity in ShA rats.  This interpretation is in line 
with reports that basal extracellular NA DA levels are decreased following 
extended or continuous access SA in rats (Weiss et al., 1992b).  Thus, while we 
were unable to detect cocaine access-/intake-dependent changes in stressor-
reactivity in the DA system, the overall activity of DA cells appears to be 
progressively reduced as cocaine intake increases, consistent with the theory 
that hedonic deficits attributable to dysfunction of dopaminergic systems emerge 
with excessive use and contribute to the onset of addiction (Koob, 2009). 
 Based on the lack of differences in stress-induced activation of DA cells 
across SA conditions and the unexpected variability in the magnitude of 
footshock-induced reinstatement, we compared the number of Fos-expressing 
TH-positive cells in the VTA in rats that displayed reinstatement with those that 
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did not, regardless of whether they were ShA or LgA rats.  Footshock only 
activated VTA DA cells in rats that displayed cocaine seeking.  The finding that 
footshock failed to produce a response in rats with no prior SA history (Sal 
control rats) or in rats in which footshock failed to evoke cocaine seeking, is 
somewhat surprising.  Studies examining the effects of stressors and aversive 
stimuli on mesocorticolimbic DA neurotransmission have yielded mixed results, 
with reports of both increases and decreases in VTA DA cell activity (Ungless et 
al., 2004, Brischoux et al., 2009) and terminal field DA release (Deutch et al., 
1985, Abercrombie et al., 1989, Kalivas and Duffy, 1995, Tidey and Miczek, 
1996, Di Chiara et al., 1999, Roitman et al., 2008, Oleson et al., 2012).  The 
observation that increases in DA cell Fos expression were only observed in a 
subgroup of SA rats, suggests that either 1) ability of stress to regulate DA cells 
in the VTA is influenced by prior history of drug use and/or 2) DA cell activation 
requires footshock exposure in a context associated with drug SA.  In either 
case, the regulation of DA cells by stress is clearly determined by additional 
factors that were not controlled for in this study, as reactivity was not solely 
predicted by SA history.  
The possibility that cocaine SA recruited the ability of footshock to regulate 
DA cells, is supported by a report that shock-induced increases in extracellular 
VTA DA are only observed in animals that have acquired SA (Wang et al., 2005) 
and a report that footshock-induced increases in VTA Fos expression are 
observed following morphine-induced conditioned place preference, but not in 
morphine-naïve rats (Ahmadi et al., 2008).  It should, however, be noted that 
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stress-induced activation of DA cells using Fos as a marker has been previously 
reported in rats with no history of cocaine SA, albeit only in a subgroup of DA 
cells that project to the mPFC (Deutch et al., 1991).    
 The prospect that footshock-induced activation of DA cells is context 
dependent and therefore relies on other inputs into the VTA is also intriguing.  
The VTA receives projections from a number of structures, many of which 
respond to both drug-associated stimuli and stress and some of which do not 
(Briand et al., 2010, Mahler and Aston-Jones, 2012).  We hypothesize that, in 
some cases, stress-activated VTA afferent projections that are otherwise 
insufficient to activate DA cells, may evoke DA responses when inputs relaying 
context-related information are concurrently active.  In support of this hypothesis, 
it has been reported that, in situations where stress itself does not reliably induce 
cocaine seeking, it can effectively evoke cocaine seeking in the presence of 
other stimuli, including drug-associated cues (Buffalari and See, 2009). 
 While our findings suggest that activation of DA cells in the VTA is 
associated with stress-induced cocaine seeking, the terminal regions to which 
these cells project was not determined.  The VTA provides DA projections to a 
number of forebrain regions, including the NA and the mPFC.  Although stress 
has been reported to elevate DA in both structures (Deutch et al., 1985, 
Abercrombie et al., 1989, Kalivas and Duffy, 1995, Tidey and Miczek, 1996, Di 
Chiara et al., 1999), stress-induced stimulation of these projections does not 
appear to be uniform (Deutch et al., 1991, Brischoux et al., 2009, Refojo et al., 
2011, Chaudhury et al., 2013).  It has been reported that footshock selectively 
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increases Fos expression in DA cells that project to the mPFC (Deutch et al., 
1991).  This finding is interesting in light of reports that mPFC DA D1 receptor 
activation is required for stress-induced cocaine seeking (Capriles et al., 2003, 
Sanchez et al., 2003, McFarland et al., 2004).  Future studies will determine if 
stress-induced cocaine seeking is selectively associated with activation of 
mesocortical DA projections. 
 The mechanisms through which stress activates DA cells in the VTA likely 
involves a number of stress-responsive processes, including actions of the 
neuropeptide CRF.  CRF is released into the VTA during footshock-induced 
reinstatement (Wang et al., 2005) and has been reported to promote excitatory 
regulation of DA cells (Ungless et al., 2003, Wanat et al., 2008, Hahn et al., 
2009).  We and others have reported that intra-VTA CRF delivery is sufficient to 
evoke cocaine seeking (Wang et al., 2005, Blacktop et al., 2011) and that 
antagonism of VTA CRF receptors prevents footshock-induced reinstatement 
(Wang et al., 2005, Blacktop et al., 2011).  Like footshock-induced cocaine 
seeking, the ability of intra-VTA CRF to induce reinstatement is augmented in rats 
with a history LgA cocaine SA (Blacktop et al., 2011).  Further, the ability of CRF 
to increase VTA DA levels requires a history of cocaine SA (Wang et al., 2005).  
The likely involvement of CRF in the stress-induced activation of DA cells in the 
VTA does not rule out potential contributions by other stress-responsive systems.  
Indeed, it has recently been reported that kappa opioid receptor antagonist 
administration into the VTA can prevent stress-induced cocaine seeking 
(Graziane et al., 2013). 
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In conclusion, we report that the activation of DA cells in the VTA is 
associated with stress-induced cocaine seeking and likely contributes to stress-
induced relapse to cocaine use.  Understanding the mechanisms through which 
DA cells are engaged and the downstream processes that lead to drug use may 
facilitate the development of new and more effective approaches for the 
management of addiction. 
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CHAPTER 4 
 
ROLE OF GABA AND GLUTAMATE RECEPTORS IN AUGMENTED COCAINE 
SEEKING IN RESPONSE TO STRESS OR CRF DELIVERED INTO THE 
VENTRAL TEGMENTAL AREA FOLLOWING LONG-ACCESS SELF-
ADMINISTRATION 
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ABSTRACT 
In the rodent model of relapse, excessive cocaine use increases susceptibility to 
stressor-induced reinstatement of drug-seeking behavior. Reinstatement of 
extinguished cocaine seeking by footshock stress is dependent on extended LgA 
cocaine self-administration, corticotropin releasing factor (CRF), and augmented 
CRF receptor 1 (CRF-R1) regulation of addiction-related neurocircuitry in the 
ventral tegmental area (VTA).  Moreover, stress-induced reinstatement is 
associated with increased dopamine neuron activation in the VTA, likely resulting 
in elevated DA levels in downstream target regions. CRF may alter DA cell 
activity either directly or indirectly through regulation of GABA or glutamate 
mechanisms to induce cocaine seeking. This study examined the role of intra-
VTA GABA and glutamate receptors in the reinstatement of extinguished cocaine 
seeking by footshock or intra-VTA CRF delivery. Bilateral intra-VTA 
administration of the GABAA receptor antagonist bicuculline (1.0 and 10.0 
ng/side), GABAB receptor antagonist 2-hydroxysaclofen (2 µg/side), NMDA 
receptor antagonist AP-5 (1.0, 3.0, and 10 µg/side), AMPA receptor antagonist 
NBQX (1.0, 3.0, and 10.0 µg/side), and the nonspecific ionotropic glutamate 
receptor antagonist kynurenic acid (24.0 µg/side) were tested for their ability to 
block footshock- and intra-VTA CRF-induced reinstatement of extinguished LgA 
cocaine-seeking behavior. 2-hydroxsaclofen and kynurenic acid but not AP-5 nor 
NBQX blocked reinstatement. These findings reveal that GABAB receptor 
signaling and nonspecific ionotropic glutamate signaling are both necessary for 
CRF actions in the VTA to reinstate extinguished LgA cocaine-seeking behavior.  
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INTRODUCTION 
 Drug addiction research is aimed to better understand the 
neuromechanisms of relapse to aid in the development of medications that 
prevent drug craving, drug seeking, and relapse. However, there are currently no 
FDA approved medications for the treatment of cocaine addiction (Vocci and 
Elkashef, 2005). Stress is a major factor in causing relapse in cocaine dependent 
individuals. Clinical evidence in humans and experimental animal models report 
that stressful events and activation of stress neurocircuitry regulates cocaine use, 
cocaine craving, and relapse to cocaine use (Marlatt, 1980, Wallace, 1989, 
Goeders and Guerin, 1994, Erb et al., 1996, Sinha et al., 1999, Grimm et al., 
2001, Karlsgodt et al., 2003, Sinha et al., 2006).  
Corticotropin releasing factor (CRF) is a 41-amino acid neuropeptide that 
plays an important role in both the stress response and stress-induced 
reinstatement of extinguished cocaine-seeking behavior (Shaham et al., 1997, 
Erb et al., 1998, Shalev et al., 2010). CRF is released during footshock stress 
producing its effects through the coordinated action of two G-protein coupled 
receptors, CRF-R1 and CRF-R2, in brain regions associated with the effects of 
drugs of abuse, notably the ventral tegmental area (VTA) (Van Pett et al., 2000, 
Dautzenberg and Hauger, 2002, Wang et al., 2005, Wang et al., 2007, Blacktop 
et al., 2011). We have previously reported that reinstatement of extinguished 
cocaine seeking by footshock stress and intra-VTA CRF administration is 
dependent on excessive LgA cocaine use, and that CRF-R1 activation in the 
VTA is necessary and sufficient for reinstatement (Blacktop et al., 2011). 
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Regulation of cocaine seeking by CRF-R1 receptors appears to require a prior 
history of very high levels of cocaine intake as seen in the long-access rodent 
model of relapse (Ahmed and Koob, 1998, Specio et al., 2008, Blacktop et al., 
2011). However, very little is known about the mechanism of action of CRF-R1 in 
the VTA during reinstatement. 
Excitatory drive on VTA dopamine neurons through glutamate 
neurotransmission is a leading hypothesis as to how intra-VTA CRF promotes 
reinstatement.  Glutamatergic afferents to VTA dopamine neurons can produce 
somatodendritic dopamine release, indicative of phasic firing (Rice et al., 1997, 
Adell and Artigas, 2004), which has been repeatedly implicated in drug-seeking 
behavior (Vorel et al., 2001, Wang et al., 2005, You et al., 2007). Following drug 
exposure intra-VTA CRF can augment ionotropic glutamate receptor signaling on 
VTA dopamine neurons (Ungless et al., 2001, Saal et al., 2003, Ungless et al., 
2003, Wanat et al., 2008, Hahn et al., 2009). In support of an excitatory role, we 
have previously reported that the magnitude of footshock stress-induced 
reinstatement is positively correlated with increased VTA dopamine 
responsiveness at the time of the reinstatement session (Chapter 3). However, 
emerging evidence suggests that inhibitory GABA signaling in the VTA may also 
be involved in stress-induced relapse. 
Footshock stress increases VTA GABA neuron activity (Lammel et al., 
2012, Tan et al., 2012) which can transiently suppress neighboring DA neurons 
(Jhou et al., 2009, Tan et al., 2012). VTA GABA neuron activation is sufficient to 
not only reduce reward consumption (van Zessen et al., 2012) but also produce 
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conditioned place aversion (Tan et al., 2012). Intra-VTA CRF can augment 
inhibition of VTA dopamine neurons through the coordinated action of CRF-R1 
and GABAB receptors (Beckstead et al., 2009) and  decrease the motivation to 
work for food rewards through inhibition of reward-evoked dopamine release 
(Wanat et al., 2013). In other brain regions binge pattern self-administration can 
augment CRF-R1 dependent GABAergic signaling (Nie et al., 2009). 
Furthermore, GABAA receptor regulation of VTA dopamine neuron activity has 
been recently reported to be essential in stress-induced reinstatement (Graziane 
et al., 2013). In summary, intra-VTA CRF appears to induce inhibitory and 
excitatory effects upon dopamine signaling to regulate reward seeking.  
The goal of this set of experiments is to characterize the role of intra-VTA 
glutamate and GABA receptor activation in both footshock- and intra-VTA CRF-
induced reinstatement. Particularly, the role of ionotropic glutamate receptor 
subtypes to build upon the work of Wise and colleagues. It is hypothesized that 
reinstatement will be dependent on ionotropic glutamate receptor activation. 
Specifically, we want to confirm the role of intra-VTA NMDA versus AMPA 
receptor activation in reinstatement. Additionally, further characterization of what 
little is known about GABA receptor signaling in footshock- and intra-VTA CRF-
induced reinstatement of extinguished LgA cocaine seeking. 
MATERIALS AND METHODS  
 Adult male Sprague–Dawley rats (Harlan Laboratories, St. Louis, MO) 
were housed individually under a 12 h/12 h reversed light/dark cycle (lights on at 
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7:00 PM) in a temperature and humidity controlled AAALAC-accredited animal 
facility. All procedures were approved by the Marquette University IACUC and 
carried out in accordance with the NIH Guide for the Care and Use of Laboratory 
Animals. 
Catheter and cannula implantation 
 For the reinstatement studies, rats were implanted with chronic indwelling 
jugular catheters under ketamine HCl (100 mg/kg, ip) and xylazine (2 mg/kg, ip) 
anesthesia and with bilateral 2.1-cm 23 gauge guide cannulae aimed at the VTA 
for intracranial injections as previously described  (Mantsch et al., 2008a, 
Blacktop et al., 2011, Graf et al., 2011). The tips of the guide cannulae were 
aimed 0.5 mm above the target injection site using the following coordinates 
determined from Paxinos and Watson (1998): 12° angle away from midline; A/P 
− 5.6 mm from bregma; M/L ± 2.2 mm from midline; and D/V − 6.7 mm from the 
skull surface. Placements for cannula targeting the VTA for rats from each of the 
experiments are depicted in Figure 28.  
Self-Administration Training  
 After recovery from surgery, rats were trained to self-administer cocaine 
(1.0 mg/kg/inf, iv; NIDA Drug Supply Program) by pressing a lever under a FR1 
schedule during daily 2-h sessions, within which the active (i.e., front) lever was 
extended into the chamber and the corresponding stimulus light was illuminated. 
Pressing the lever resulted in an iv infusion of drug or saline solution (200 μl over 
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5 s) followed by a 25-s time-out period during which the stimulus light was 
extinguished but the lever remained extended. Responding on a second, inactive 
(i.e., back) lever was recorded but had no programmed consequences. 
Response requirements were gradually increased until rats displayed stable 
responding (within 10% of the 3-session mean) under an FR4 schedule at which 
time they entered into a 14-day period of self-administration testing. 
Long-Access, Extinction, and Reinstatement 
 To examine GABA and glutamate receptor signaling in intake-dependent 
intra-VTA CRF- and footschock-induced reinstatement of extinguished LgA 
cocaine-seeking-behavior, rats were assigned to LgA groups following 
acquisition which had access to cocaine for six hrs daily for the next 14 days. 
Following 14 days of LgA self-administration, rats underwent extinction during ten 
consecutive 2-h sessions within which the cocaine solution was replaced by 
saline. After 14 days of LgA self-administration and extinction, rats were tested 
twice for footshock- and twice for intra-VTA CRF-induced reinstatement in 
counterbalanced sequence: once following intra-VTA pretreatment with an 
antagonist and once following pretreatment with vehicle (aCSF; Tocris 
Biosciences). All microinfusions delivered a volume of 0.25 μl/side over a 1-min 
period ten minutes prior to the reinstatement session.  
Stress-induced reinstatement, was tested for the ability of electric 
footshock, delivered though the stainless steel grid floors of the self-
administration chambers, to reinstate cocaine seeking. During the 15-min 
158 
 
footshock period, the houselight was illuminated and the levers were retracted 
and stimulus lights extinguished. Shocks (0.5 mA, 0.5” duration) were delivered 
an average of every 40 sec (range 10-70 sec). We have reported that these 
parameters produce robust reinstatement after long-access, but not short-
access, self-administration (Mantsch et al., 2008). As was the case with 
footshock, rats were tested twice for intra-VTA CRF-induced reinstatement in 
counterbalanced fashion: once following intra-VTA pretreatment with an 
antagonist and once following pretreatment with vehicle. Responding on both the 
active and inactive levers were recorded during the 2-h reinstatement sessions 
which were otherwise identical to extinction conditions. The order of testing with 
drug and vehicle pretreatment to both footshock and intra-VTA CRF-induced 
reinstatement varied across rats in each group to avoid potential sequence 
effects. Rats underwent additional extinction sessions between reinstatement 
test sessions and were required to display less than 20 cocaine lever responses 
during an intervening extinction session in order to be tested again for 
reinstatement. 
Effects of GABA Receptor Antagonists on both Footshock and Intra-VTA CRF-
induced Reinstatement in LgA Animals 
 
 
 The ability of both footshock and intra-VTA CRF (500 ng/side; 420 µM; 
Sigma Aldrich) delivery to reinstate extinguished LgA cocaine seeking was tested 
following a 10-min bilateral intra-VTA pretreatment (0.25 μl/side over 1 min) of 
the GABAA receptor selective antagonist, bicuculline, and the GABAB receptor 
selective antagonist, 2-hydroxysaclofen. The more water soluble and stable form 
of a selective GABAA receptor antagonist (-)-bicuculline methiodide (1.0 and 10.0 
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ng/side; 7.85 and 78.5 µM; Tocris Bioscience; n=19) was utilized as a 
pretreatment to both footshock and intra-VTA CRF-induced reinstatement of 
extinguished LgA cocaine seeking. Bicuculline doses were chosen from primary 
literature demonstrating behavioral effects through intra-VTA GABAA receptor 
blockade (Sandner et al., 1996, David et al., 1997, Trojniar and Klejbor, 1999, 
Grubb et al., 2002). Higher doses of bicuculline were omitted due to seizure 
activity. GABAA receptor pharmacological blockade can induce DA neuron burst 
firing (Paladini et al., 1999b, Paladini and Tepper, 1999).Intra-cerebral injection 
of GABAergic antagonists such as bicuculline have been reported to elicit 
convulsions at high doses (Florio and Longo, 1972). Convulsions were not 
observed at a 1.0-1.5 ng dose (David et al., 1997). 
The more water soluble and stable form of a prototypical GABAB receptor 
antagonist 2-hydroxysaclofen (2 µg/side; 30 mM; Tocris Bioscience; n=14) prior 
to both footshock and intra-VTA CRF-induced reinstatement of extinguished LgA 
cocaine-seeking was additionally characterized. The 2-Hydroxysaclofen dose 
was chosen from primary literature demonstrating behavioral effects through 
intra-VTA GABAB receptor blockade (Xi and Stein, 1999, Ackerman et al., 2003, 
Miner et al., 2010). 
 
Effects of Ionotropic Glutamate Receptor Antagonists on both Footshock and 
Intra-VTA CRF-induced Reinstatement in LgA Animals 
 
 
 The ability of both footshock and intra-VTA CRF (500 ng/side; Sigma 
Aldrich) delivery to reinstate cocaine seeking was tested following a 10-min 
bilateral intra-VTA pretreatment (0.25 μl/side over 1 min) with an NMDA, AMPA, 
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and nonspecific ionotropic glutamate receptor antagonist. The more active and 
water soluble form of a selective and competitive NMDA receptor antagonist D-
AP5 was administered at three different doses (1.0, 3.0, and 10 µg/side; 20.3, 
60.9, and 203 mM; Tocris Bioscience; n=23). Doses were initially chosen from 
primary literature demonstrating behavioral effects through intra-VTA NMDA 
receptor blockade (Ranaldi et al., 2011) and scaled up proportionately due to 
failure to attenuate reinstatement (Park et al., 2002, Famous et al., 2007).  The 
more water soluble form of a potent, selective, and competitive AMPA receptor 
antagonist NBQX disodium salt (1.0, 3.0, and 10.0 µg/side; 10.5, 31.5, 105 mM; 
Tocris Bioscience; n=26) was determined in separate groups of LgA rats.  
A pilot study in another separate group of LgA rats with the more water 
soluble form of the nonspecific ionotropic glutamate receptor antagonist 
kynurenic acid sodium salt (24.0 µg/side; 454 mM; Tocris Bioscience; n=3) was 
administered to measure the ability of both footshock and intra-VTA CRF to 
reinstate. At this dose kynurenic acid antagonizes both the NMDA (Kessler et al., 
1989, Stone, 1993) and the AMPA/Kainate family of ionotropic glutamate 
receptors (Stone, 1993). 
Food Self-Administration  
 In order to confirm that the effects of intra-VTA 2-hydroxysaclofen and 
kynurenic acid on reinstatement were not attributable to non-specific motor 
impairments, rats were tested for effects on sucrose pellet-reinforced lever 
pressing. These rats were maintained at 90% of their free-feeding body weights 
and trained to self-administer 45 mg sucrose-sweetened food pellets (BioServ) 
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by pressing a response lever under a FR4 schedule of reinforcement during 30-
min sessions. Once stable response patterns were observed (responding within 
10% of the mean over 3 sessions), separate groups of rats were tested for the 
effects of intra-VTA delivery of 2-hydroxysaclofen (2 µg/side; n=7) or kynurenic 
acid (multiple doses; n=7), as described above, on responding. Each rat was 
tested two or three times with intra-VTA treatment in counterbalanced sequence 
with the 2-hydroxysaclofen, kynurenic acid, or vehicle. 2-hydroxysaclofen and 
kynurenic acid were administered in separate groups of rats. 
Histological Confirmation of Injection Sites  
 The accuracy of cannula implantation was confirmed postmortem in each 
rat after cardiac perfusion with 60-ml NaCl followed by 60-ml 2.5% buffered 
neutral formalin under sodium barbital anesthesia (55 mg/kg). Brains were 
removed and stored in 2.5% buffered formalin for at least one day. 200-μm 
sections were cut using a vibrotome, slide-mounted, and stained with cresyl 
violet for placement confirmation using a light microscope. Rats with injection 
sites outside of the VTA were excluded from data analysis. 
Statistical Analyses  
Statistical analyses were conducted using Predictive Analytics SoftWare 
statistics software (SPSS, Inc.). Statistical significance was determined using 
paired students t-test, 1-way ANOVA, and 2-way ANOVA followed, when 
appropriate, by further analyses of main effects and interactions using 
Bonferroni-corrected t-test post-hoc testing. 
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Histology 
 The histological confirmation of all injection sites in animals included in 
data analysis is shown in the Figure 28. All placements are in the VTA and 
depicted by cohort. 
Figure 28: Schematic depiction of injection sites within the VTA for different 
treatment conditions in LgA rats including: A) bicuculline B) 2-hydoxysaclofen C) 
2-hydroxysaclofen food controls, D) AP-5, E) NBQX, and F) kynurenic acid. 
Open circles represent the injection site upon coronal brain section images from 
the atlas of Paxinos and Watson (2005). 
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RESULTS  
Cocaine Self-Administration and Extinction  
 Cocaine self-administration (SA) on days one and 14 of testing in rats 
provided 14 days of LgA (6 hrs) along with the first and last day of extinction 
training is shown is shown in Table 1 for animals pretreated with bicuculline, 2-
hydroxysaclofen, AP-5, NBQX, and kynurenic acid. Cocaine SA and extinction 
did not vary across groups.  The mean and standard error data are shown in 
Table 3. 
Table 3: Total number of infusions on days 1 and 14 of LgA cocaine self-
administration and the total number of responses on the active lever on extinction 
days 1 and 10 (±S.E.) in animals that were tested with intra-VTA pretreatments of 
bicuculline, 2-hydroxysaclofen, AP-5, NBQX, and kynurenic acid to both 
footshock- and intra-VTA CRF-induced reinstatement. Self-administration 
infusions and extinction responses did not significantly vary amongst animals 
treated with different antagonists. 
 
Reinstatement 
Group 
SA Day 1 
(Inf ± S.E.) 
SA Day 14 
(Inf ± S.E.) 
EXT Day 1 
(Resp ± S.E.) 
Final EXT 
Day 
(Resp ± S.E.) 
Bicuculline 81.25 (±4.14) 92.67 (±7.75) 47.0 (±8.49) 11.33 (±1.35) 
Saclofen 72.63 (±3.68) 83.38 (±3.78) 66.0 (±10.70) 7.88  (±1.60) 
AP-5 84.65 (±5.22) 88.30 (±4.01) 49.15 (±8.28) 6.8 (±1.58) 
NBQX 84.24 (±5.88) 87.88 (±4.16) 77.18 
(±13.55) 
10.53 (±1.52) 
Kynurenic Acid 80.42 (±4.77) 84.17 (± 
5.28) 
69.75 (±9.27) 10.42 (±0.97) 
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Effects of Intra-VTA GABA Receptor Antagonists on Footshock and CRF-
Induced Reinstatement 
 
 
 As the effects of GABA antagonists administered into the VTA on stress 
and CRF-induced reinstatement have not been previously tested, we initially 
investigated the effects of intra-VTA administration of the GABAA receptor 
antagonist, bicuculline, and the GABAB antagonist, 2-hydroxylsaclofen on 
reinstatement in response to footshock or intra-VTA CRF delivery (500 ng/side; 
Sigma-Aldrich).  
 
Effects of Intra-VTA GABAA Receptor Antagonists on Footshock and CRF-
Induced Reinstatement 
 
 
 We initially tested rats for the effects of intra-VTA bicuculline at a dose of 1 
ng/side (David et al., 1997, Trojniar and Klejbor, 1999).  As this dose failed to 
produce effects on reinstatement, we subsequently tested rats for the effects of a 
10-fold higher bicuculline dose (10 ng/side) (Sandner et al., 1996, Grubb et al., 
2002, Ackerman et al., 2003).  Notably, higher doses than 10 ng/side tend to 
generate aberrant electrical activity and promote seizures (unpublished 
observation). Therefore, we did not test higher concentrations of bicuculline.  The 
effects of intra-VTA bicuculline on reinstatement are shown in Figure 29.  Neither 
bicuculline dose significantly attenuated reinstatement when administered into 
the VTA prior to testing with footshock or intra-VTA CRF.  Since within subject 
testing for the effects of bicuculline on reinstatement was conducted in different 
groups of rats for each dose, we performed separate 2-way repeated measures 
ANOVA examining the effects of each dose (1 ng, 29A and 29D and 10 ng, 29B 
165 
 
and 29E) on reinstatement in response to each stimulus (footshock, 29A and 29B 
and CRF, 29D and 29E).  
Two-way repeated measures reinstatement x drug pretreatment ANOVAs 
showed either overall reinstatement main effects of or near-significant trends for 
reinstatement testing in response to either footshock (1 ng/side bicuculline: 
F1,5=9.967; P<0.05; 10 ng/side bicuculline: F1,5=54.921; P=0.001) or intra-VTA 
CRF (1 ng/side bicuculline: F1,6=35.698; P<0.01; 10 ng/side bicuculline: 
F1,5=12.317; P<0.05).  However, in no cases were significant main effects of 
bicuculline or interactions between bicuculline pretreatment and reinstatement 
testing condition observed.  To permit analysis of reinstatement across dose 
conditions, we also consolidated veh-pretreated rats into one group and 
conducted one-way ANOVA assessing changes in cocaine lever responding 
relative to the prior extinction session following either footshock or intra-VTA CRF 
(29C and 29F).  Despite some variability across groups, significant overall effects 
of bicuculline pretreatment were not observed in either case.   Notably, to 
address the small sample size in some of the groups and within-group variability, 
additional rats are currently undergoing testing. 
Figure 29: Effects of intra-VTA injections of the GABAA receptor antagonist 
bicuculline on reinstatement by footshock stress and intra-VTA CRF delivery in 
LgA rats. Data represent the effects of bilateral injections of 1ng/side bicuculline 
on reinstatement induced by footshock (29A; n=6) or intra-VTA CRF (29D; n=7) 
or 10ng/side bicuculline on reinstatement by footshock (29B; n=5) or intra-VTA 
CRF (500 ng/side; 29E; n=5).  Overall reinstatement main effects of or near-
significant trends for reinstatement testing in response to either footshock (1 
ng/side bicuculline: F1,5=9.967; P<0.05; 10 ng/side bicuculline: F1,5=54.921; 
P=0.001) or intra-VTA CRF (1 ng/side bicuculline: F1,6=35.698; P<0.01; 10 
ng/side bicuculline: F1,5=12.317; P<0.05) were observed. Significant overall 
effects of bicuculline pretreatment or interactions between bicuculline 
pretreatment and reinstatement were not observed (29C and 29F). 
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Effects of Intra-VTA GABAB Receptor Antagonists on Footshock and CRF-
Induced Reinstatement 
 
 
 
 The effects of intra-VTA 2-hydroxysaclofen (2-HS) on reinstatement were 
tested at a single dose (2 µg/side) (Xi and Stein, 1999, Ackerman et al., 2003, 
Miner et al.) and are shown in Figure 30. The effects of 2-HS were assessed 
using a) 2-way repeated measures 2-HS treatment x reinstatement test condition 
ANOVA (30A and 30C) examining total cocaine lever responding and b) a paired 
t-test examining differences in reinstatement relative to the previous extinction 
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session following intra-VTA 2-HS or vehicle.  2-HS effects on footshock-induced 
reinstatement are shown in 30A and 30B.Two-way ANOVA examining effects of 
intra-VTA 2-HS footshock cocaine seeking showed a significant main effect of 
footshock (F1,7=14.322;P<0.01) but not intra-VTA 2-HS pretreatment and a 
significant footshock x 2-HS interaction (F1,7=6.666;P<0.05).  Post-hoc testing 
(Bonferroni-corrected t-test) showed that footshock-induced reinstatement in rats 
pretreated with intra-VTA vehicle (P<0.05 vs. extinction) but not 2-HS and that 
cocaine seeking was greater following vehicle than after 2-HS (P<0.05).  To 
further examine difference in shock-induced reinstatement conditions, we also 
used a paired t-test to compare differences in the magnitude of reinstatement 
(change in responding vs. prior extinction session).  Intra-VTA 2-HS significantly 
decreased footshock-induced reinstatement (t7=2.582; P<0.05). 
2-HS effects on reinstatement in response to intra-VTA CRF delivery are 
shown in panels 30C and 30D.  Two-way ANOVA examining effects of 2-HS on 
CRF-induced cocaine seeking showed significant main effects of CRF 
(F1,6=12.655;P<0.05) and intra-VTA 2-HS pretreatment (F1,6=8.897;P<0.05) and 
a significant CRF x 2-HS interaction (F1,6=10.206;P<0.05; 30C).  Post-hoc testing 
showed that intra-VTA CRF induced reinstatement in rats pretreated with intra-
VTA vehicle (P<0.05 vs. extinction) but not 2-HS and that cocaine seeking was 
greater following vehicle than after 2-HS (P<0.05).   A paired t-test comparing 
differences in the magnitude of reinstatement showed that intra-VTA 2-HS 
significantly decreased CRF-induced reinstatement (t6=3.195;P<0.05; 30D). 
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To ensure that the attenuation of reinstatement by intra-VTA 2-HS was not 
attributable to impairment of motor activity that would prevent rats from displaying 
lever pressing behavior, an additional group of rats was trained to lever press 
under a FR4 schedule of sucrose-sweetened pellet (45 mg) reinforcement 
followed by testing for the effects of intra-VTA vehicle or 2-HS administration 
(30E and 30F).  2-HS failed to alter lever-pressing in these rats.  Two-way 
repeated measures ANOVA showed no main effect of or interaction involving 
intra-VTA 2-HS.  Likewise A paired student’s t-test failed to show a significant 
reduction in food reinforced responding following intra-VTA 2-HS. 
 
 
Figure 30: Effects of intra-VTA injections of GABAB receptor antagonists on 
reinstatement by footshock stress and intra-VTA CRF delivery in LgA rats.  Data 
represent the effects of bilateral injections of 2-hydroxysaclofen (2-HS; 2 µg/side) 
as a pretreatment to footshock stress (30A/B; n=7) or intra-VTA CRF delivery 
(500 ng/side; 30C/D; n=7).  In all cases, significant reinstatement was observed 
in rats pretreated with vehicle (*P<0.05 vs. Ext) but not 2-HS in both footshock 
and intra-VTA CRF-induced reinstatement, with cocaine seeking being greater 
following vehicle than after 2-HS (P<0.05). 2-HS failed to significantly alter or 
reduce food reinforced responding following intra-VTA 2-HS administration 
(30E/F; n= 7). 
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Effects of Intra-VTA Glutamate Receptor Antagonists on Footshock and CRF-
Induced Reinstatement 
 
 
 Since other reports suggest a role for glutamatergic neurotransmission in 
the VTA in reinstatement in response to footshock or CRF (Wang et al., 2005, 
Wang et al., 2007) and CRF actions in the VTA (Ungless et al., 2003), we also 
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examined the effects of intra-VTA delivery of antagonists at NMDA (AP-5) and 
AMPA (NBQX) receptors on reinstatement. 
Effects of Intra-VTA NMDA Receptor Antagonists on Footshock and CRF-
Induced Reinstatement 
 
 
 The effects of intra-VTA AP-5 administration on footshock-induced 
reinstatement are shown in Figure 31.  Since a number of rats were not tested 
under both vehicle and AP-5 conditions, mixed 2-way ANOVA with shock (vs. 
ext) as a repeated measure and intra-VTA AP-5 (vs. veh) as a between subjects 
measure was conducted at each dose.  Initially AP-5 was tested at a dose of 1 
µg/side (Cornish et al., 2001, Covington et al., 2008, Ranaldi et al., 2011).  As 
this dose failed to attenuate reinstatement, we subsequently tested rats for 
effects of higher AP-5 doses (3 and 10 µg/side).  In all cases, intra-VTA AP-5 
failed to block footshock-induced reinstatement. For each dose tested, a 
significant main effect of footshock was observed (1 µg/side dose: F1,7=11.086; 3 
µg/side dose: F1,7=9.776; 10 µg/side dose: F1,4=18.434; P<0.05 for each), but no 
main effects of AP-5 pretreatment and no AP-5 x footshock interactions. 
Additionally, one-way ANOVA was conducted to examine the magnitude 
of footshock reinstatement across AP-5 dose conditions.  No effect of treatment 
was observed (31D).  To confirm that our inability to block reinstatement was not 
due to the AP-5 dose, we tested two rats at 30 µg/side, a very large intracranial 
dose (Dunn et al., 2005).  Footshock-induced reinstatement was observed, even 
at this dose (mean increase vs. extinction of 45.5 responses; data not shown).  
Intra-VTA AP-5 did not significantly alter inactive lever pressing at any dose 
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tested with footshock (Table 4), nor did it induce cocaine seeking, when tested 
alone, when tested in two rats (not shown). 
Figure 31: Intra-VTA AP-5 failed to block footshock-induced reinstatement at all 
doses tested which included 1 µg/side (31A; n=4), 3 µg/side (31B; n=5), and 10 
µg/side (31C; n=3).  For each dose tested, a significant main effect of footshock 
was observed (1 µg/side dose: F1,7=11.086; 3 µg/side dose: F1,7=9.776; 10 
µg/side dose: F1,4=18.434; P<0.05 for each) but no main effects of AP-5 
pretreatment and no AP-5 x footshock interactions. No effect of treatment was 
observed on the magnitude of footshock reinstatement across AP-5 dose 
conditions (31D). 
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Table 4: Total number of inactive lever presses (±S.E.) in LgA rats receiving 
intra-VTA pretreatments of 1, 3, and 10 µg/side doses of either AP-5 or NBQX to 
footshock- and intra-VTA CRF-induced reinstatement. 
 
Intra-
VTA 
Drug 
 
Reinstatement 
“Inactive” Lever Responses (± S.E.) 
Veh 1 µg/side 3 µg/side 10 µg/side 
AP5 Shock 7.09 
(±2.80) 
5.67 
(±1.77) 
3.25 
(±2.92) 
10.00 
(±4.00) 
CRF 6.13 
(±2.57) 
--- 2.00 
(±0.77) 
2.67 (±2.18) 
NBQX Shock 4.60 
(±2.28) 
14.00 
(±2.31) 
16.33 
(±9.24) 
8.00 (±3.81) 
CRF 6.42 
(±2.24) 
--- 7.20 
(±1.96) 
9.75 (±3.29) 
 
The effects of intra-VTA AP-5 administration on reinstatement in response 
to intra-VTA CRF are shown in Figure 32.  For these experiments, only the 3 and 
10 µg/side AP-5 doses were tested.  Neither dose blocked reinstatement in 
response to intra-VTA CRF.  Effects were assessed using 2-way ANOVA.  In 
both cases, main effects of CRF were observed (3 µg/side dose: F1,8=30.958; 10 
µg/side dose: F1,5=10.016; P<0.05 for each; 32A/B), but main effects of AP-5 
pretreatment or AP-5 x CRF interactions were not.    
One-way ANOVA also failed to show that the magnitude of intra-VTA 
CRF-induced reinstatement varied across AP-5 dose conditions (32C).  As was 
the case with shock-induced reinstatement, 30 µg/side AP-5 (a very high dose) 
also failed to block CRF-induced reinstatement (mean increase vs. extinction = 
41.5 responses).  Inactive lever pressing during the sessions was not altered by 
AP-5 (Table 4). 
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Figure 32: Intra-VTA AP-5 failed to block CRF-induced reinstatement at all 
doses tested which included 3 µg/side (32A; n=6), and 10 µg/side (32B; n=5).  
For each dose tested, main effects of CRF were observed (3 µg/side dose: 
F1,8=30.958; 10 µg/side dose: F1,5=10.016; P<0.05 for each), but main effects of 
AP-5 pretreatment or AP-5 x CRF interactions were not. 
 
 
Effects of Intra-VTA AMPA Receptor Antagonists on Footshock and CRF-
Induced Reinstatement 
 
 
 The effects of intra-VTA NBQX administration on shock-induced 
reinstatement are shown in Figure 33.  As with AP-5 pretreated rats, mixed 2-
way ANOVA with shock (vs. ext) as a repeated measure and intra-VTA NBQX 
(vs. veh) as a between subjects measure was conducted at each dose.  Initially 
NBQX was tested at a dose of 1 µg/side (Nolan et al., 2010, Millan and McNally, 
2011).  However, since this dose failed to attenuate reinstatement, we 
subsequently tested rats for effects of higher NBQX doses (3 and 10 µg/side).  
Intra-VTA NBQX produces dose-dependent effects on reinstatement with no 
effects at the 1 µg/side dose and an apparent augmentation at the higher doses.   
At the 1 µg/side dose, a significant main effect of footshock was observed (1 
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µg/side dose: F1,6=20.120; P<0.05), but no main effects of NBQX pretreatment 
and no NBQX x footshock interaction (33A). At the 3 µg/side dose, a significant 
main effect of footshock (F1,5=40.457; P=0.001) and a significant interaction 
between footshock and intra-VTA NBQX pretreatment (F1,5=9.627; P<0.05) were 
observed.  Post-hoc testing showed that not only was significant reinstatement 
observed in both groups (P<0.05 vs. extinction) but that shock-induced 
reinstatement of cocaine seeking following intra-VTA NBQX was increased 
compared to vehicle controls (P=0.05; 33B).  At the highest NBQX dose tested 
(10 µg/side), a similar pattern was present.  However, while a significant main 
effect of shock was observed (F1,10=7.717; P<0.05), a significant shock x NBQX 
pretreatment interaction was not (33C).  Additionally, one-way ANOVA was 
conducted to examine the magnitude of footshock reinstatement across AP-5 
dose conditions.  However, despite dose-dependent increases in reinstatement 
magnitude following intra-VTA NBQX delivery, a significant overall effect was not 
observed (33D).  Although also not significant, dose-dependent increases in 
responding on the previously inactive lever were also observed (Table 4). 
 The effects of intra-VTA NBQX administration on reinstatement in 
response to intra-VTA CRF are shown in Figure 34.  As was the case with AP-5, 
for these experiments, only the 3 and 10 µg/side NBQX doses were tested.  
Neither NBQX dose blocked reinstatement in response to intra-VTA CRF.   
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Figure 33: Intra-VTA NBQX failed to block footshock-induced reinstatement at all 
doses tested which included 1 µg/side (33A; n=4), 3 µg/side (33B; n=3), and 10 
µg/side (33C; n=6). In all cases, significant reinstatement was observed in rats 
pretreated with vehicle or the AMPA receptor antagonists (*P<0.05 vs. Ext). At 
the 3 µg/side dose, NBQX increased reinstatement compared to vehicle controls 
(P=0.05). A significant interaction between footshock and intra-VTA NBQX 
pretreatment of 3 µg/side (F1,5=9.627; P<0.05) was observed. A significant 
overall effect of reinstatement magnitude and NBQX delivery was not observed 
at the 1, 3, or 10 µg/side dose (33D). 
 
 
 
 
 
 
 
 
 
 
 
Effects were assessed using 2-way ANOVA. In both cases, significant 
main effects of CRF were observed (3 µg/side dose: F1,8=71.892; 10 µg/side 
dose: F1,16=12.880; P<0.05 for each), but main effects of NBQX pretreatment or 
NBQX x CRF interactions were not. One-way ANOVA also failed to show that the 
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magnitude of intra-VTA CRF-induced reinstatement varied across AP-5 dose 
conditions.  Although reinstatement magnitude tended to increase with NBQX 
dose, one-way ANOVA failed to show a statistically significant overall effect of 
intra-VTA NBQX pretreatment on the magnitude intra-VTA CRF-induced 
reinstatement (34C).  Significant effects on previously inactive lever pressing 
during the reinstatement session were not observed (Table 2). 
 
Figure 34: Intra-VTA NBQX failed to block CRF-induced reinstatement at all 
doses tested which included 3 µg/side (34A; n=4), and 10 µg/side (34B; n=9).  
For each dose tested, main effects of CRF were observed (3 µg/side dose: 
F1,8=71.892; 10 µg/side dose: F1,16=12.880; P<0.05 for each), but main effects of 
NBQX x CRF interactions were not. A statistically significant overall effect of 
intra-VTA NBQX pretreatment on the magnitude intra-VTA CRF-induced 
reinstatement was not observed at any dose tested (34C). 
 
Since intra-VTA NBQX tended to increase reinstatement in response to 
either footshock or intra-VTA CRF, we hypothesized that NBQX, via AMPA 
receptor blockade in the VTA, may alone induce cocaine seeking.  To test this 
hypothesis, we selected four rats that displayed high levels of reinstatement 
when tested for CRF-induced reinstatement following pretreatment with NBQX 
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and tested them for reinstatement in response to 10 µg/side intra-VTA NBQX by 
itself (Figure 35).   
 
Figure 35: In the absence of footshock or CRF delivery NBQX (10 µg/side) 
increased mean active lever responses by 32, although the difference did not 
reach statistically significance (t3=1.860; P=.160) (35A; n=4). Mean increases in 
responding by NBQX alone, NBQX and CRF, or CRF alone suggest that NBQX 
didn’t prevent nor block reinstatement by CRF (35B). 
 
 
 
 
 
 
 
Although the difference was not statistically significant (t3=1.860; P=.160), 
NBQX alone produced a mean increase in lever pressing of 32 responses in 
these rats (35A).  Notably the mean increase in responding in these rats relative 
to extinction when they received NBQX prior to CRF was 73.25 responses and 
the mean difference in responding during the session prior to which they received 
NBQX/CRF and that prior to which they received only NBQX was 41.25 
responses, a number that is comparable to the mean level of reinstatement 
observed when the same rats received only intra-VTA CRF delivery (35B).  Thus, 
even though intra-VTA NBQX evoked cocaine seeking, CRF-induced cocaine 
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seeking was observed, suggesting that NBQX was neither preventing nor 
masking reinstatement. 
To test the possibility that blockade of both AMPA and NMDA receptors in 
the VTA is necessary to reveal a role for glutamatergic neurotransmission in 
stress and CRF-induced cocaine seeking, we conducted a preliminary study in 
which we tested rats for the effects of intra-VTA kynurenic acid (KA) delivery on 
reinstatement.  In addition to other pharmacological properties, KA antagonizes 
both AMPA and NMDA receptors.  In fact, Wang et al (2005) have reported that 
intra-VTA delivery of KA can prevent reinstatement of cocaine seeking in 
response to both footshock and intra-VTA CRF administration. The effects of 
intra-VTA KA administration on reinstatement in response to footshock (36A and 
36B) intra-VTA CRF (36C and 36D) are shown in Figure 36. 
Effects of KA on footshock-induced reinstatement were tested in four rats 
using a 24 µg/side KA dose (Vorel et al., 2001).  A two-way repeated measure 
KA pretreatment x footshock condition ANOVA showed a significant overall effect 
of intra-VTA KA pretreatment (F1,3=20.461; P<0.05) but not shock on cocaine 
seeking and a significant KA pretreatment x shock condition interaction 
(F1,3=11.788; P<0.05).  Post-hoc testing showed that cocaine seeking following 
shock was significantly reduced following intra-VTA KA compared to intra-VTA 
vehicle control conditions (36A; P<0.05).  Further, a paired t-test comparing the 
magnitude of shock-induced reinstatement in KA-pretreated rats with that in 
vehicle treated controls showed a significant KA-induced reduction (t3=3.433; 
P<0.05; 36B).   
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Figure 36: Effects of intra-VTA injections of kynurenic acid (KA) on reinstatement 
by footshock stress and intra-VTA CRF delivery in LgA rats. Data represent the 
effects of bilateral injection of KA (24 µg/side) as a pretreatment to footshock 
stress (36A/B; n=4), intra-VTA CRF delivery (500 ng/side; 36C/D; n=3), or KA in 
absence of footshock or CRF (36E; n=4). Reinstatement by shock was 
significantly reduced following intra-VTA KA compared to intra-VTA vehicle 
control conditions (36A; P<0.05), and significantly reduced the magnitude of 
shock-induced reinstatement as compared to vehicle controls (t3=3.433; P<0.05; 
36B). KA attenuated CRF-induced cocaine seeking but failed to reach 
significance due to a small sample size (36C/D). KA alone produces activational 
instead of suppressive effects in active lever pressing in the absence of shock or 
CRF (36E). 
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The effects of 24 µg/side intra-VTA KA on reinstatement in response to 
intra-VTA CRF were tested in only three rats and are shown in 36C and 36D.  
Because of the small sample size, statistically significant effects were not 
observed.  However, as was the case with footshock, KA attenuated CRF-
induced cocaine seeking.  Although preliminary studies investigating the effects 
of intra-VTA KA on sucrose-pellet reinforced responding suggest that this dose of 
KA may impair lever pressing, intra-VTA administration of KA alone in rats with a 
history of cocaine SA produced an increase in lever pressing, suggesting that it 
either reinstated cocaine seeking or produced an activational rather than 
suppressant effect (36E).  Notably KA-induced increases in previously inactive 
lever pressing were observed (increase from 5.67 responses to 23).  
Nonetheless, we have begun testing for the effects of lower intra-VTA KA doses 
on stress- and CRF-induced cocaine seeking. 
DISCUSSION 
 Stress during periods of drug abstinence contributes to relapse in cocaine-
dependent individuals. In the rodent model of relapse, excessive cocaine use 
increases susceptibility to stressor-induced reinstatement of drug-seeking 
behavior.  We previously reported that the reinstatement of extinguished cocaine 
seeking by a stressor (footshock) is corticotropin releasing factor (CRF) 
dependent, and is characterized by increased VTA dopamine neuron 
responsiveness during the reinstatement session. Furthermore, excessive 
cocaine use increases susceptibility to later stressor-induced relapse at least in 
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part by augmenting CRF-R1 receptor-dependent regulation of addiction-related 
neurocircuitry in the ventral tegmental area (VTA).  The VTA represents a 
convergence point whereby dopamine, glutamate, GABA, and CRF neurons 
interact to regulate motivated behavior including stress-induced reinstatement. 
Footshock stress can cause GABA release into the VTA and activate VTA 
GABA neurons (Tan et al., 2012, Jennings et al., 2013). Ionotropic GABAA 
receptors and metabotropic GABAB receptors are present in the VTA (Kalivas, 
1993, Westerink et al., 1996, Westerink et al., 1998). GABAA receptors are 
located predominantly, but not exclusively, on GABA neurons while GABAB 
receptors are predominantly located on dopamine neurons (Churchill et al., 1992, 
Klitenick et al., 1992, Xi and Stein, 1998, Magreta-Mitrovic, 1999, Laviolette and 
van der Kooy, 2001, Laviolette et al., 2004). Therefore, GABAergic interneuron 
inhibition of VTA DA neurons is regulated by ionotropic GABAA receptors (Sugita 
et al., 1992, Kalivas, 1993), while direct GABA inhibition of dopamine neurons is 
regulated by metabotropic GABAB receptors (Xi and Stein, 1998, Margeta-
Mitrovic et al., 1999). Additionally, GABAB receptors are located on presynaptic 
GABA and glutamate terminals in the VTA inhibiting neurotransmitter release 
(Bonci and Williams, 1997, Shen and Johnson, 1997, Manzoni and Williams, 
1999, Wu et al., 1999, Giorgetti et al., 2002, Michaeli and Yaka, 2010). 
Intra-VTA GABAA receptors have been implicated in neuroadaptations 
regulating effects of stress and cocaine on midbrain dopamine neurons (Giorgetti 
et al., 1998, Tan et al., 2012). Moreover, intra-VTA GABAA receptors can 
regulate aversion, reward, and relapse (David et al., 1997, Ikemoto et al., 1997a, 
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Ikemoto et al., 1997b, Tan et al., 2012, Graziane et al., 2013). For these reasons 
we characterize the role of GABAA receptors in the LgA rodent model of relapse.  
Intra-VTA administration of the GABAA antagonist (1 and 10 ng/side) fails to 
significantly attenuate both footshock- and intra-VTA CRF-induced reinstatement 
of extinguished LgA cocaine seeking.  The initial dose of 30 ng/side was chosen 
based of primary literature (Sandner et al., 1996) but produced potent seizure 
like effects. The 10 ng/side dose is the highest concentration that didn’t produce 
these effects and is therefore utilized. The potent effects of bicuculline are 
presumably due to powerful disinhibition of dopamine neurons through blocking 
GABAA receptors on resident VTA GABA interneurons (Churchill et al., 1992, 
Kalivas, 1993, Laviolette and van der Kooy, 2001, 2004); which control the 
excitability of VTA dopamine neurons (Grace and Bunney, 1979, Waszczak and 
Walters, 1980, Wirtshafter and Klitenick, 1989, Oakley et al., 1991, Westerink et 
al., 1996, Westerink et al., 1998, Xi and Stein, 1998, Laviolette and van der 
Kooy, 2001, 2004). These results are indicative that intra-VTA GABAA receptor 
activation is not necessary for footshock- and intra-VTA CRF-induced 
reinstatement of LgA cocaine seeking. 
In contrast to GABAA receptors, GABAB receptors are functionally and 
anatomically preferentially expressed by VTA DA neurons (Xi and Stein, 1998, 
Margeta-Mitrovic et al., 1999, Laviolette and van der Kooy, 2001, Margolis et al., 
2012). Therefore, in addition to the role of GABAA receptors we also characterize 
the role of GABAB receptors. This lead to the novel finding from this set of 
experiments. GABAB receptor antagonism (2-hydroxysaclofen; 2 µg/side) blocks 
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both footshock- and intra-VTA CRF-induced reinstatement of extinguished LgA 
cocaine-seeking behavior. 
Moreover, GABAB and CRF-R1 can have coordinated function on VTA 
dopamine neurons. We have previously shown that CRF-R1 activation in the 
VTA is necessary and sufficient for reinstatement of extinguished LgA cocaine 
seeking (Blacktop et al., 2011). Notably, others have found that intra-VTA CRF-
R1 activation can facilitate GABAB inhibition of VTA dopamine neurons 
(Beckstead et al., 2009). This inhibition of VTA dopamine neurons occurs 
through GABAB-receptor coupling to G protein activated inwardly rectifying 
potassium (GIRK) channels (Beckstead et al., 2009). CRF robustly increases 
GABAB activated GIRK-induced IPSCs on VTA dopamine neurons through CRF-
R1 activation (Beckstead et al., 2009).  
These findings are consistent with the notion that GABAB receptors, GIRK 
channels, CRF, and CRF-R1 receptors synergistically inhibit VTA dopamine 
neurons. This is one possible postsynaptic mechanism by which stress facilitates 
reinstatement of extinguished LgA cocaine-seeking behavior. However, under 
these conditions GABAB receptor blockade would be expected to increase VTA 
dopamine neuron activity not inhibit it. Although this is a possibility, it is not the 
only mechanism by which the GABAB receptor can regulate dopamine neuron 
excitation. 
Presynaptic GABAB receptor activation can inhibit release of both 
glutamate and GABA in the VTA (cite) (Bonci and Williams, 1997, Manzoni and 
Williams, 1999, Wu et al., 1999, Giorgetti et al., 2002, Michaeli and Yaka, 2010). 
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Repeated psychostimulant administration can augment the ability of GABAB 
receptors to inhibit postsynaptic dopamine neurons and recruit the ability of 
GABAB receptors to inhibit presynaptic glutamate release in the VTA (Giorgetti et 
al., 2002). This suggests that following drug exposure the GABAB receptor 
functions to inhibit VTA neuron excitation by decreasing glutamate input.  
These previous findings suggest that GABAB receptor antagonism could 
be blocking reinstatement by: (1) decreasing inhibitory drive of the motive circuit 
by decreasing GIRK IPSCs on VTA dopamine neurons (Giorgetti et al., 2002, 
Beckstead et al., 2009), (2) increasing GABA and/or glutamate release in the 
VTA by decreasing GABAB mediated inhibition of neurotransmitter release on 
presynaptic GABA and/or glutamate neurons (Bonci and Williams, 1997, Shen 
and Johnson, 1997, Manzoni and Williams, 1999, Wu et al., 1999, Giorgetti et al., 
2002, Michaeli and Yaka, 2010), (3) or even coding for optimal phasic firing of 
VTA dopamine neurons (Beckstead et al., 2004, Ford et al., 2009). It is important 
to note that the mechanism may or may not involve coordinated actions of 
GABAB and CRF-R1. GABAB receptor blockade may be producing downstream 
effects independent of CRF dependent processes to regulate relapse. However, 
GABAB receptor activation is necessary for CRF actions in the VTA to produce 
reinstatement. 
Repeated cocaine self-administration can recruit the ability for footshock 
stress and intra-VTA CRF to provide excitatory drive on VTA dopamine neurons 
through presynaptic glutamate release and subsequent ionotropic glutamate 
receptor conductance on dopamine neurons (Ungless et al., 2003, Wang et al., 
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2005, Wanat et al., 2008, Hahn et al., 2009). Stress-induced CRF release in the 
VTA occurs in both drug-naïve and drug-experienced animals. However, only in 
drug-experienced animals has the recruitment of presynaptic glutamate and 
postsynaptic somatodendritic dopamine signaling been reported (Wang et al., 
2005). Footshock-induced reinstatement and the recruited concurrent increases 
in somatodendritic dopamine but not glutamate concentrations can be blocked by 
administration of a nonspecific ionotropic glutamate receptor antagonist (Wang et 
al., 2005). For these reasons we also characterize the role of ionotropic 
glutamate receptor subtypes in reinstatement.  
Intra-VTA administration of AP-5 or NBQX failed to significantly attenuate 
reinstatement to both footshock stress and direct VTA CRF delivery. Intra-VTA 
CRF receptor activation can excite both dopaminergic and GABAergic neurons in 
the VTA (Korotkova et al., 2006), both of which express NMDA and non-NMDA 
ionotropic glutamate receptors (Kalivas et al., 1989, Seutin et al., 1990, Wang 
and French, 1995). Moreover, glutamate can activate these receptors on both 
dopamine and GABA neurons (Christie et al., 1985, Sesack and Pickel, 1992, 
Steffensen et al., 1998). Perhaps the inability of NMDA or AMPA receptor 
antagonists to block reinstatement is due to an opposition between dopamine 
and GABA neurons both expressing NMDA and AMPA receptors. This would 
produce opposition not allowing for direct control of phenotypic excitatory drive 
within the VTA.  
Alternatively, the inability to block cocaine seeking by AP-5 and NBQX 
may suggest that reinstatement is dependent on the coordinated action of both 
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AMPA and NMDA receptors consistent with magnesium block dependent 
neuroplasticity to regulate drug seeking. For these reasons we test the role of the 
nonspecific ionotropic glutamate receptor antagonist kynurenic acid (KA). A 
preliminary pilot study reports that KA (24 µg/side) significantly attenuates 
footshock stress-induced reinstatement and with more subjects will likely block 
intra-VTA CRF-induced reinstatement. This may suggest that the coordinated 
action of both NMDA and AMPA receptors are necessary. Alternatively, 
reinstatement may be dependent on kainate receptor activation.  
Kainate ionotropic glutamate receptors are substantially understudied, 
present in the VTA, and known to regulate intra-VTA dopamine neuron activity 
(Wang and French, 1993a, Barrera et al., 2005). AP-5 and NBQX do not target 
the kainate receptor. In contrast, kynurenic acid (KA) blocks both the kainate 
receptor (Alt et al., 2004) and stress-induced reinstatement. Initial investigation of 
KA (24 µg/side) reports significant reductions in food reinforced responding in 
drug naïve rats trained in sucrose pellet reinforcement behavior (data not 
shown). However, KA (24 µg/side) does not affect the ability of drug-experienced 
animals to press the lever in the absence of drug, stress, or intra-VTA CRF. In 
fact, KA produced an activational effect not a suppressive one (Figure 36E).  
Kynurenic acid, in addition to being an antagonist at the NMDA, AMPA, 
and kainate ionotropic glutamate receptors, is an antagonist at alpha(α)7 nicotinic 
receptors (Hilmas et al., 2001, Stone, 2007). Alpha 7 nicotinic receptors are 
present in the VTA and reported to regulate not only dopamine neuron excitation 
(Calabresi et al., 1989, Pidoplichko et al., 1997, Schilstrom et al., 2000) but also 
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drug self-administration (Corrigall and Coen, 1994). Therefore, the ability of KA to 
block reinstatement also holds the possibility to be regulated by alpha 7 nicotinic 
receptors. 
When interpreting these findings, it is important to note that in contrast to 
our self-administration rats, sucrose trained rats have no history of cocaine intake 
and are food-restricted, possibly altering their sensitivity to NMDA, AMPA, 
kainate, or alpha 7 nicotinic receptor antagonism. This may suggest differential 
responses of drug naïve and drug-experienced animals to the same intra-VTA 
KA dose. Alternatively, KA may be inhibiting sucrose-seeking and drug-seeking 
through a similar motivational mechanism without altering their ability to press the 
lever. Moreover, it is still possible that the effects of KA on reinstatement are 
attributable to locomotor impairments.  
Moreover, glutamate could be regulating reinstatement through 
metabotropic but not ionotropic receptors. Metabotropic glutamate receptor 
(mGluR) activation in the VTA has been shown to regulate cocaine-induced 
plasticity involving potentiation of excitatory input onto VTA dopamine neurons 
(Bellone and Luscher, 2006). Specifically, activation of mGluR receptors reverses 
cocaine-induced insertion of calcium permeable AMPA receptors into the 
membrane of VTA dopamine neurons; termed mGluR-LTD (Bellone and Luscher, 
2005, 2006, Mameli et al., 2007, Luscher and Huber, 2010). In addition to 
regulating cocaine-induced AMPA neuroplasticity, mGluR current can be 
enhanced by CRF release in the VTA (Riegel and Williams, 2008). However, 
mGluR expression levels in the VTA have been reported to be unchanged 
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following extended access to cocaine (Ben-Shahar et al., 2009, Ghasemzadeh et 
al., 2011). 
In summary, the findings from this series of experiments involving 
ionotropic glutamate receptors is difficult to interpret. To this end, the exact role 
of AMPA and NMDA receptors in stress-induced reinstatement of extinguished 
LgA cocaine-seeking remains unclear. Current studies are being conducted to 
look at the role of an NMDA/AMPA receptor specific antagonist cocktail (3 µg of 
both AP-5 and NBQX per side). There are possible roles for kainate, alpha 7 
nicotinic, and metabotropic glutamate receptors in stress-induced reinstatement 
that were not addressed by the current set of experiments. 
The current findings suggest that GABAB but not GABAA, NMDA, or AMPA 
receptors by themselves are necessary for both footshock- and intra-VTA CRF-
induced reinstatement of extinguished LgA cocaine seeking. These results are 
surprising, it was hypothesized that both NMDA and AMPA antagonists would 
block reinstatement while GABAA and GABAB antagonists would augment it. 
However, only 2-hydroxysaclofen, the GABAB receptor antagonist, reliably 
blocked reinstatement by both footshock stress and intra-VTA CRF delivery. This 
does not suggest that GABAA, NMDA, or AMPA receptors are not involved in 
stress-induced reinstatement, but rather likely reflects the inability to isolate 
neuronal phenotype specific activation by these receptors. However, the novel 
finding of this set of experiments is that GABAB receptor activation is necessary 
for both footshock- and intra-VTA CRF-induced reinstatement.  
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The ability of stressful life events to precipitate drug use through actions 
involving GABAB receptors in the VTA may or may not represent an emergent 
consequence of excessive cocaine use. Identification of the precise mechanisms 
behind the necessity of GABAB receptor activation in footshock- and intra-VTA 
CRF-induced reinstatement of extinguished LgA cocaine seeking should provide 
important insight into how stress responsiveness in cocaine addicts promotes 
cocaine craving and relapse. 
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CHAPTER 5 
GENERAL DISCUSSION: VENTRAL TEGMENTAL AREA REGULATION OF 
STRESS-INDUCED REINSTATEMENT OF COCAINE-SEEKING BEHAVIOR 
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SUMMARY OF FINDINGS BY CHAPTER 
 This dissertation addresses key unknown mechanisms behind addiction-
related drug-induced neuroplasticity and how such neuroplasticity gates the 
ability of stress to cause relapse. The high relapse rates in drug abstinent addicts 
have made preventing relapse central for the long-term management of drug 
addiction. In order to better understand how to prevent relapse, we must further 
understand the neurobiological processes that contribute to it. Primary questions 
of importance related to relapse are: 1) what are the primary triggers for relapse, 
2) what systems of the brain regulate these triggers of relapse, and 3) what 
maintains the vulnerability for these triggers to cause relapse even following 
periods of prolonged drug abstinence? Stressful life events are unpredictable and 
unavoidable causes of relapse in human addicts. In this dissertation stress-
induced relapse was modeled using the long-access cocaine self-
administration/stress-induced reinstatement rodent model. General questions 
addressed in this dissertation are: 1) what are the primary mechanisms of stress-
induced reinstatement, 2) what part of the brain regulates stress-induced 
reinstatement, and 3) what maintains the vulnerability for stress to trigger 
reinstatement even after extinction of drug seeking? 
Very little is known about the neuromechanisms through stress contributes 
to the relapse process. Previous work from our laboratory has demonstrated that 
intake dependent neuroplasticity occurs with repeated cocaine use. This 
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neuroplasticity, in turn, interacts with the stress-related neuropeptide 
corticotropin-releasing factor (CRF) to facilitate stress-induced reinstatement of 
cocaine-seeking behavior. Importantly, stress-induced reinstatement only occurs 
in animals with a prior history of daily long-access but not short-access cocaine 
use (Mantsch et al., 2008a, Blacktop et al., 2011, Graf et al., 2011). This 
suggests that stress-induced reinstatement in our animal model is dependent on 
cocaine intake-dependent neuroplasticity. The exact brain regions where this 
neuroplasticity and the neuropeptide CRF are interacting to regulate 
reinstatement are not fully defined. To this end, areas of convergence between 
motivational- and stress-related neurocircuitry provide opportunity for the study of 
the neuromechanisms by which stress facilitates relapse. A major area of 
convergence between motivational- and stress-related neurocircuitry examined in 
this dissertation is the ventral tegmental area (VTA). This area was examined 
because it represents a site where there is convergence of resident motivational-
related dopamine neurons and inputs that release the stress-related 
neuropeptide corticotropin releasing factor (CRF) (Wise and Rompre, 1989, 
Korotkova et al., 2006, Tagliaferro and Morales, 2008, Wanat et al., 2008, Hahn 
et al., 2009, Almela et al., 2012, Wanat et al., 2013). Novel CRF-related 
neurobiological mechanisms within the ventral tegmental area that contribute to 
stressor-induced reinstatement of cocaine seeking are described.  
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CHAPTER 2 
 Chapter two characterizes whether CRF actions in the VTA represent a 
primary mechanism responsible for stress-induced reinstatement, and, if so, 
which CRF receptor CRF is acting through. This was accomplished using site-
specific pharmacological manipulations within the VTA and the rodent 
reinstatement model of relapse. The hypotheses of chapter are that intra-VTA 
CRF administration is sufficient to reinstate drug seeking in high- (long-access) 
but not moderate-intake (short-access) animals and that CRF-R1, but not CRF-
R2, activation in the VTA is necessary and sufficient for reinstatement.  
Chapter two reports that CRF actions in the VTA do in fact represent a 
primary mechanism underlying stress-induced reinstatement. Intra-VTA CRF-
administration is sufficient to reinstate drug seeking in a similar way to footshock 
stress and this is only observed following long-access self-administration. 
Footshock stress and intra-VTA CRF administration produces robust 
reinstatement following LgA but not ShA cocaine self-administration. Footshock 
stress- and intra-VTA CRF-induced reinstatement are both dependent on CRF-
R1 receptor activation and not CRF-R2 receptor activation. Moreover, intra-VTA 
administration of a CRF-R1 but not CRF-R2 specific agonist is sufficient to 
reinstate drug seeking in a similar way to intra-VTA CRF administration. 
Therefore, intra-VTA CRF-R1 activation is necessary and sufficient for 
reinstatement of extinguished long-access cocaine-seeking behavior.  
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Altogether, the results of chapter two are indicative that excessive cocaine 
use increases the susceptibility to stressor-induced relapse at least in part by 
augmenting CRF-R1 dependent regulation of addiction-related neurocircuitry in 
the VTA. Importantly, these findings reveal a site specific neuromechanism that 
regulates stress-induced reinstatement of cocaine-seeking behavior. The findings 
of chapter 2 also suggest that CRF actions, by way of CRF-R1 activation in the 
VTA, may be one way through which stressful life events facilitate relapse in 
human addicts. 
CHAPTER 3 
 Chapter three characterizes whether stressor-induced reinstatement of 
cocaine-seeking behavior involves an increase or a decrease in VTA dopamine 
neuron activation. This was done utilizing dual immunohistochemistry to detect 
stress-induced expression of an indicator of neuronal activation, c-Fos (Sagar et 
al., 1988), with tyrosine hydroxylase, a known marker for dopamine neurons in 
the VTA (Hokfelt, 1984). It was hypothesized that a significant increase in 
dopamine neuron activation would only be observed under conditions in which 
footshock stress reinstates cocaine seeking. Therefore, it was hypothesized that 
a significant increase in intra-VTA dopamine neurons that co-express c-Fos in 
response to footshock stress would occur in long-access but not short-access 
animals. This hypothesis was guided by previous findings from our laboratory 
reporting that footshock stress only reinstates drug-seeking in animals with a 
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history of long-access but not short-access cocaine self-administration (Mantsch 
et al., 2008a, Blacktop et al., 2011, Graf et al., 2011).  
In contrast to previous findings, and the original hypotheses, it was found 
that 30% of short-access and 60% of long-access animals receiving footshock 
showed reinstatement of cocaine-seeking behavior. This is a disproportionately 
high percentage of ShA and low percentage of LgA rats relative to our previous 
reports. Independent of whether the animals received footshock or not animals 
with a history of short-access cocaine self-administration displayed increased, 
while animals with a history of long-access displayed decreased, VTA dopamine 
neuron activation. Surprisingly, the overall number and percent of dopamine 
neurons expressing Fos were found to be significantly increased in ShA but not 
LgA rats. Despite overall differences in dopamine (TH-positive) neuron activation 
(Fos positive) across groups, significant footshock stress-induced increases in 
dopamine cellular c-Fos reactivity were not observed in any cocaine self-
administration access group.  
Although, stress-induced reinstatement tends to be increased in LgA 
animals, an increase in c-Fos immunoreactivity was not observed under any 
condition. Interestingly, when LgA and ShA animals were combined, the 
percentage of TH-positive cells co-expressing c-Fos following stress-induced 
reinstatement was positively correlated with reinstatement magnitude. Further 
analysis of reinstatement and dopamine neuron activation was conducted on 
animals that did or did not reinstate in response to footshock (i.e. combining both 
ShA and LgA subjects). When examining across these groups and comparing to 
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non-stress, saline controls, and non-reinstating rats, the number and percentage 
of VTA Fos-expressing TH-positive cells was significantly increased in rats that 
displayed stress-induced reinstatement.  In other words, footshock stress 
produces a significant increase in VTA dopamine neuron activation only in 
animals that reinstated. Importantly, this suggests that stress-induced 
reinstatement of cocaine seeking is correlated with increased VTA dopamine 
neuron activation and that individual differences in VTA dopamine neuron 
activation by stress may also contribute to stress-induced reinstatement. The 
findings of chapter three suggest that stressful life events may cause relapse in 
human addicts by increasing VTA dopamine neuron activation, and that 
individual differences in the stress response of the addict can regulate the 
susceptibility to relapse. 
CHAPTER 4 
 Lastly, chapter 4 characterizes whether both stress- and intra-VTA CRF-
induced reinstatement of extinguished cocaine-seeking behavior is dependent on 
excitatory or inhibitory receptor activation in the VTA. More specifically, the 
necessity of AMPA, NMDA, GABAA, and GABAB receptor activation in this 
reinstatement was examined. This was also examined using site-specific 
pharmacological manipulations within the VTA and the rodent reinstatement 
model of relapse. It was hypothesized that both stress- and intra-VTA CRF-
induced reinstatement of extinguished long-access cocaine-seeking behavior 
would be dependent on excitatory (glutamate) but not inhibitory (GABA) receptor 
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activation within the VTA. Therefore, it was more specifically hypothesized that 
both NMDA and AMPA antagonists would block while both GABAA and GABAB 
antagonists would augment both stress- and intra-VTA CRF-induced 
reinstatement in long-access animals. These hypotheses are supported by 
earlier reports implicating excitatory glutamatergic activation of VTA dopamine 
neurons in CRF-dependent stress-induced reinstatement of cocaine-seeking 
behavior (Wang et al., 2005, Wang et al., 2007). 
In contrast to our original hypotheses, multiple doses of intra-VTA delivery 
of NMDA and AMPA receptor specific antagonists alone failed to block, while 
both GABAA and GABAB specific antagonists alone failed to augment 
reinstatement by either footshock stress or intra-VTA CRF delivery. Even more 
surprisingly, intra-VTA administration of a GABAB receptor specific antagonist 
alone blocked both footshock- and intra-VTA CRF-induced reinstatement in rats 
with a history of long-access self-administration in a similar way to CRF-R1 
antagonism described in chapter 2. Not only is this finding contrary to our original 
hypotheses but it is novel and implicates inhibitory GABAB receptor signaling in 
reinstatement of extinguished LgA cocaine seeking. These findings may also 
suggest that stressful life events precipitate relapse by engaging activation of the 
GABAB receptor in the ventral tegmental area. 
In summary the findings from chapters two through four suggest that: 1) 
stress is a primary trigger for relapse to cocaine use, 2) the CRF and dopamine 
systems within the ventral tegmental area regulate stress triggered relapse, 3) 
long-term vulnerability to stress-induced relapse involves drug-induced 
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neuroplasticity which in turn interacts with CRF and, possibly, dopamine systems 
within the VTA, 4) stress-induced relapse is correlated with increased activation 
of VTA dopamine neurons, and 5) stress-induced relapse is dependent on CRF-
R1 and GABAB receptor activation within the VTA. The findings from this 
dissertation provide much needed insight into the cocaine-induced 
neuroadaptations that occur within the VTA and which systems interact with 
those neuroadaptations to regulate later stressor-induced relapse in cocaine 
addicts. The hope is that these findings will make current drug addiction 
therapies more effective or help with the development new drug therapies for the 
long-term management of cocaine addiction. The following chapter will discuss 
the significance of the findings from chapters two through four in further detail. 
CRF RECEPTOR SUBTYPES AND THE VTA  
 CRF and both its receptors appear to be functionally expressed within the 
VTA (Ungless et al., 2003, Korotkova et al., 2006, Wanat et al., 2008). CRF-R1 
mRNA has been found in both dopaminergic and GABAergic neurons of the VTA 
(Korotkova et al., 2006, Tagliaferro and Morales, 2008, Refojo et al., 2011). 
Although, the VTA does express CRF-R1 mRNA it does so at much lower levels 
than in other brain regions (Sauvage and Steckler, 2001). For this reason, CRF-
R1 expression may be increased following LgA cocaine self-administration. 
Although not reported in this dissertation, a current collaborative study between 
our laboratory and the Seasholtz laboratory at the University of Michigan is being 
conducted. This study is utilizing double in situ hybridization for CRF-R1 or CRF-
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BP mRNA in dopamine and GABA neurons in rats with a history of ShA or LgA 
self-administration and in saline controls. Preliminary reports show a greater 
proportion of CRF-R1 mRNA in dopamine neurons than in GABA neurons within 
the VTA. 
Although the distribution of CRF receptor subtype mRNA expression has 
been extensively studied (Van Pett et al., 2000), the neurochemical identity of 
neurons expressing CRF-R1 protein remains largely unknown. A clear 
understanding of the localization of CRF receptor subtype receptors in the VTA 
awaits the availability of better antibodies for immunohistochemical 
characterization. This is largely due to difficulties generating CRF-R subtype 
specific antibodies (Chen et al., 2000, Campbell et al., 2003). Although, there are 
reports of CRF receptor subtype protein expression in the rat brain (Lukkes et al., 
2011) the general consensus is that commercially available CRF-R1 antibodies 
are insufficient in sensitivity and specificity to detect endogenous physiological 
levels of CRF-R1 protein in the brain (Refojo et al., 2011). Unfortunately, this has 
made characterizing CRF-R1 protein expression in the VTA under conditions in 
which it regulates relapse difficult. 
CRF RECEPTOR SIGNALING IN THE VTA AND STRESS 
 Potent anxiogenic effects have been reported following ventricular 
administration of CRF (Britton et al., 1982, Sutton et al., 1982, Gosnell et al., 
1983, Veldhuis and De Wied, 1984, Eaves et al., 1985, Berridge and Dunn, 
1986, Britton et al., 1986a, Britton et al., 1986b, Ruckebusch and Malbert, 1986, 
200 
 
Sherman and Kalin, 1986, Berridge and Dunn, 1987, Dunn and File, 1987, Ehlers 
and Chaplin, 1987, Sherman and Kalin, 1987, Swerdlow et al., 1989, Dunn and 
Berridge, 1990); see corticotropin releasing factor section in chapter one. In 
contrast to ventricular administration, the role of intra-VTA CRF has been under-
characterized. However, early reports have implicated intra-VTA CRF in 
increased locomotor activity (Kalivas et al., 1987) with chronic cocaine 
administration increasing CRF binding, as measured using autoradiography, 
within the VTA (Goeders et al., 1990). These findings are consistent with indirect 
observations from our laboratory in which intra-VTA CRF administration in drug-
experienced animals produces increased locomotor activity, anxiogenic like 
behaviors (i.e. increased grooming, agitation, and aggression), and reinstatement 
of cocaine seeking. 
CRF-R1 SIGNALING IN THE VTA AND STRESS 
 The finding that CRF-R1 regulates stress-induced relapse is consistent 
with its primary role in the stress response of an organism. CRF-R1 expression is 
more abundant and consistently reported in the VTA as compared to CRF-R2 
(Van Pett et al., 2000, Sauvage and Steckler, 2001, Refojo et al., 2011). 
Moreover, CRF has a tenfold higher affinity for CRF-R1 over CRF-R2 (Perrin et 
al., 1995), and is the receptor subtype that results in ACTH release and HPA-axis 
activation. CRF-R1 activation produces anxiogenic pro-stress effects (Bale and 
Vale, 2004) with CRF-R1 antagonists producing anxiolytic anti-stress effects 
(Schulz et al., 1996, Deak et al., 1999, Okuyama et al., 1999). Paradoxically, 
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selective deletion of CRF-R1 in midbrain dopaminergic neurons increases 
anxiety-like behavior and reduces dopamine release in the terminal fields of the 
VTA (Refojo et al., 2011). This suggests that CRF-R1 activation in the VTA can 
increase medial prefrontal dopamine concentrations and regulate stress-related 
behavior. This is consistent with stress-induced increases in mesocortical 
dopamine release (Thierry et al., 1976, Lavielle, 1978, Herman et al., 1982, Sorg 
and Kalivas, 1993). However, the finding that CRF-R1 activation in the VTA can 
be anxiolytic (Refojo et al., 2011) is not consistent with our findings that CRF-R1 
antagonist administration into the VTA blocks footshock stress-induced 
reinstatement (Blacktop et al., 2011).  
Similarly, the central function of the CRF-R2 receptor is not as well 
understood and has been implicated in both stress-protective and stress-coping 
effects (Bale et al., 2000, Valdez et al., 2002). Even less is known about the 
exact role of the CRF-R2 receptor within the ventral tegmental area. Therefore, 
the exact role of intra-VTA CRF release and activation of its receptors in 
anxiogenic and anxiolytic behavior in both drug naïve and drug-experienced 
animals needs to be investigated. It is possible that anxiogenic behavior induced 
by CRF administration into the VTA is augmented or even recruited following 
cocaine self-administration. Alternatively, anxiogenic effects of CRF may be 
mediated elsewhere in the CNS with intra-VTA CRF regulating other important 
aspects of stress reactivity (e.g., coping behaviors). These explanations are 
consistent with the emergent ability of intra-VTA CRF to cause reinstatement that 
is reported in chapter two. 
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LONG-ACCESS VERSUS SHORT-ACCESS COCAINE-INDUCED 
NEUROPLASTICITY 
 
 The amount of cocaine used is positively correlated with stress-induced 
cocaine craving in human addicts (Fox et al., 2005). Cocaine-induced 
neuroplasticity appears to involve increased stress responsiveness and cocaine 
craving (Sinha et al., 1999). In preclinical animal models of drug addiction and 
relapse, the long-access (LgA) approach has been utilized to examine drug-
induced neuroplasticity (Ahmed and Koob, 1998, 1999, Mantsch et al., 2008a, 
Blacktop et al., 2011, Graf et al., 2011). Reinstatement is augmented in response 
to cocaine (Mantsch et al., 2004, Madayag et al., 2011), cocaine cues following 
long-access cocaine self-administration (Kippin et al., 2006), and stress (Mantsch 
et al., 2008a, Blacktop et al., 2011, Graf et al., 2011). 
Reinstatement by footshock stress, ventricular CRF administration, and 
intra-VTA CRF administration appears to represent an emergent intake 
dependent phenomenon (Mantsch et al., 2008a, Blacktop et al., 2011, Graf et al., 
2011). Specifically, reinstatement by acute footshock stress exposure, ventricular 
CRF administration, and intra-VTA CRF administration is more reliably observed 
following high intake long-access (LgA; 14 x 6 hrs/day; ~70 mg/kg/day) but not 
short-access (ShA; 14 x 2 hrs/day; ~15 mg/kg/day) cocaine self-administration 
(Mantsch et al., 2008a, Blacktop et al., 2011, Graf et al., 2011). These findings 
suggest that the emergent ability of stress and CRF delivery to reinstate cocaine 
seeking is the likely consequence of cocaine-induced neuroplasticity in the 
circuitry of motivated behavior. This hypothesis is further supported by the 
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findings that CRF signaling (Richter and Weiss, 1999, Zorrilla et al., 2001, Specio 
et al., 2008, Zorrilla et al., 2012) is augmented following extended LgA cocaine 
self-administration. Altogether, this would suggest that the circuitry of motivated 
behavior becomes hypersensitized to CRF signaling following long-access 
cocaine self-administration. 
ROLE OF CRF RECEPTOR SUBTYPES IN THE VTA IN STRESSOR- AND 
INTRA-VTA CRF-INDUCED REINSTATEMENT OF EXTINGUISHED LONG-
ACCESS COCAINE-SEEKING BEHAVIOR 
 
 Excessive long-access cocaine self-administration increases the 
susceptibility to stressor-induced relapse at least in part by augmenting CRF-R1 
dependent regulation of addiction-related neurocircuitry in the VTA (Blacktop et 
al., 2011). The chapter two findings that VTA CRF-R1 receptors are necessary 
and sufficient for reinstatement of cocaine seeking is further supported by 
previous studies which found that footshock stress-induced reinstatement is 
inhibited by systemic or ventricular delivery of CRF-R1 but not CRF-R2 receptor 
antagonists (Shaham et al., 1998, Lu et al., 2001). However, these findings are 
inconsistent with previous reports of Wise and colleagues suggesting the 
involvement of intra-VTA CRF-R2 instead of CRF-R1 receptors along with an 
unknown mechanism involving the CRF-binding protein (Wang et al., 2005, 
Wang et al., 2007). 
Wise and colleagues reported that reinstatement, increased glutamate 
transmission, and increased somatodendritic dopamine signaling were all 
prevented by administration of a CRF-R2 antagonist and not a CRF-R1 
204 
 
antagonist (Wang et al., 2007). Furthermore, CRF receptor agonists found to be 
sufficient to cause reinstatement included ligands that bound to both the CRF-R1 
and CRF-R2 receptors (Wang et al., 2007). However, every agonist that 
reinstated also bound to the CRF-BP while ineffective agonists did not (Wang et 
al., 2007, Wise and Morales, 2010). For these reasons, the authors hypothesized 
a distinct role for both the CRF-R2 receptor and the CRF-BP in intra-VTA CRF 
dependent reinstatement of cocaine seeking. 
In contrast to Wang et al. (2007), chapter two reports that the CRF-R1 
specific agonist, cortagine, was sufficient while the CRF-R2 specific agonist, rat 
Urocortin 2 (rUcn2), was insufficient  to reinstate cocaine-seeking when 
administered into the VTA (Blacktop et al., 2011). Cortagine does not bind to the 
CRF-BP (Tezval et al., 2004) while rUcn2 does (Jahn et al., 2004). These 
findings suggest that the involvement of CRF-BP in reinstatement is yet another 
inconsistency between our findings reported in chapter two and those of Wise 
and colleagues. 
DISPARATE FINDINGS & METHODOLOGIES: CHAPTER TWO AND WISE 
AND COLLEAGUES 
 
 The reason for the inconsistencies between our findings and those of 
others is unclear but may involve differential experimental methodologies. These 
include the mode of delivery of CRF and CRF antagonist/agonists (microinjection 
vs. reverse dialysis), CRF receptor antagonist/agonist doses (90 µM to 5.5 mM 
vs. 1 to 10 µM), different rat strains (Sprague Dawley vs. Long-Evans), 
differential experimental cocaine histories (6 hrs vs. 4 hrs), and most notably the 
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amount of total cocaine intake. The daily cocaine reported in our LgA animals 
was greater than 70 mg/kg compared to 33 mg/kg (Wang et al., 2007, Blacktop 
et al., 2011). It is possible that regulation of cocaine seeking by CRF-R1 
receptors in VTA requires a prior history of very high levels of cocaine intake. In 
our hands excessive cocaine intake has been required for stress-induced 
reinstatement (Mantsch et al., 2008a). This is supported by previous findings 
reporting CRF-R1 only reduces cocaine self-administration following escalation in 
LgA rats (Specio et al., 2008).  
The method of intra-VTA CRF delivery (microinjection vs. reverse dialysis) 
may have determined which CRF receptor was necessary for reinstatement. 
Agonist stimulation of CRF-R1 results in the desensitization of CRF-R1 signaling, 
as a consequence of both second messenger-dependent protein kinase activity 
and G protein-coupled receptor kinase phosphorylation (Oakley et al., 2007). 
This promotes β-arrestin recruitment to CRF-R1 facilitating endocytosis (Holmes 
et al., 2006, Oakley et al., 2007). Following CRF binding CRF-R1 receptors are 
internalized and degraded (Reyes et al., 2006, Reyes et al., 2008).  
CRF has a tenfold higher affinity for CRF-R1 over CRF-R2 (Perrin et al., 
1995) producing differential effects of β-arrestin recruitment and therefore 
internalization. Specifically, preferential CRF-R1 over CRF-R2 internalization 
occurs in the micromolar range (Oakley et al., 2007, Hauger et al., 2013), as 
utilized by Wise and colleagues during reverse dialysis. At this concentration 
there is only weak β-arrestin recruitment to the CRF-R2 receptor but strong 
recruitment to the CRF-R1 receptor (Oakley et al., 2007, Hauger et al., 2013). 
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Considering that reverse dialysis is a more extended approach it is possible that 
preferential internalization of the CRF-R1 receptor occurred. Although our dose 
of CRF (420 µM) is significantly greater than the 10 µM used by Wang et al., 
(2007) it was acutely administered. Therefore, our dose likely readily activated 
both receptors but likely did not cause internalization prior to the phase of 
reinstatement testing during which cocaine seeking was observed. In contrast, 
reverse dialysis at the 10 µM concentration may have caused preferential CRF-
R1 internalization throughout the reinstatement session. In summary, 
endogenous CRF-R1 signaling was likely intact in our experiments and may not 
have been in others at the time of reinstatement. This may explain the CRF 
receptor subtype discrepancies between chapter two and Wise and colleagues.  
CRF RECEPTOR G-PROTEIN COUPLING 
 The complexities of CRF receptor subtype-dependent behaviors is 
enhanced considering the promiscuity of their G-protein coupling. CRF receptors 
may change their downstream signaling pathway in the ventral tegmental area 
(VTA) following high intake of cocaine. This possible change in G-protein 
coupling could account for differences observed in which CRF-receptor subtype 
is regulating drug seeking in the VTA (Wang et al., 2007, Blacktop et al., 2011). 
Therefore, characterizing downstream signaling cascades for both CRF receptor 
subtypes following extended cocaine access may be informative as to how 
cocaine history is changing CRF responsiveness in the VTA. In support, CRF 
receptors are known to couple to multiple G-proteins including Gs, Gi, and Gq 
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proteins (Grammatopoulos et al., 1999, Grammatopoulos et al., 2000, 
Grammatopoulos et al., 2001, Blank et al., 2003, Wietfeld et al., 2004, Berger et 
al., 2006). Different receptor states or conformations can have different G-protein 
couplings and different G protein couplings can have different affinities for 
different conformational states (Kenakin, 2002). The active allosteric 
conformational states of the CRF-R1 receptor are thought to determine the G-
protein coupling preference (Nielsen et al., 2000, Assil et al., 2001, Kenakin, 
2002, Hoare et al., 2003, Hoare et al., 2004, Wietfeld et al., 2004, Berger et al., 
2006). 
 It is well established that Gs activates PKA, Gi inhibits PKA, while Gq 
activates PKC all of which have different complex downstream signaling 
cascades. Chronic cocaine administration followed by acute withdrawal can 
produce a shift from CRF-R2 dependent Gs to Gq coupling in other brain regions 
(Liu et al., 2005). The promiscuous signaling of CRF receptors may help explain 
why CRF-R1, CRF-R2, PKA, and PKC have all been implicated in neuroplasticity 
of VTA dopamine neurons (Ungless et al., 2003, Wanat et al., 2008, Beckstead 
et al., 2009, Hahn et al., 2009). Therefore, there is the possibility that CRF-R1 
may change its receptor coupling in the VTA following high cocaine intake. 
Future studies need to address the coupling and downstream signaling of the 
CRF-R1 receptor in the VTA in both cocaine naïve and long-access cocaine-
experienced animals. 
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INTRACRANIAL CHEMICAL INJECTIONS: CHAPTERS TWO AND FOUR 
 Intracranial chemical injections (ICIs) play a critical role in the investigation 
and localization of neuromechanisms involved in drugs of abuse and relapse. 
However, there are significant caveats of the methodologies used that need to be 
taken into consideration. Pharmacological controls are necessary to assess non-
receptor-mediated local actions of the drug, anatomical controls are necessary to 
rule out drug efflux to distal sites of action, and behavioral controls are necessary 
to separate the neuromechanism of interest from generalized activational or 
suppressive effects of the administered drugs (Wise and Hoffman, 1992). 
The ventricular hypothesis involves the sphere of influence of ICI having 
and that sphere having the potential to spread from the site of ICI administration 
to the ventricular system (Routtenberg, 1972). Therefore, the anatomical region 
of interest along with spread must be considered when using site specific 
intracranial chemical injections. ICI material spreads through extracellular space 
(Bondareff and Pysh, 1968, Bondareff et al., 1970, Bondareff et al., 1971) with 
removal of ICI material occurring via blood vessels located near or at the 
injection site (Grossman and Stumpf, 1969). 
In fact, liquid application has less spread and more immediate effects than 
crystalline application of drug (Routtenberg and Olds, 1966, Stein and Levitt, 
1971). However, liquid administration has its own challenges. For example, a 
large injection volume, such as 1 µl, produces damage at the injection site in the 
form of a large vacuole at the site of the cannula tip (Routtenberg and Olds, 
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1966, Routtenberg, 1972). This is not surprising since a 1 µl volume is occupying 
1 mm3 within the brain (Routtenberg, 1972). To circumvent this, others have tried 
using much smaller volumes (ex. 0.05 µl) which failed to produce repeatable 
results (Routtenberg, 1972). Therefore, a compromise was made setting the 
standard for ICI volume methodology. The compromise involved a volume with 
minimal damage yet repeatable administration which occurred at either 0.5 or 
0.25 µl (Routtenberg and Simpson, 1971, Routtenberg, 1972). The spread of 
these smaller volumes was determined using dye and radiolabeled phosphorus 
with the same methodologies (ex. rate, cannula diameter, volume) and similar 
characteristics to the drug being administered (ex. pH, osmolarity, viscosity)  
(Maclean, 1957, Myers, 1966). These studies reported minimal restricted spread 
when 0.5 or 0.25 µl volumes are used. For these aforementioned reasons the 
0.25 µl volume was used for this dissertation.  
A 1 µl injection has an approximate spread radius of 0.6 mm producing a 
sphere of 1.2 mm in diameter (Lomax, 1966). Although 1 µl ICI showed 
considerable more spread than the 0.5 and 0.25 µl ICI (Routtenberg and 
Simpson, 1971, Routtenberg, 1972) it can be used as a conservative ratiometric 
estimate of spread for these smaller volumes. Using this volume to spread ratio a 
0.25 µl ICI, as administered in this dissertation, can be calculated to have a 
spread radius of 0.15 mm and a sphere of 0.30 mm in diameter. Considering the 
VTA in the rat has a conservative bilateral radius of 0.5 mm (Paxinos, 2007) it is 
reasonable to assume that upon histological confirmation of an injection site the 
spread will be likely localized to the VTA, within reason. It is important to note 
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that without a certain amount of spread ICI’s would be much less effective. The 
optimal amount of spread is necessary for three dimensional diffusion into the 
area of interest that has not been damaged upon insertion of cannula. In this 
way, diffusion can be an advantage and not a disadvantage for experimention.  
 
Figure 37: Depiction of the area of spread by a microinjection in the VTA. The 
black circle is demonstrating a 1 mm2 area representing the VTA area of interest, 
and the red circle is representing the calculated spread for a 0.25 µl injection of ~ 
0.30 mm in diameter (Paxinos, 2007). 
 
 
 
 
 
 
 
In addition to spread, there is damage to the site where the cannulae are 
placed within the brain. Tissue damage (e.g., reactive astrocytes, increased 
extracellular space) can, in turn, effect the neurochemistry of the injection site 
which can interact with the effects of the drugs being administered (Stavraky, 
1961, Miller et al., 1964, Routtenberg, 1968, Weiss and Heller, 1969, 
Routtenberg, 1971). These effects can be minimized by using smaller gauge 
cannulae, using a dummy probes that are longer than the actual microinjector, 
and allowing ample recovery time from surgery. 
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To further minimize complications, the effect of injector cannula insertion 
by itself must be taken into account. The insertion of injector cannulae alone has 
been shown to effect behavior (Goddard, 1965). If this is suspected or of concern 
sham microinjections can be used as a control. In addition to cannula insertion, 
the rate of volume infusion can affect the rate of spread, amount of tissue 
damage, time course of the drug effect, and even the behavioral outcome (Booth, 
1968, Routtenberg, 1971, Routtenberg and Simpson, 1971). A very slow rate of 
infusion (1 µl over 1-hr) and a very fast rate of infusion (1 µl over 1-minute; 0.5 µl 
over 10-sec) have been assessed for behavioral efficacy; with faster infusion 
rates producing most reliable results (Booth, 1968, Routtenberg, 1971, 
Routtenberg and Simpson, 1971). Therefore, the balance between latency of 
desired effect and possible tissue damage due to the rate of delivery must be 
considered. However, to reduce the possibility of ICI liquid from traveling back up 
the cannulae (i.e. path of least resistance) the injector cannula should be held in 
place for a period of time after the cessation of the injection. Repeatability of rate 
specific volumes can be applied using Hamilton syringes. For these reasons, 
0.25 µl was infused over a period of 1-minute with a Hamilton syringe, with the 
injector cannula being left in for an additional minute past cessation of the 
injection.  
Another factor that needs to be taken into consideration is the number of 
microinjections being applied to one injection site. The ideal number of intra-
cranial microinjections is one (Olds et al., 1964, Routtenberg, 1972). However, 
one injection may become impractical under certain paradigms. This is especially 
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true for long-access cocaine self-administration followed by extinction, which 
requires reinstatement testing following both vehicle and pharmacological pre-
treatments. To minimize damage to the injection site and the confound of this 
damage interacting with treatment-order bias, treatment conditions must be 
counter balanced with a maximum of 3-4 microinfusions per site. Alternatively, 
the experimenter can design between-group experimental methods at the 
expense of time and resources. In summary, the majority of methodological 
issues discussed cannot be entirely avoided but merely minimized. It is important 
to note that every method, when critically analyzed, will have its weaknesses.  
However, it is important not to lose sight of the powerful advantages that 
ICI gives the experimenter. ICI avoids complications of first pass metabolism and 
the difficulty of the blood-brain barrier. ICI is reproducible and the properties of 
the liquid being applied can be tightly controlled (ex. pH, osmolarity, spread, rate, 
any other important properties of an aqueous solution) (Routtenberg, 1972). This 
includes dose-response testing that includes both very low and high 
concentrations of drug. Moreover, findings from different research groups can be 
compared with a certain amount of reproducibility. Intracranial injections give the 
experimenter a much needed, albeit blunt, instrument with the ability to access 
presynaptic, postsynaptic, and astrocytic targets. This gives the experimenter the 
ability to characterize neuromechanisms at the tripartite synapse in freely 
behaving animals in vivo. It is particularly useful in determining which brain sites 
and receptors regulate behavior, such as drug seeking. 
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COCAINE ABSTINENCE AND STRESSOR RESPONSIVENESS 
 Longer periods of abstinence can produce heightened responsiveness to 
stressors (Erb et al., 1996, Sorge and Stewart, 2005) and dopamine neuron 
activation by CRF is greatly affected by prior cocaine exposure and the stage of 
drug abstinence (Beckstead et al., 2009). Footshock-induced reinstatement of 
cocaine seeking is relatively suppressed in the first 24 hrs after withdrawal from 
cocaine in animals provided prolonged cocaine self-administration (Sorge and 
Stewart, 2005). The findings that footshock is relatively ineffective in inducing 
reinstatement in the early withdrawal period appears to be specific to animals 
with a history of prolonged drug exposure. Interestingly, early withdrawal is when 
the anxiogenic effects are the highest (Weddington et al., 1990, Markou and 
Koob, 1991, 1992, Miller et al., 1993, Barros and Miczek, 1996) – thus, there is a 
functional disconnect between cocaine seeking and withdrawal-induced anxiety. 
Suppressed responding to footshock 24 hrs after withdrawal from cocaine is not 
observed in animals that self-administer cocaine for only 2 h per day (Sorge and 
Stewart, 2005). This suggests that LgA animals are fundamentally different than 
ShA animals during early abstinence following extinction training.  
Diminished footshock-induced reinstatement observed during early 
cocaine withdrawal normalizes within 48 hrs (Erb et al., 2004, Rudoy and Van 
Bockstaele, 2007). Furthermore, footshock-induced reinstatement can became 
progressively augmented over time (Sorge and Stewart, 2005) with stressor 
responsiveness being significantly greater in animals with prolonged cocaine 
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exposure (Sorge and Stewart, 2005). To this end, the amount of cocaine 
exposure is positively correlated with the magnitude of stress-induced 
reinstatement (active lever pressing) following forced abstinence and extinction 
training (Mantsch et al., 2008a). Augmented reinstatement magnitude in 
extended access cocaine self-administration animals was further supported by 
chapter two of this dissertation reporting augmented footshock- and intra-VTA 
CRF-induced reinstatement in LgA but not ShA animals. 
C-FOS AND NEURON ACTIVATION 
 Due to insufficient antibodies for both the CRF-R1 and CRF-R2 receptors 
protein cannot be characterized in the VTA following LgA conditions. Therefore, 
we characterized dopamine neuron activation following footshock in the VTA 
following different cocaine self-administration histories (saline/cocaine naive, 
short-access cocaine, long-access cocaine; ± footshock). Characterizing c-Fos 
protein expression, a marker for neuronal activation, with tyrosine hydroxylase 
(TH), a marker for dopamine cells in the VTA, allowed us to determine dopamine 
neuron activation under conditions in which footshock does and does not 
reinstate cocaine seeking. 
Immediate early genes (IEGs) are the first set of genes activated by 
external signals and do not require de novo protein synthesis (Sheng and 
Greenberg, 1990, Herrera and Robertson, 1996) making their induction both 
rapid and transient. IEGs are thought to function by encoding/activating 
transcription factors that will modify the expression of other genes, referred to as 
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target genes (TG) (Franza et al., 1988, Sheng and Greenberg, 1990). The most 
widely studied IEG in the CNS has been c-Fos (c-fos = mRNA, c-Fos = protein) 
(Herrera and Robertson, 1996, Kovacs, 2008). Importantly, in most cases, 
increased neuronal activity in vivo induces c-f/Fos expression in the nucleus of 
neurons (Curran et al., 1984, Dragunow and Robertson, 1987a, b, Hunt et al., 
1987, Morgan et al., 1987). To this end, c-f/Fos is used as a generic marker for 
neuronal activation following a diverse array of different stimuli (Sagar et al., 
1988, Cole et al., 1989, Dragunow and Faull, 1989). This provides a cellular 
method to label polysynaptically activated neurons within functional brain 
pathways (Sagar et al., 1988). 
Fos is reported in the nuclei of neurons in both normal and pathological 
states (Dragunow and Robertson, 1987b, a, Hunt et al., 1987, Morgan et al., 
1987) being transiently expressed in neurons after synaptic stimulation (Sagar et 
al., 1988). This makes the time course of Fos expression critical. The peak 
expression of c-fos mRNA is ½-1 hr after the cessation of the stimulus of interest, 
while the peak expression of c-Fos protein is 1-3 hr after cessation of the 
stimulus of interest (Sonnenberg et al., 1989, Chan et al., 1993, Imaki et al., 
1993, Ding et al., 1994, Ikeda et al., 1994, Cullinan et al., 1995, Kovacs and 
Sawchenko, 1996a, b, Kovacs, 1998). Fos expression then gradually disappears 
from the nucleus after 4-6 hrs after the stimulus of interest (Sonnenberg et al., 
1989, Chan et al., 1993, Imaki et al., 1993, Ding et al., 1994, Ikeda et al., 1994, 
Cullinan et al., 1995, Kovacs and Sawchenko, 1996a, b, Kovacs, 1998).  
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Neuronal c-f/Fos expression can be induced by neurotropic factors, 
neurotransmitters, depolarization, and an increase in intracellular Ca2+ either 
through influx or release from intra-cellular/nuclear stores (Greenberg and Ziff, 
1984, Szekely et al., 1987, Didier et al., 1989, Morgan and Curran, 1989, Szekely 
et al., 1989, Doucet et al., 1990, Sheng and Greenberg, 1990, Vaccarino et al., 
1992, Bading et al., 1993, Ghosh et al., 1994, Gaiddon et al., 1996). Mechanisms 
of c-f/Fos induction include PKA/cAMP/CaM Kinase/CRE activation (e.g., Gs-
GPCRs) (Sassone-Corsi et al., 1988, Gonzalez and Montminy, 1989, Sheng and 
Greenberg, 1990, de Groot and Sassone-Corsi, 1993, Bito et al., 1996); 
PKC/ras/MAPK/ERK activation (ex. growth factors, Gq-GPCRs, and calcium 
detection via voltage dependent Ca2+ channel influx) (Treisman, 1992, Hill and 
Treisman, 1995), and ligand gated Ca2+ NMDAR/MAPK activation (Greenberg et 
al., 1986, Morgan and Curran, 1986, Bading et al., 1993, Ghosh et al., 1994).  
Fos is the most widely used functional anatomical marker for activated 
neurons within the CNS for several reasons: 1) it is expressed at low levels in the 
intact brain under basal conditions (Curran, 1988, Kovacs, 2008), 2) it is typically 
induced in response to several extracellular signals, including ions, 
neurotransmitters, growth factors, and drugs (Kovacs, 2008), 3) the response is 
transient (Kovacs, 2008), and 4) detection of c-fos mRNA or c-Fos protein is 
simplistic (Kovacs, 2008).  
However, the canonical mRNA and protein labelling technique used has 
low temporal resolution and does not provide information about the connectivity 
of the activated neuron in vivo (Kovacs, 2008). Neuronal activation can occur 
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without induction of IEGs and markers for neuronal activation such as c-f/Fos are 
not expressed in chronically activated neurons (Kovacs, 2008). Under basal 
conditions c-f/Fos levels are very low (Hughes et al., 1992, Fenelon et al., 1993, 
Kaczmarek and Chaudhuri, 1997, Kovacs, 1998). Moreover, different stimuli can 
activate the same IEGs at the same time (Kovacs, 2008). This suggests that it is 
much more likely that afferent inputs and/or changes in external stimuli induce c-
f/Fos expression rather than tonic activation (Luckman et al., 1994). This 
suggests that c-f/Fos expression is very informative under the appropriate 
circumstances.  
c-fos mRNA and its protein product c-Fos are reliable markers for 
identifying activated cells and central nervous system circuits that respond to: 
daily rhythm (Maywood et al., 1995, Recio et al., 1996, Duffield et al., 1998, 
Vuillez et al., 1998), sleep/wake cycle (Novak et al., 2000), oestrus (Funabashi et 
al., 1997, Hairston et al., 2003), mating (Tetel et al., 1993, Wersinger et al., 1993, 
Cameron et al., 2004), lactation (Fenelon et al., 1993, Hoffman et al., 1994, Pape 
et al., 1996), drug of abuse (Graybiel et al., 1990, Young et al., 1991, Curran et 
al., 1996, Rotllant et al., 2010, Fanous et al., 2011, Zhao-Shea et al., 2011), and 
various stressors. 
C-FOS INDUCTION AND STRESSORS 
 The various stressors known to induce c-f/Fos include those involved in 
drug seeking paradigms such cold (Pacak and Palkovits, 2001), restraint 
(Cullinan et al., 1995, Imaki et al., 1995, Dayas et al., 2001, Viau and 
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Sawchenko, 2002), predator exposure (Chang et al., 2001, Bennett et al., 2002, 
Figueiredo et al., 2003), novelty (Emmert and Herman, 1999), forced swim 
(Duncan et al., 1993, Cullinan et al., 1995, Cullinan et al., 1996) and most 
notably, footshock (Campeau et al., 1991, Smith et al., 1992, Adolfsson et al., 
1998, Bale et al., 2000, Morrow et al., 2001).  
Stress-induced c-Fos activation can result from a complex interaction 
between catecholamines, glutamate, and CRF (Dragunow et al., 1990, Campeau 
et al., 1991, Arnold et al., 1992, Pezzone et al., 1992, Smith et al., 1992, 
Covenas et al., 1993, Harbuz et al., 1993, Imaki et al., 1993, Pezzone et al., 
1993, Wan et al., 1993, Wan et al., 1994). Footshock stress has been shown to 
cause reinstatement of cocaine seeking and CRF release within the brain under 
conditions shown to increase c-Fos expression; an effect prevented by pre-
treatment with a CRF-R antagonist (Arnold et al., 1992, Erb et al., 2005, Wang et 
al., 2005, Wang et al., 2007). This suggests that CRF receptor activation can 
induce c-Fos expression in the brain in response to a stressor. Cocaine and 
amphetamine exposure both induce c-Fos expression in the nucleus accumbens, 
prefrontal cortex, and VTA (Graybiel et al., 1990, Young et al., 1991, Colussi-Mas 
et al., 2007, Rotllant et al., 2010, Fanous et al., 2011). Moreover, previous 
cocaine exposure can increase footshock-induced c-Fos expression in the VTA 
(Morrow et al., 2001). Therefore, it is reasonable to hypothesize that intra-VTA 
CRF released via footshock stress will increase c-Fos expression in an intake 
dependent manner (i.e. short-access vs. long-access). 
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Stressful stimuli both induce c-Fos expression in (Deutch et al., 1991, Ma 
et al., 1993b, a) and increase firing of (Guarraci and Kapp, 1999, Anstrom and 
Woodward, 2005, Anstrom et al., 2009, Brischoux et al., 2009) VTA dopamine 
neurons. Importantly, c-Fos immunolabeling has been used to characterize 
footshock-induced neuronal activity (Van Pett et al., 2000) and reinstatement of 
drug seeking (Zhao et al., 2006). Therefore, it is possible that co-localization of c-
Fos with VTA dopamine neurons in response to footshock stress will be 
significantly greater under LgA self-administration conditions, as compared to 
ShA conditions. This could be attributed to a functional change following LgA 
self-administration, whereby footshock stress and intra-VTA CRF can now 
reinstate cocaine-seeking behavior. If footshock stress-induced reinstatement 
involves increased dopamine neuron activity in the VTA, it is logical to 
hypothesize that an increase in c-Fos immunoreactivity in dopamine neurons by 
footshock stress will only occur in LgA animals. 
FOOTSHOCK-INDUCED VTA DOPAMINE NEURON ACTIVATION  
 In chapter three a disproportionately high percent of short-access (ShA; 
30%) and low percent of long-access (LgA; 60%) animals reinstated in response 
to footshock stress. This is in comparison to chapter two reporting negligible 
reinstatement in ShA rats. These discrepancies cannot be easily explained but 
likely reflect the possibility that stress-induced reinstatement does not only occur 
following LgA cocaine self-administration but rather that a much higher 
percentage of rats reinstate in response to stress with extended-access to 
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cocaine. Nonetheless, while prior intake is one predictor of stress-induced 
cocaine seeking, other factors may also dictate the ability of stress to activate 
VTA dopamine neurons. This is consistent with others reporting stress-induced 
reinstatement under ShA conditions (Erb et al., 1996, Shalev et al., 2000). 
However, some of these other reports utilized three 2-h sessions per day to 
reliably induce reinstatement by footshock. Therefore, it is still likely that cocaine 
intake is in fact positively correlated with stress-induced reinstatement 
magnitude.  
Individual responsiveness to stress likely facilitated relapse in our short-
access (ShA) animals instead of drug intake. The reason for this conclusion is 
that, there was not a correlation between cocaine intake and reinstatement 
magnitude in ShA rats. Although, the findings of chapter two indicate that prior 
intake is one predictor of stress-induced cocaine seeking, chapter three suggests 
that other factors (e.g., pre-existing individual differences in stress reactivity) can 
also dictate the ability of stress to activate VTA dopamine neurons. Future 
studies characterizing these individual differences may give further insight into 
the factors regulating the propensity to relapse as a result of stressor exposure 
following periods of abstinence in human cocaine addicts.  
Chapter three also reports increased and decreased dopamine neuron 
activation in ShA and LgA animals, respectively. Surprisingly, overall number and 
percentage of dopamine neurons expressing c-Fos was significantly increased in 
ShA but not LgA rats relative to saline (Sal) controls. In fact, the c-Fos 
expression in TH-positive cells in LgA animals more closely resembled that of 
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Sal-treated animals. Despite overall differences in dopamine (TH-positive) 
neuron activation (Fos positive) across groups, significant footshock stress-
induced increases in dopamine cellular c-Fos immunoreactivity was not observed 
in any self-administration access group (Sal, ShA, and LgA). These findings are 
surprising in that they suggest that LgA rats display less dopamine neuron 
activation in the self-administration environment as compared to ShA rats. 
The basal levels of dopamine neuron activation in ShA versus LgA 
suggests that, in ShA animals, dopamine neurons show increased activation to 
the drug self-administration environment. Alternatively, in LgA animals there is 
either: (1) decreased activation to the drug self-administration environment, or 
there is an (2) extended up-regulation of an inhibitory tone imprint that can be 
removed by salient stressful stimuli in the drug self-administration context. ShA 
animals show increased, while LgA animals show decreased, dopamine neuron 
activation while in the drug self-administration context. This may also reflect a 
loss in dopamine neuron function in LgA animals. However, animals that 
reinstate in response to footshock stress exhibit increased VTA dopamine neuron 
activation. Moreover, the findings that inhibitory drive (i.e. GABAB receptor 
activation; Chapter 4) may be facilitating relapse is not consistent with increased 
c-Fos responsiveness during relapse in cocaine experienced animals unless it is 
coding for optimal phasic firing of VTA dopamine neurons (Beckstead et al., 
2004, Ford et al., 2009) in response to salient drug environmental cues during 
stress. 
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Although, chapter three reports that LgA animals appear to be less 
responsive to the drug self-administration context than ShA animals (i.e., Fos 
expression in TH-positive cells in the VTA under stress-free conditions is lower), 
the self-administration context appears to be an important component for 
reinstatement of cocaine seeking (Shalev et al., 2000). Drug self-administration 
context cues have been shown to reinstate extinguished cocaine seeking and 
induce c-Fos expression in VTA dopamine neurons of ShA animals (Kufahl et al., 
2009). Alternatively, LgA cocaine self-administration could be inhibiting the 
activation of dopamine cells in this brain region independent of the drug self-
administration context. For example, in the reinstatement rodent model of 
relapse, extinction is necessary to measure increases in drug-seeking behavior 
by stress and may affect VTA dopamine neuron excitation differentially in LgA 
animals as compared to ShA animals. Extinction neurocircuitry is another factor 
to take into consideration when comparing long-access and short-access 
animals. Extinction training may have divergent effects on VTA dopamine neuron 
activation in response to stress in an intake-dependent manner. Alternatively, 
others have supported context-independent effects of extended access to 
cocaine in the absence of extinction training on mesocorticolimbic dopamine 
neurotransmission. Specifically, extended-access to cocaine has been found to 
be associated with decreased mesocorticolimbic dopamine system activity during 
protracted withdrawal independent of context (Weiss et al., 1992a, Weiss et al., 
1992b).  
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In chapter three, when all rats were included in the analysis (i.e., short-
access and long-access rats combined), a positive overall correlation between 
the number and percentage of TH-positive cells co-expressing c-Fos and 
reinstatement magnitude (active lever presses) was observed.  Moreover, when 
reinstating rats were compared to non-stress, saline controls, and non-reinstating 
rats, the number and percentage of VTA TH-positive cells co-express c-Fos was 
significantly increased in rats that display stress-induced reinstatement. This 
suggests that footshock stress-induced reinstatement of cocaine-seeking 
behavior is positively correlated activation of VTA dopamine neurons.  
COCAINE-INDUCED NEUROPLASTICITY AND VTA DOPAMINE NEURON 
ACTIVATION BY STRESS 
 
 Drug experience may recruit the ability of footshock stress to increase Fos 
expression in the VTA, which may be dependent on intact upstream extended 
amygdala neurocircuitry (Ahmadi et al., 2008). To this end, drug experience is 
likely necessary for stress-induced activation of VTA dopamine neurons by CRF 
(Wang et al., 2005, Wang et al., 2007). Accordingly, CRF- and glutamate-
dependent somatodendritic release of dopamine has been reported to be 
dependent on cocaine experience in rats (Wang et al., 2005, Wang et al., 2007). 
However, the same studies found that footshock-induced CRF release was found 
to be comparable in both drug-naïve and drug-experienced animals (Wang et al., 
2005). This suggests that VTA dopamine neurons are more readily activated by 
CRF following drug exposure.  In contrast, evidence suggests that VTA CRF 
inputs express more CRF and are more active following drug exposure (Richter 
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and Weiss, 1999, Harris and Aston-Jones, 2003b, Zorrilla et al., 2012), these 
findings suggest that VTA neurons or downstream processes are likely more 
responsive to CRF as a result of drug-induced neuroplasticity.  
Fos immunoreactivity is significantly increased in the extended amygdala 
at the time of drug seeking during protracted withdrawal (Harris and Aston-Jones, 
2003b). Following extended cocaine self-administration CRF immunoreactivity is 
also increased in the extended amygdala (Zorrilla et al., 2012), further supporting 
increased neuron activation by stress in upstream targets that release CRF into 
the VTA. Moreover, elevated anxiety during drug abstinence may reflect 
increased sensitivity to stress that is not evident in resting baseline conditions 
(Aston-Jones and Harris, 2004). This is congruent with elevated stress sensitivity 
in addiction (Kreek and Koob, 1998, Sinha et al., 1999, Mantsch et al., 2008a). In 
summary, the finding from chapter three that footshock-induced VTA dopamine 
neuron activation is positively correlated with reinstatement magnitude likely 
reflects increased VTA dopamine neuron activation by CRF. In support, chronic 
cocaine administration increases CRF binding in the VTA (as measured by 
autoradiography) (Goeders et al., 1990), preliminary reports from a collaborative 
effort with the Seasholtz lab suggest a greater proportion of CRF-R1 mRNA in 
dopamine neurons than in GABA neurons within the VTA (unpublished findings), 
cocaine experience increases the excitatory effects and decreases the inhibitory 
effects of CRF actions upon VTA dopamine neurons (Ungless et al., 2003, Wang 
et al., 2005, Korotkova et al., 2006, Wang et al., 2007, Wanat et al., 2008, 
Beckstead et al., 2009, Hahn et al., 2009), CRF antagonists inhibit evoked 
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mesolimbic (measured by in vivo microdialysis) dopamine release (Lodge and 
Grace, 2005), and selective deletion of the CRF-R1 gene in VTA dopamine 
neurons decreases dopamine release in the prefrontal cortex (Refojo et al., 
2011). 
HETEROGENEOUS VTA DOPAMINE NEURON POPULATIONS: RESPONSE 
TO FOOTSHOCK STRESS 
 
 Aversive events and stressors have often been associated with reductions 
in the activity of mesolimbic dopamine projections and increases in the activity of 
mesocortical dopamine projections (Thierry et al., 1976, Herman et al., 1982, 
Deutch et al., 1985, Roth et al., 1988, Deutch et al., 1990, Deutch et al., 1991, 
Ungless et al., 2004, Ungless et al., 2010, Wanat et al., 2013). VTA dopamine 
neurons can be activated or inhibited by footshock stress (Brischoux et al., 
2009). Approximately, half of VTA dopamine neurons that are inhibited by 
footshock stress display excitation at the offset of the stimulus (Brischoux et al., 
2009). This suggests the possibility that the offset of an aversive stimulus may 
excite VTA dopamine neurons contributing to the increase in dopamine neuron 
Fos expression seen in reinstatement of cocaine seeking reported in chapter 3.  
Figure 38: Demonstration of different VTA dopamine responses to footshock 
stress from Brischoux et al., (2009); peristimulus time histogram averaged across 
6 footshocks + SEM; 500-ms bins. A) Excitatory response to footshock stress B) 
Inhibitory response to footshock stress followed by a rebound in activity. Both A 
and B conditions could result in increased c-Fos in VTA dopamine neurons. 
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An increase in footshock-induced Fos immunoreactivity in VTA dopamine 
neurons could reflect an increase in activation by footshock stress or possibly 
removal of footshock stress. Behavioral reports suggest that the offset of an 
aversive stimulus can act as a reward (Tanimoto et al., 2004) and can excite 
dopamine neurons (Daw et al., 2002) especially at the onset of appetitive events. 
Therefore, removal of the footshock may result in activation of the same 
dopamine neuron subpopulation that is inhibited by footshock stress (Daw et al., 
2002, Tanimoto et al., 2004, Brischoux et al., 2009, Ungless et al., 2010). 
Footshock removal-induced activation of VTA dopamine neurons as a key 
mechanism in Fos induction and reinstatement is much more likely if footshock is 
producing uniform inhibition of VTA dopamine neurons as reported by others 
(Ungless et al., 2004). However, this conclusion cannot be made without 
characterization of VTA dopamine neuron activation in response to footshock 
using high temporal resolution techniques (ex. voltammetry) in saline, ShA, and 
LgA animals. 
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The dysphoric effects of footshock stress in combination with the 
presentation of salient drug-associated cues (cocaine self-administration context) 
may produce overwhelming drug craving and motivation to use, in turn, resulting 
in reinstatement of drug seeking. Coinciding with the termination of footshock 
stress is both the extension of levers (both active and inactive) and the 
presentation of drug-associated cues (houselight), albeit extinguished cues, 
which may themselves activate VTA dopamine neurons in a manner that is 
dependent on prior cocaine self-administration history. Alternatively, a stressor, 
in the drug self-administration context, and in the presence of extinguished 
cocaine-assocaited cues may all be necessary for reinstatement of cocaine 
seeking that is characterized by increased Fos expression in VTA dopamine 
neurons. 
Due to the low temporal resolution (1-3 hrs) of c-Fos immunoreactivity the 
increased in c-Fos in VTA dopamine neurons in animals that reinstate in 
response to footshock stress may be induced by: 1) the actual stressor, 2) 
removal of the stressor, 3) presentation of the active lever, 4) chamber light 
activation, or 5) any combination of these factors. Equally important, it is possible 
that all of these factors together are needed to get footshock-induced 
reinstatement, which in turn may contribute to c-Fos induction in VTA dopamine 
neurons.  
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COORDINATED ACTION OF CRF ON MESOLIMBIC AND MESOCORTICAL 
SYSTEMS: CRF AN OPPORTUNISTIC NEUROMODULATOR IN THE VTA 
 
 
 While the VTA sends dense dopaminergic projections to the NAc, 
dopamine neurons activated by stress preferentially project to the medial 
prefrontal cortex (Thierry et al., 1976, Tassin et al., 1980, Herman et al., 1982, 
Deutch et al., 1985, Lammel et al., 2011, Lammel et al., 2012). When measuring 
dopamine activation at the level of the VTA it is very difficult to determine which 
cell populations are regulated by CRF and contribute to stress-induced 
reinstatement of cocaine seeking. This is particularly important when considering 
the selective heterogeneous regulation (mesocortical over mesolimbic) of the 
mesocorticolimbic dopamine system by stress and CRF. 
Dopamine is essential for information processing in the prefrontal cortex 
(Goldman-Rakic et al., 2000) and alterations of dopamine function within these 
systems have been implicated in drug addiction (Volkow et al., 1996, Volkow and 
Fowler, 2000, McFarland et al., 2004, Kalivas and Volkow, 2005, Peters et al., 
2008). Optimal dopamine receptor signaling on both pyramidal and non-
pyramidal cells within the mPFC is required for proper functional output (Penit-
Soria et al., 1987, Vincent et al., 1993, Gaspar et al., 1995, Seamans et al., 
1995, Fritts et al., 1998, Gulledge and Jaffe, 1998, Seamans et al., 1998, 
Gulledge and Jaffe, 2001, Wang and O'Donnell, 2001, Dong and White, 2003). 
When the PFC dopamine system signaling becomes dysregulated, a disruption 
of informational processing results (Sawaguchi and Goldman-Rakic, 1991, 
Williams and Goldman-Rakic, 1995, Zahrt et al., 1997, Seamans et al., 1998, 
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Seamans et al., 2001, Seamans and Yang, 2004) which has been implicated in 
stress-induced reinstatement of cocaine seeking (McFarland et al., 2004).  
The mesocortical DA projection arises primarily from the ventral tegmental 
area (VTA) and terminates mainly on pyramidal neurons in deep layers V and VI 
of medial PFC (mPFC) (Berger et al., 1976, Bjorklund et al., 1978, Emson and 
Koob, 1978, Berger et al., 1991, Carr et al., 1999). These neurons project back to 
the VTA and to the nucleus accumbens, and as a result, mesocortical dopamine 
input can also modulate VTA dopamine neuronal activity and mesolimbic 
dopamine inputs and NAc MSN dopamine responsiveness (Sesack and Pickel, 
1992, Taber et al., 1995, Carr and Sesack, 2000b, Geisler et al., 2007).  
STRESS SELECTIVELY ACTIVATES MESOCORTICAL OVER MESOLIMBIC 
DOPAMINE NEURONS 
 
 
 Stress, by way of CRF release in the VTA, may be modulating the 
mesocorticolimbic circuit in such a way that, upon drug context informational 
processing, drug seeking is engaged (Mantsch et al., 2014). To accomplish this, 
intra-VTA CRF might be acting as a coordinator of mesocorticolimbic function 
silencing dopamine neuronal activity in the absence of drug-associated stimuli 
while opportunistically promoting signaling in the presence of drug-associated 
stimuli   (Mantsch et al., 2014). This may take the form of increased mesocortical 
and decreased mesolimbic dopamine signaling during periods of stress and upon 
exposure to the drug self-administration context. 
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Figure 39: Mesocorticolimbic connectivity. Schematic demonstrating dopamine 
terminal fields in both the medial prefrontal cortex and nucleus accumbens, 
glutamate input to the nucleus accumbens from the medial prefrontal cortex, and 
GABAergic feedback from the nucleus accumbens to the VTA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exposure to certain stressors, notably footshock, selectively activate VTA 
dopamine neurons that project to the medial prefrontal cortex and not the 
nucleus accumbens (Thierry et al., 1976, Westerink and Korf, 1976, Fadda, 
1978, Lavielle, 1978, Tissari et al., 1979, Blanc et al., 1980, Fadda et al., 1980, 
Tassin et al., 1980, Herman et al., 1982, Reinhard et al., 1982, Bannon and Roth, 
1983, Deutch et al., 1985, Roth et al., 1988). Importantly, stress has been shown 
to selectively increase Fos expression in neurons of the VTA that project to the 
medial prefrontal cortex and not in the nucleus accumbens, as defined using 
retrograde tracers (Deutch et al., 1991). This is consistent with the hypothesis 
that stress preferentially targets the medial prefrontal cortex while dopamine 
neurons that project to the nucleus accumbens signal reward and salience 
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(Thierry et al., 1976, Tassin et al., 1980, Herman et al., 1982, Deutch et al., 1985, 
Lammel et al., 2011, Lammel et al., 2012). 
The selective regulation of mesocortical versus mesolimbic dopamine 
neurons in the VTA is currently under investigation by numerous groups with the 
goal of functionally and anatomically characterizing how each cell type 
differentially responds to stress and reward. However, the current literature 
suggests the intra-VTA nuclei/region of origin for the various mesolimbic versus 
mesocortical dopamine neurons that are differentially activated by both stress 
and/or reward is very convoluted (Bannon and Roth, 1983, Murase et al., 1993a, 
Murase et al., 1993b, Schultz, 1998, Ungless et al., 2004, Brischoux et al., 2009, 
Lammel et al., 2011, Lammel et al., 2012). In summary, ther is currently no clear 
organization model that defines where these dopamine neurons originate. 
Nonetheless, there are dopamine neurons that are preferentially activated by 
stress that project to the medial prefrontal cortex and dopamine neurons that are 
preferentially activated by reward that project to the nucleus accumbens.  
 
Figure 40: Differential effects of footshock stress on mesocortical versus 
mesolimbic neurotransmission. Schematic illustrating preferential activation of 
VTA dopamine neurons projecting to the medial prefrontal cortex and not the 
nucleus accumbens. Magnitude is indicated by width of the arrow. CRF-R1 is 
hypothesized to be on dopamine neurons projecting to the prefrontal cortex. 
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Figure 41: Effects of footshock stress on animals that reinstate. Proposed 
mechanism behind reinstatement and increased c-Fos in TH neurons by 
footshock in those animals. The dopamine neurons that are activated by 
footshock stress increase prelimbic cortex dopamine concentrations, providing 
excitatory glutamate input into the “Go” nucleus accumbens core circuit. 
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EFFECTS OF DRUG EXPOSURE ON STRESS-INDUCED MEDIAL 
PREFRONTAL DOPAMINE RELEASE 
 
 
 In drug-naïve animals, footshock stress increases dopamine levels in the 
medial prefrontal cortex (Sorg and Kalivas, 1993). However, prior daily pre-
treatment with amphetamine or cocaine decreases footshock-induced dopamine 
release in the PFC (Robinson et al., 1985, Sorg and Kalivas, 1993). Importantly, 
the time course of the footshock can dictate whether mesocortical dopamine 
levels increase or decrease in drug experienced animals. Early on (5-10 min) 
after footshock onset dopamine signaling is increased, but decreases to baseline 
or even lower levels with continued footshock exposure (20-30 min) (Robinson et 
al., 1987, Kalivas and Duffy, 1989). This is in stark contrast to marked increases 
in prefrontal dopamine signaling in cocaine naïve animals receiving footshock for 
20 minutes in duration (Thierry et al., 1976, Roth et al., 1988). Moreover, 
repeated footshock decreases cocaine challenge-induced increases in prefrontal 
dopamine concentrations (Sorg and Kalivas, 1993). These data suggest that 
repeated stress or cocaine exposure can induce tolerance in mesocortical 
dopamine release to footshock or a cocaine challenge, respectively (Sorg and 
Kalivas, 1993). This is important when considering that footshock stress in the 
experiments described in this dissertation involved cocaine-experienced rats, 
lasted 15 minutes, and, in some cases, was counterbalanced, and repeatedly 
delivered.  
Fos data described in chapter 3 would suggest that footshock increases 
VTA dopamine activity only when reinstatement occurs and that reinstatement 
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may involve increases in VTA dopamine neuron activation. However, it is unclear 
if stress alone is activating dopamine cells or if it is enhancing the ability of the 
self-administration context to produce activation. To investigate this, the effect of 
footshock stress of VTA dopamine neuron activation in the absence of the drug 
context in both drug naïve and drug experienced animal’s needs to be examined. 
Likewise, footshock-induced c-Fos induction in the prefrontal cortex needs to be 
characterized in drug-naïve and drug-experienced animals inside and outside the 
drug self-administration context. 
Although, the exact effect of stress on mesolimbic dopaminergic 
neurotransmission is still up for debate, recent evidence suggests that VTA CRF 
signaling may decrease NAc dopamine (Wanat et al., 2013). This decreased 
mesolimbic response is likely signaling dysphoria, while increased dopamine in 
the prefrontal cortex and its regulation of glutamatergic projections to the nucleus 
accumbens core may be more important for drug craving and relapse (Figure 
41). Decreased mesolimbic dopamine in parallel with increased mesocortical 
dopamine may regulate different aspects of the stress response, differentially 
contributing to relapse. Increased mesocortical dopamine originates from the 
VTA and terminates in both the prelimbic and infralimbic cortices in the rat 
(Berger et al., 1976, Van Eden et al., 1987). Mesocortical dopamine may also 
regulate the mesolimbic dopamine stress response. Depletion of dopaminergic 
signaling in the prefrontal cortex has been reported to both increase and 
decrease the mesolimbic dopamine response to stress (Deutch et al., 1990, 
Feenstra et al., 1992, King et al., 1997, Harden et al., 1998, Moghaddam, 2002). 
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Stress may be selectively activating mesocortical and inhibiting 
mesolimbic VTA dopamine projection neurons but how does CRF-R1 activation 
contribute? It has been reported that deletion of CRF-R1 in VTA dopaminergic 
neurons reduces stress-induced dopamine release selectively in the prefrontal 
cortex (Refojo et al., 2011). This suggests that in the VTA CRF-R1 may be 
selectively express in dopamine neurons that project to the prefrontal cortex. 
Therefore, CRF-R1-dependent stress-induced reinstatement of extinguished 
long-access cocaine-seeking behavior may be the result of increasing dopamine 
release in the medial prefrontal cortex via CRF-R1 activation in the VTA.  
 
 
Figure 42: CRF-R1 antagonist effects upon footshock stress on mesocortical 
versus mesolimbic dopamine neurotransmission. CRF-R1 antagonism is 
hypothesized to block mesocortical increases in dopamine by stress, and 
increase mesolimbic dopamine levels. 
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Figure 43: Proposed effects of CRF-R1 antagonism on mesocortical input. CRF-
R1 antagonism is hypothesized to decrease stress-induced increases in 
mesocortical prelimbic dopamine concentrations, blocking relapse by inhibiting 
glutamate input into the nucleus accumbens core “Go” circuit. 
 
In summary, there are increases and decreases in VTA dopamine neuron 
activation in ShA and LgA animals in the self-administration context in the 
absence of stress relative to sline control rats, respectively. Importantly, saline 
controls did not exhibit significant changes in VTA dopamine neuron activity in 
response to footshock stress. The data from chapters 2 and 3 suggest that 
footshock-induced reinstatement in either ShA or LgA animals is positively 
correlated with increased activation of VTA dopamine cells that may target the 
medial prefrontal cortex through a CRF-R1 dependent mechanism. The apparent 
differential regulation of dopamine neuronal activity by different cocaine self-
administration histories (ShA versus LgA) upon exposure to the drug-taking 
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context is intriguing. This suggests the possibility that dopamine neuron 
activation in LgA animals is fundamentally different than in ShA animals. 
Previous studies have implicated the importance of context in cocaine 
experienced animals on both VTA dopamine neuron activation and footshock-
induced reinstatement (Shalev et al., 2000, Kufahl et al., 2009). Future studies 
should characterize dopamine neuron activation by footshock stress outside of 
the drug self-administration context in both short-access and long-access 
cocaine experienced animals that have undergone extinction training. 
REWARD AND DOPAMINE SIGNALING  
 Rewarding stimuli, including drugs of abuse, increase VTA dopamine cell 
firing, thereby increasing downstream dopamine release in the nucleus 
accumbens (Wise and Rompre, 1989, Wise, 1996, Moisan and Rompre, 1998, 
Hernandez and Shizgal, 2009). Increase dopamine in the nucleus accumbens is 
strongly associated with both reward perception and motivated behavior 
(Mogenson et al., 1980) such as drug seeking. Increased dopaminergic activity 
within the prefrontal cortex, especially for cocaine, is also associated with 
motivation (Gariano and Groves, 1988, Chang et al., 1998, Tzschentke, 2000), 
suggesting that burst firing of VTA dopamine neurons target both the nucleus 
accumbens and the prefrontal cortex (Gariano and Groves, 1988). The rewarding 
value of a stimulus is signaled by a shift from tonic to phasic burst firing of VTA 
dopamine neurons (Gonon, 1988, Schultz, 2007a). Burst firing activity of VTA 
dopamine neurons optimizes terminal field release of dopamine concentrations 
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that are significantly greater than those evoked by spikes within a non-bursting 
mode (Gonon, 1988, Nissbrandt et al., 1994). 
VTA DOPAMINE NEURON BURST FIRING: REGULATION BY GLUTAMATE 
AND GABA 
 
 Ventral tegmental area dopamine neuron burst firing activity is regulated in 
an opposing manner by excitatory glutamatergic and inhibitory GABAergic inputs. 
Glutamatergic inputs increase (West et al., 2003) while inhibitory GABAergic 
inputs decrease (Di Chiara et al., 1979, Stanford and Lacey, 1996, Steffensen et 
al., 1998) VTA dopamine neuron burst firing activity. Glutamate-induced 
increases in burst firing are dependent on NMDAR and AMPAR activation while 
GABA-induced decreases in burst firing are dependent on GABABR and 
GABAAR activation (Johnson et al., 1992, Klitenick et al., 1992, Overton and 
Clark, 1992, Chergui et al., 1993, Ikemoto et al., 1997a, Overton and Clark, 
1997, Paladini et al., 1999b, Laviolette and van der Kooy, 2001, Erhardt et al., 
2002, Georges and Aston-Jones, 2002, Zweifel et al., 2008, Deister et al., 2009, 
Tan et al., 2012). 
In the VTA, glutamatergic nerve terminals synapse upon both dopamine 
and GABA neurons (Carr and Sesack, 2000b, Omelchenko et al., 2009, Dobi et 
al., 2010). NMDA and AMPA receptors are located on both VTA dopamine and 
GABA neurons, with NMDA and AMPA receptor agonists increasing dopamine 
and GABA neuron activation (Kalivas et al., 1989, Seutin et al., 1990, Mereu et 
al., 1991, Suaud-Chagny et al., 1992, Chergui et al., 1993, Wang and French, 
1993b, a, Wang et al., 1994, Wang and French, 1995, Tong et al., 1996, White, 
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1996, Gronier and Rasmussen, 1998, Giorgetti et al., 2001, Schultz, 2007a). 
GABA interneuron activation in the VTA can in inhibit dopamine neurons (Grace 
et al., 2007a). In this way, glutamate regulates the output of VTA DA neurons 
through the ratio of direct excitatory and indirect inhibitory activity mediated by 
glutamate receptor activation on dopamine and GABA neurons, respectively. 
THE VENTRAL TEGMENTAL AREA, GLUTAMATE, REWARD, AND DRUG 
SEEKING 
 
 A significant role for midbrain glutamate transmission in cocaine addiction-
related process has been reported ranging from drug-induced neuroplasticity in 
the VTA, to reward, to the regulation of drug-seeking behavior in response to 
stress, cue, and drug (Boyson et al., Kalivas and Duffy, 1998, Ungless et al., 
2001, Vorel et al., 2001, Carlezon and Nestler, 2002, Tzschentke and Schmidt, 
2003, Dunn et al., 2005, Sun, 2005, Wang et al., 2005, Wang et al., 2007, Chen 
et al., 2008, Covington et al., 2008, Yap and Miczek, 2008, Wise, 2009, Nolan et 
al., 2010, Lane et al., 2011).  
Glutamate stimulates intra-VTA DA cell firing acting through several 
ionotropic receptors including NMDA- and AMPA-receptors (Gonon, 1988, Seutin 
et al., 1990, Wang and French, 1993b, a, Ungless et al., 2001, Sziraki et al., 
2002, Harris et al., 2004, Zweifel et al., 2009, Jalabert et al., 2011, Lammel et al., 
2012). For example, these receptors meiate synaptic plasticity in the VTA in the 
form of LTP and LTD. The AMPA receptor regulates fast and short 
depolarization, while the NMDA receptor regulates longer lasting depolarization 
(Mereu et al., 1991, Johnson and North, 1992b).  
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Activation of both mesolimbic and mesocortical dopamine pathways are 
dependent on ionotropic glutamate receptor activation. In vivo glutamate and 
glutamate receptor agonist application into the VTA increases dopamine 
signaling in the nucleus accumbens and the medial prefrontal cortex (Kalivas et 
al., 1989, Suaud-Chagny et al., 1992, Chergui et al., 1993, Wang et al., 1994, 
Jedema and Moghddam, 1996, Karreman et al., 1996, Westerink et al., 1996, 
Schilstrom, 1998, Giorgetti et al., 2001, Tye et al., 2013) with increased 
dopamine in the NAc and mPFC being blocked by NMDA and AMPA receptor 
antagonism in the VTA (Westerink et al., 1996, Mathe et al., 1998, Schilstrom et 
al., 1998, Westerink et al., 1998, Giorgetti et al., 2001, Lammel et al., 2012).  
Paradoxically, both activation and inhibition of VTA NMDA receptors can 
increase nucleus accumbens dopamine release (French et al., 1993, Karreman 
et al., 1996, Mathe et al., 1998, Kretschmer, 1999). Moreover, rats can be trained 
to self-administer the NMDA antagonist AP-5 into the VTA suggesting there are 
potential positive motivational properties associated with blocking the NMDA 
receptor in the VTA (Webb et al., 2012). Intra-VTA NMDAR antagonism has also 
been shown to increase reward signal via intracranial stimulation (Bergeron and 
Rompre, 2013, Ducrot et al., 2013). Therefore, NMDA receptor blockade in the 
VTA has been shown to be reinforcing by multiple groups. 
Less is known about VTA AMPAR activation and reward. Intra-VTA AMPA 
receptor specific antagonism (NBQX) (Sheardown et al., 1990) can dose 
dependently reduce reward elicited by intracranial stimulation (Miliaressis et al., 
1986, Ducrot et al., 2013). However, intra-VTA AMPA receptor antagonism has 
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been reported to increase operant responding for conditioned reinforcement, and 
induce conditioned place preference both of which reflect a positive motivational 
property (Harris and Aston-Jones, 2003a, Harris et al., 2004, Nolan et al., 2010). 
Increased reinforcement measures and operant responding by intra-VTA AMPA 
receptor blockade can occur (Ducrot et al., 2013).  
NMDA, AMPA, AND COCAINE SEEKING 
 Glutamate release into the VTA appears to play a central role in cocaine 
seeking. In support, increases in extracellular glutamate concentrations in the 
VTA precedes and coincides with active lever pressing in rats responding during 
extinction (You et al., 2007), and intra-VTA administration of the glutamate 
receptor agonist NMDA can reinstate cocaine-seeking behavior (Vorel et al., 
2001). Moreover, cocaine seeking in response to drug exposure can be 
attenuated by intra-VTA treatment with both an NMDA and AMPA receptor 
antagonist (You et al., 2007, Schmidt et al., 2009). Specifically, cocaine seeking 
can be significantly decreased by intra-VTA administration with AP5 (NMDA 
antagonist), CNQX (AMPA antagonist), both AP5 and CNQX simultaneously, and 
kynurenic acid a nonspecific ionotropic glutamate receptor antagonist (Vorel et 
al., 2001, Wang et al., 2005, You et al., 2007, Schmidt et al., 2009).  This 
suggests that, under some circumstances, cocaine seeking may be dependent 
on stimulation of both NMDA and AMPA receptors in the VTA. 
The hypothesis that intra-VTA AMPAR antagonism would decrease 
cocaine seeking has been previously tested by other groups. Our results that 
NMDA and AMPA receptor blockade failed to block intra-VTA CRF- and 
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footshock stress-induced of cocaine-seeking behavior failed to support this 
hypothesis. Moreover, our results suggest that AMPAR antagonism causes 
general activating effects, and may enhance reinstatement, similar to previously 
reported effects on the capacity of cocaine conditioned stimuli to function as 
conditioned reinforcers as reported by others (Nolan et al., 2010). The 
discrepancy between Nolan et al. (2010) and You et al. (2007) could be due to 
differences in methodology. You et al. (2007) administered drug to the VTA via 
reverse dialysis whereas Nolan et al., (2010) administered drug via 
microinjection. You et al. (2007) used CNQX, while Nolan et al. (2010) used 
NBQX. NBQX has been demonstrated to be a more effective blocker of AMPA 
receptors than CNQX (Yu and Miller, 1995), and CNQX, even though considered 
an AMPA receptor antagonist, has significant blocking action at the glycine site of 
NMDA receptors (Sheardown et al., 1990, Yu and Miller, 1995, Mead and 
Stephens, 1999). Lastly, You et al. (2007) had the majority of their cannulae sites 
at -5.6 mm from bregma, while Nolan et al. (2010) had most cannulae sites 
between -5.8 to -6.3 mm from bregma consistent with the location of high 
GABAergic populations (Perrotti et al., 2005, Olson and Nestler, 2007, Kaufling 
et al., 2009). Interestingly, methodologies and data from chapter 4 of this 
dissertation are most similar and consistent to Nolan et al. (2010), whose finding 
that AMPAR antagonism in the VTA enhanced cocaine seeking are similar to our 
own with stress- and intra-VTA CRF-induced reinstatement. Altogether, the 
current data suggest that reward is more complex than simple ionotropic 
glutamate receptor activation of mesolimbic dopamine neurons. This complexity 
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most certainly also applies to drug seeking induced by aversive events such as 
footshock stress. 
IONOTROPIC GLUTAMATE RECEPTORS AND REINSTATEMENT 
 Exposure to drugs of abuse, such as cocaine, produces neuroplastic 
changes involving ionotropic glutamate receptor function in the VTA. This 
plasticity includes enhanced AMPA and NMDAR signaling (Ungless et al., 2001, 
Schilstrom et al., 2006). Moreover, CRF itself appears to also enhance ionotropic 
glutamate receptor signaling in cocaine-experienced animals (Ungless et al., 
2003, Wang et al., 2005) suggesting that cocaine use can augment the ability of 
stress to facilitate ionotropic glutamate receptor function in the VTA.  
The mechanism of action of intra-VTA CRF-R1 receptor-dependent 
reinstatement of extinguished cocaine seeking was hypothesized to involve 
augmented excitatory drive on VTA dopamine neurons either through 
enhancement of glutamate release and/or ionotropic glutamate receptor signaling 
on VTA DA neurons (Sun, 2005, Wang et al., 2005, Hahn et al., 2009). More 
specifically, it was hypothesized that if the reinstating effects of CRF in the VTA 
involve an increase in in mesocorticolimbic dopamine system by way of 
glutamatergic signaling, then blockade of either AMPA or NMDA ionotropic 
glutamate receptors should prevent reinstatement in response to footshock 
stress or intra-VTA delivery of CRF. To test this hypothesis, the necessity of 
intra-VTA NMDAR and AMPAR function in both footshock- and intra-VTA CRF-
induced reinstatement of extinguished cocaine-seeking behavior was tested 
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using the ionotropic glutamate receptor antagonists reported in Chapter 4 of this 
dissertation.  
Surprisingly, neither intra-VTA AMPA nor NMDA receptor blockade alone 
blocked reinstatement at the doses tested. It remains unclear if intra-VTA 
AMPAR- or NMDAR- receptor activation is involved in intra-VTA CRF-dependent 
stress-induced reinstatement of cocaine-seeking behavior. The findings from this 
series of experiments involving ionotropic glutamate receptors is difficult to 
interpret. To this end, the exact role of AMPA and NMDA receptors in stress-
induced reinstatement of extinguished LgA cocaine-seeking remains unclear. It is 
possible that inactivation of both AMPA and NMDA receptors is necessary to 
block reinstatement. Current studies are being conducted to look at the ability of 
whether an NMDA/AMPA receptor specific antagonist cocktail (3 µg of both AP-5 
and NBQX per side) can block reinstatement. Another possible interpretation of 
the inability of NMDA or AMPA receptor antagonists, by themselves, to block 
reinstatement may be due to an opposition between dopamine and GABA 
neurons both expressing NMDA and AMPA receptors. This would produce 
opposition inhibiting excitation of both dopamine and GABA neurons within the 
VTA. Alternatively, glutamate may be regulating reinstatement not through AMPA 
or NMDA receptors but through either kainate or metabotropic glutamate 
(mGluRs) receptors, both of which are not targeted by either AP-5 or NBQX. 
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OPPOSITION BETWEEN NEURONAL PHENOTYPES BOTH EXPRESSING 
NMDA AND AMPA RECEPTORS 
 
 
 Slice electrophysiology studies have demonstrated that intra-VTA CRF 
receptor activation can excite both dopaminergic and GABAergic neurons in the 
VTA (Korotkova et al., 2006), both of which express NMDA and AMPA ionotropic 
glutamate receptors (Kalivas et al., 1989, Seutin et al., 1990, Wang and French, 
1995) and receive excitatory inputs (Christie et al., 1985, Sesack and Pickel, 
1992, Steffensen et al., 1998, Lammel et al., 2012, Jennings et al., 2013). 
Therefore, one explanation for the unexpected inability of antagonists to block 
reinstatement using intra-VTA AMPAR or NMDAR antagonists is that the 
combined effects on both neuronal phenotypes resulted in opposing effects on 
behavior.  
MESOLIMBIC AND MESOCORTICAL AFFERENT NEURONS BOTH EXPRESS 
NMDA AND AMPA RECEPTORS 
 
 
 Stress appears to specifically target the prefrontal cortex increasing both 
dopamine and glutamate concentrations (Thierry et al., 1976, Tassin et al., 1980, 
Herman et al., 1982, Deutch et al., 1985, Abercrombie et al., 1989, Cenci et al., 
1992, Moghaddam, 1993, Moghaddam et al., 1994, Karreman and Moghaddam, 
1996, Bagley and Moghaddam, 1997, Lammel et al., 2011, Lammel et al., 2012). 
Blockade of both NMDA and AMPA receptors in the VTA blocks stress-induced 
increases in medial prefrontal dopamine signaling (Kalivas et al., 1989, Jedema 
and Moghaddam, 1994, Takahata and Moghaddam, 2000).  
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The VTA is a major site for glutamatergic regulation of cortical dopamine 
increases in response to stress (Kalivas et al., 1989, Enrico et al., 1998, 
Takahata and Moghaddam, 1998, Wang et al., 2005). If reinstatement by 
footshock stress and intra-VTA CRF delivery is dependent on increased 
dopamine in the prefrontal cortex, then blockade of either the NMDA or AMPA 
receptor should block reinstatement. However, this is not what occurred in the 
studies described in chapter four. By blocking AMPA or NMDA receptors on all 
cell phenotypes inactivation of the whole mesocorticolimbic dopamine system 
(i.e. cell that project to multiple downstream regions) likely occurred. This stands 
in likely contrast to the selective regulation of the PFC by CRF in the VTA and 
stress and may prevent activation of circuits that constrain drug seeking as well 
as pathways that promote it. Paradoxically, reinstatement by both footshock and 
intra-VTA CRF delivery not only still still occurred following intra-VTA antagonist 
delivery, but in some cases it was augmented. Not only does this suggest that 
AMPA and NMDA receptor activation is not necessary for reinstatement but it 
may suggest that reinstatement involves selective inactivation of isolated 
components of the mesocorticolimbic system. 
Elevations in both CRF and glutamate in the VTA by footshock stress 
have been found to be TTX-sensitive (Wang et al., 2005) suggesting that they 
are the consequence of afferent nerve terminal release. Activation of 
postsynaptic ionotropic glutamate receptors has been found to produce 
increases in somatodendritic dopamine release, an effect that is likely dependent 
on presynaptic CRF receptor activation, as it is blocked by CRF antagonist 
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administration into the VTA (Wang et al., 2005). These findings indicate that 
footshock-induced reinstatement is dependent on both CRF and ionotropic 
glutamate receptor activation in the VTA (Wang et al., 2005). CRF receptor 
blocked footshock-induced increases in glutamate but not dopamine suggesting 
that CRF receptor activation is increasing presynaptic glutamate release (Wang 
et al., 2005, Wang et al., 2007). However, CRF excites postsynaptic dopamine 
neurons (Ungless et al., 2003, Wanat et al., 2008, Hahn et al., 2009) suggesting 
that postsynaptic of dopamine neurons express CRF receptors. To this end, CRF 
antagonists would be expected to block stress-induced dopamine release in the 
terminal fields of the VTA. Importantly, stress-induced reinstatement and 
concomitant increases in dopamine but not glutamate concentrations were 
blocked by intra-VTA application of kynurenic acid, a nonspecific ionotropic 
glutamate receptor antagonist (Wang et al., 2005). Altogether, this seems to 
suggest that footshock-induced reinstatement of cocaine seeking is dependent 
on postsynaptic ionotropic glutamate receptor activation of VTA dopamine 
neurons as a result of CRF-dependent increases in VTA glutamate release. 
KYNURENIC ACID BEHAVIORAL PHARMACOLOGY 
 Although a role for glutamatergic excitation of VTA dopamine neurons has 
been proposed, we report that neither NMDA (AP-5) nor AMPA (NBQX) receptor 
antagonists, across a wide range of doses, prevents stress- or intra-VTA CRF-
induced reinstatement. Previously, Wang et al., (2005) showed that intra-VTA 
administration of the nonspecific ionotroptic glutamate receptors antagonist, 
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kynurenic acid (KA), was sufficient to block both stress- and intra-VTA CRF-
induced reinstatement, along with concomitant increases in somatodendritic 
dopamine concentrations in the VTA (Wang et al., 2005). 
Preliminary findings from chapter four suggest that KA (24 µg/.25µl per 
side) significantly attenuates both footshock- and intra-VTA CRF-induced 
reinstatement of extinguished cocaine-seeking behavior. These findings replicate 
those reported by Wang et al., (2005). The ability of KA but not AP-5 or NBQX to 
prevent reinstatement is unexpected but may be attributed to the unique 
pharmacological properties of KA. Kynurenic acid (KA) is referred to as a broad 
spectrum antagonist of ionotropic glutamate receptors with a preferential 
selectivity at the strychnine-insensitive glycine site of the NMDA receptor (IC50 
=15 µM) (Birch et al., 1988, Danysz et al., 1989, Kessler et al., 1989, Stone, 
1993) over the NMDA recognition site (Szalardy et al., 2012). In addition, the 
compound is an antagonist at the glutamate recognition-site of the NMDA 
receptor at moderate concentrations (IC50 = 200-500 µM) (Kessler et al., 1989). 
Kynurenic acid also blocks the AMPA receptor at high concentrations 
(micromolar to millimolar range), but at lower concentrations (nanomolar to 
micromolar) it facilitates AMPA receptor signaling (Stone, 1993, Prescott et al., 
2006, Rozsa et al., 2008). In addition to blocking the NMDA and AMPA receptor 
it also blocks the ionotropic kainate receptor at moderate doses (IC50 = 200 to 
600 µM) (Alt et al., 2004). Moreover, kynurenic acid at low concentrations, 
(micromolar or submicromolar) is also a competitive antagonist at α7 nicotinic 
receptors (IC50 ~ 7 µM) (Hilmas et al., 2001, Stone, 2007) and therefore may also 
249 
 
prevent excitatory regulation of VTA DA cells via ACh. Stimulation of the α7 
nicotinic receptor in the VTA increases the firing of VTA dopamine neurons 
(Schilstrom et al., 2003). Lastly, in addition to inhibiting the α7 nicotinic receptor 
kynurenic acid also inhibits GABAA receptors at very high concentrations with an 
IC50 of 3 mM (Bruijnzeel et al., 2009).  
Prior reports that reverse dialysis of kynurenic acid blocks stress-induced 
reinstatement of cocaine seeking and somatodendritic dopamine release (Wang 
et al., 2005) used at a concentration of 1 mM at which kynurenic acid is likely 
blocking all three ionotropic glutamate receptors (NMDA, AMPA, and Kainate). In 
chapter four we report (24 µg/side; 454 mM) bilateral microinjections of KA 
blocks stress-induced reinstatement. Although this dose is extremely high, it is 
only roughly twice the concentration previously reported to block reinstatement of 
cocaine-seeking induced by ventral subiculum stimulation (Vorel et al., 2001). 
Microinfusions inherently have higher concentrations than those used for 
microdialysis due to the fact that they are an acute bolus injection. Nonetheless, 
smaller doses are currently being tested for their ability to block reinstatement. 
Notably, the 24 µg/side intra-VTA KA dose that blocked reinstatement also 
produced substantial nonspecific motor impairments in drug naïve animals 
trained to lever press unde a schedule of food pellet reinforcement (data not 
shown). Side effects consisted of head weaving, turning behavior, and ataxia. 
These effects were observed all the way down to an 11 mM concentration (0.6 
µg/side). Our finding that kynurenic acid dose dependently reduces food 
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reinforced responding is consistent with previous studies that injected kynurenic 
acid (3.2 and 5.6 µg/0.5 µl; 34 and 59 mM) into the VTA (Sun, 2005).  
In contrast, the 24 µg/0.25µl per side dose of kynurenic acid did not affect 
the ability of cocaine SA experienced animals to lever press during reinstatement 
conditions (i.e. responding did not drop below extinction levels). This suggests 
that perhaps drug experience can change how an animal responds to intra-VTA 
KA delivery through changes in ionotropic glutamate receptor signaling. 
Alternatively, KA could decrease sucrose-seeking in a similar way to cocaine-
seeking independent of motor impairments.  
Although we tested for the effects of intra-VTA AP-5 and NBQX delivery 
individually on reinstatement, we never tested for the effects of combinated VTA 
AMPAR and NMDAR blockate. Activation of both AMPA and NMDA receptors 
may be necessary for reinstatement. Due to the nonspecific pharmacological 
effects of KA along with the inability of AP-5 and NBQX to individually block 
reinstatement current studies are underway to characterize the role of a AP-
5/NBQX (3 µg of each drug/side) cocktail to examine the potential contribution of 
a coordinated action of these receptors in the VTA to stress-induced cocaine 
seeking. However, unreported data from a pilot study suggests that a very low 
dose of 0.5 µg per side of both AP-5 and NBQX (cocktail) fails to block 
reinstatement by both footshock and intra-VTA CRF delivery.  
Altogether, the inability of NMDA or AMPA receptor antagonists to block 
both footshock- and intra-VTA CRF-induced reinstatement is not supportive of 
excitatory drive on VTA DA neurons through AMPA or NMDA glutamate 
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receptors alone as a mechanism for intra-VTA CRF-dependent reinstatement. 
However, it also does not rule this possiblility out. It is clear that additional 
experiement are needed. 
ALTERNATIVE EXCITATORY MECHANISMS OF INTRA-VTA CRF 
 Kynurenic acid is commonly referred to as a nonspecific excitatory 
ionotropic receptor antagonist (Birch et al., 1988). Kynurenic acid is an 
antagonist for kainate ionotropic glutamate receptors (Alt et al., 2004) and alpha 
7 nicotinic receptors (Hilmas et al., 2001, Stone, 2007) in addition to the AMPA 
and NMDA ionotropic glutamate receptors. For this reason and the finidng that 
kynurenic acid appears to block stress-induced reinstatement while antagonist’s 
specific for NMDA (AP-5) and AMPA (NBQX) receptors do not potentially reveals 
another mechanism through which CRF and stress regulate VTA function. The 
possibility that kynurenic acid may be blocking reinstatement through excitatory 
mechanisms mediated by either kainate ionotropic glutamate receptors and/or 
alpha 7 nicotinic acetylcholine receptors should be considered and represent 
another area for further investigation. 
KAINATE RECEPTOR REGULATION OF VTA DA NEURON EXCITABILITY 
 Ionotropic glutamate receptors are named after their agonists NMDA, 
AMPA, and kainate (Watkins and Evans, 1981, Monaghan et al., 1989, Young 
and Fagg, 1990). NMDA receptors mediate slow excitatory responses while 
AMPA and kainate receptors mediate fast excitatory responses (Collingridge and 
Lester, 1989, Cossart et al., 1998). Although, kainate ionotropic glutamate 
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receptors are widely expressed throughout the brain (Bettler et al., 1990, 
Egebjerg et al., 1991, Werner et al., 1991, Herb et al., 1992, Wisden and 
Seeburg, 1993, Bahn et al., 1994, Feldmeyer and Cull-Candy, 1994) and known 
to regulate excitatory neurotransmission (Chittajallu et al., 1996, Castillo et al., 
1997), they are substantially understudied, and their role in brain 
neurophysiology is largely unknown (Feldmeyer and Cull-Candy, 1994). Kainate 
receptors are present in the VTA and known to regulate intra-VTA dopamine 
neuron activity as well as dopamine release (Mayer et al., 1984, Kalivas and 
Stewart, 1991, Wang and French, 1993a, White, 1996, Westerink et al., 1998, 
Barrera et al., 2005, Ye et al., 2005). This suggests that the ability of kynurenic 
acid to block reinstatement may be regulated by kainate ionotropic glutamate 
receptor activation. 
ACH RECEPTOR REGULATION OF VTA DA NEURON EXCITABILITY 
 In the brain, alpha 7 nicotinic acetylcholine receptors (α7-nAChRs) can 
excite neurons at both pre- and postsynaptic sites by increasing calcium 
permeability (Berg and Conroy, 2002). α7-nAChRs are present in the VTA at 
somatodendritic sites on dopamine and GABA neurons as well as on presynaptic 
glutamate terminals (Jones and Wonnacott, 2004). In support, VTA α7-nAChRs 
can facilitate LTP by enhancing release from presynaptic glutamatergic terminals 
(Mansvelder and McGehee, 2000). α7-nAChRs not only regulate VTA dopamine 
neuron excitation (Calabresi et al., 1989, Pidoplichko et al., 1997, Mansvelder 
and McGehee, 2000, Schilstrom et al., 2000, Mansvelder et al., 2002) but also 
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drug self-administration (Corrigall and Coen, 1994). Therefore, the ability of 
kynurenic acid to block reinstatement may also be regulated mediated by α7-
nAChRs. 
MGLUR RECEPTOR REGULATION OF VTA DA NEURON EXCITABILITY 
 Alternatively, glutamate may still be an integral part of intra-VTA CRF-
dependent reinstatement of cocaine seeking but may be regulating dopamine 
cells through metabotropic instead of ionotropic receptors. Group 1 metabotropic 
glutamate receptors (mGluR1 and mGluR5) (Conn and Pin, 1997) are expressed 
on dopamine neurons in the VTA (Kane et al., 2005). Group 1 metabotropic 
glutamate receptor activation in the VTA can facilitate and inhibit burst firing of 
VTA dopamine neurons (Fiorillo and Williams, 1998, Zheng and Johnson, 2002), 
producing both excitatory and inhibitory effects on VTA dopamine neurons by 
way of group 1 mGluR stimulation. Whether or not group 1 mGluR activation is 
excitatory or inhibitory depends on both pattern and frequency of afferent input 
(Fiorillo and Williams, 1998). 
MGLUR RECEPTOR INVOLVEMENT IN DRUG-INDUCED NEUROPLASTICITY 
 Group 1 mGluRs have been shown to regulate cocaine-induced plasticity 
involving potentiation of excitatory input onto VTA dopamine neurons (Bellone 
and Luscher, 2006). Specifically, activation of group 1 mGluR receptors reverses 
cocaine-induced insertion of calcium permeable AMPA receptors into the 
membrane of VTA dopamine neurons; a process termed mGluR-LTD (Bellone 
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and Luscher, 2005, 2006, Mameli et al., 2007, Luscher and Huber, 2010). In 
addition to regulating cocaine-induced AMPA neuroplasticity, group 1 mGluR 
currents can be enhanced by CRF release into the VTA (Riegel and Williams, 
2008). However, mGluR expression levels in the VTA have been reported to be 
unchanged following extended access to cocaine for SA (Ben-Shahar et al., 
2009, Ghasemzadeh et al., 2011). 
GABA RECEPTORS AND VTA DOPAMINE SIGNALING  
 Burst firing patterns of intra-VTA dopamine neurons optimize and 
potentiate release of dopamine at both terminal and somatodendritic sites 
(Gonon, 1988, Wightman and Zimmerman, 1990, Nissbrandt et al., 1994). In this 
way, somatodendritic dopamine elevation in the VTA is indicative of burst firing of 
midbrain dopamine neurons (Bjorklund and Lindvall, 1975, Geffen et al., 1976, 
Kalivas and Duffy, 1991, Rice et al., 1997, Jaffe et al., 1998, Adell and Artigas, 
2004). This burst firing is essential for reward perception, reward seeking, reward 
expectancy, and salience (Nishino et al., 1987, Schultz et al., 1997, Berridge and 
Robinson, 1998, Tsai et al., 2009, Zweifel et al., 2009).  
As previously mentioned, VTA DA neuron burst firing is primarily by both 
excitatory glutamatergic NMDA receptor activation and inhibitory GABAB-receptor 
activation. NMDA receptor activation stimulates burst firing while GABAB receptor 
activation inhibits burst firing (Overton and Clark, 1992, Overton and Clark, 1997, 
Erhardt et al., 2002). Therefore, the burst firing of midbrain dopamine neurons is 
tightly controlled by the coordinated actions of NMDA and GABAB receptors 
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(Erhardt and Engberg, 2002). Since, in our hands, NMDA receptor blockade, 
which would be expected to inhibit VTA burst firing, did not affect reinstatement, 
the next candidates that may contribute to the control of dopamine neuron burst 
firing are GABA receptors. In addition to GABAB receptors, VTA dopamine 
neuron activity can be inhibited upon activation of GABAA receptors on dopamine 
neurons (Tan et al., 2012, Graziane et al., 2013) and excited by GABAA 
receptors on GABAergic interneurons that provide tonic inhibition of dopamine 
cells and, thereby also regulate phasic firing (Kalivas et al., 1990, Johnson and 
North, 1992a, Xi and Stein, 1998). 
INTRA-VTA GABA MECHANISMS AND REINSTATEMENT OF DRUG 
SEEKING 
 
 
 VTA synaptic plasticity implicated in stress-induced reinstatement of 
cocaine seeking includes both long term potentiation (LTP) and long term 
depression (LTD) of GABAergic synapses onto VTA DA neurons that emerges 
following repeated drug exposure (Nugent et al., 2007, Pan et al., 2008, Dacher 
and Nugent, 2011, Dacher et al., 2013). Recent findings suggest that LTP and 
LTD at GABAergic synapses upon VTA DA neurons display Hebbian 
characteristics effecting postsynaptic dopamine neurons in the VTA (Nugent et 
al., 2007, Nugent et al., 2009, Dacher et al., 2013, Graziane et al., 2013, 
Kodangattil et al., 2013). 
GABAERGIC DRUG-INDUCED NEUROPLASTICITY 
 Acute exposure to nicotine, ethanol, cocaine, or stress has been shown to 
block LTP at GABAergic synapses on VTA dopamine neurons, thereby removing 
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an inhibitory brake on the dopaminergic system (Morita et al., Nugent et al., 
2007, Nugent et al., 2009, Niehaus et al., 2010). However, this mechanism is 
dependent on postsynaptic NMDA receptor activation which produces nitric oxide 
which undergoes retrograde diffusion, and initiates presynaptic GABA release, 
thereby activating GABAA receptors on postsynaptic VTA dopamine neurons 
(Nugent et al., 2007, Nugent et al., 2009). Stress appears to remove this 
inhibitory brake on dopamine neurons by releasing dynorphin and activating the 
kappa opioid receptor in the VTA to block LTP GABA and facilitate relapse 
(Graziane et al., 2013). Blockade of the kappa receptor with Nor-BNI can block 
stress-induced reinstatement and rescue LTP GABA (Graziane et al., 2013). This 
mechanism is acute and appears to synergize with increased glutamatergic drive 
of the circuit. However, it is unlikely that this is the mechanism we are observing 
with GABAB receptor blockade. Chapter four reports that antagonism of both 
NMDA and GABAA receptors fail to inhibit or augment both footshock stress- and 
intra-VTA CRF-induced reinstatement in LgA animals. Moreover, blockade of 
GABAB receptor signaling is most likely removing an inhibitory break instead of 
rescuing one to block relapse. 
CONVERGENCE OF CRF-R1 AND GABAB IN DRUG-INDUCED 
NEUROPLASTICITY 
 
 
 CRF-R1 activation can facilitate both excitatory NMDA and AMPA 
receptor signaling as well as inhibitory GABAB signaling (Beckstead et al., 2009, 
Hahn et al., 2009) in VTA dopamine neurons. Following repeated cocaine 
exposure, the excitatory effects of CRF are augmented (Hahn et al., 2009) and 
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the inhibitory effects of CRF are diminished (Beckstead et al., 2009), likely 
resulting in a net shift toward excitatory CRF-R1 receptor-mediated regulation of 
VTA dopamine neurons. Therefore, it was originally hypothesized that, if the 
reinstating effects of CRF involves decreased inhibitory drive through GABA 
receptor signaling, then blockade of GABA receptors should augment cocaine 
seeking in response to both footshock and intra-VTA CRF administration. In 
contrast to this hypothesis, GABAB receptor antagonism blocked reinstatement in 
response to both footshock and intra-VTA CRF delivery. The only antagonist 
other than CRF-R1 antagonists (Antalarmin and CP-376395) to reliably block 
reinstatement without producing secondary locomotor effects was the GABAB 
receptor antagonist, 2-hydroxysaclofen. This suggests that GABAB receptor 
activation is regulating the neurocircuitry of the VTA in such a way to facilitate 
stress-induced reinstatement of cocaine-seeking. It also suggests that 
reinstatement involves an increase and not a decrease in GABAergic signaling in 
the VTA and supports reports in the literature demonstrating inhibition of VTA 
dopamine neurons by aversive stimuli (Schultz and Romo, 1987, Mantz et al., 
1989, Mirenowicz and Schultz, 1996, Guarraci and Kapp, 1999, Ungless et al., 
2010). 
GABAB AS A PHARMACOLOGICAL TARGET TO TREAT ADDICTION 
 Paradoxically, GABAB receptor agonists and other compounds that 
activate inhibitory G protein-coupled inwardly-rectifying potassium (GIRK) 
channels have been proposed as therapeutic candidates to help treat alcoholism 
and drug addiction (Brebner et al., 2002, Kobayashi et al., 2004, Walker and 
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Koob, 2007). For example, GABAB receptor agonists decrease the reinforcing 
effects of cocaine (Roberts et al., 1996, Roberts and Koob, 1997, Brebner et al., 
1999), self-administration of cocaine as measured using self-administration, 
(Brebner et al., 1999, Brebner et al., 2000, Backes and Hemby, 2008), and 
increases in terminal field dopamine levels (Kalivas et al., 1990, Klitenick et al., 
1992, Westerink et al., 1996). The finding that GABAB antagonism blocks both 
footshock- and intra-VTA CRF is consistent with the idea that GABAB antagonists 
rather than GABAB agonists could serve as potential medications. It should be 
noted that we tested for the ability of the GABAB receptor agonist (baclofen; 2 
µg/side) injected into the VTA to cause relapse in the absence of stress or CRF. 
The result was substantial motor impairment, consistent with global neuronal 
inhibition, both pre- and postsynaptically as predicted (personal communication 
with John T. Williams). However, conclusions cannot be deduced from one 
subject and lower doses of baclofen should be tested due to its potent effects 
before drawing firm conclusions regarding the effects of GABAB receptor 
activation in the VTA. 
POSSIBLE MECHANISMS OF VTA GABAB ANTAGONISM 
 In a set of elegant studies, Westerink et al., (1996, 1998) characterized 
intra-VTA pharmacological manipulations on downstream mesolimbic and 
mesocortical dopamine concentrations using dual-probe microdialysis in drug 
naïve animals. Examination of effects on the mesocortical system revealed that 
intra-VTA administration of a GABAB agonist decreased dopamine 
concentrations in the PFC, while a GABAB antagonist increased dopamine 
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concentrations in the PFC (Westerink et al., 1998). Likewise, examination of 
effects on the mesolimbic system revealed that intra-VTA administration of a 
GABAB agonist decreased nucleus accumbens dopamine concentrations 
(Westerink et al., 1996), while a GABAB antagonist did not significantly change 
dopamine concentrations in the nucleus accumbens (Westerink et al., 1996). 
This suggests that intra-VTA GABAB receptor antagonism preferentially 
increases dopamine in the prefrontal cortex in drug naïve rats (Westerink et al., 
1996, Westerink et al., 1998). This conclusion should be met with some caution 
because the function of intra-VTA GABAB receptor blockade in drug naïve 
animals may or may not be similar to SA-experienced animals who’ve undergone 
extinction, and are exposed to stress with an environment associated with 
cocaine availability. 
GABAB ANTAGONISM IN THE VTA SELECTIVELY TARGETS 
MESOCORTICAL PROJECTING NEURONS 
 
 Since GABAB receptor antagonism was the only manipulation that likely 
preferentially targeted the mesocortical dopamine neurons (Westerink et al., 
1996, Westerink et al., 1998), it should not be surprising that it was the only drug 
sufficient to block stress-induced reinstatement. Considering that GABAB 
receptor antagonism increases (not decreases) dopamine levels in the medial 
prefrontal cortex (mPFC), how can it be that this manipulation blocks stress-
induced reinstatement, which is likely dependent on increased mPFC dopamine 
release? A possible explanation is related to the anatomical organization of the 
medial prefrontal cortex.  
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As previously mentioned in Chapter 1, reinstatement is driven by an 
increase in prelimbic medial prefrontal cortex glutamate input into the nucleus 
accumbens core (Cornish et al., 1999, Cornish and Kalivas, 2000, McFarland 
and Kalivas, 2001, McFarland et al., 2003, McFarland et al., 2004, Kalivas and 
Volkow, 2005, LaLumiere and Kalivas, 2008). By contrast, glutamate projections 
from the ventromedial prefrontal cortex to the nucleus accumbens shell are 
thought to suppress drug-seeking behavior following extinction (Fuchs et al., 
2008, Peters et al., 2008, Peters et al., 2009). 
Projections from mPFC to the NA are organized into a dorsal-ventral 
pattern. The dorsal mPFC projects predominantly to the nucleus accumbens core 
and is a final common pathway for reinstatement of drug seeking, while the 
ventral mPFC projects to the nucleus accumbens shell and suppresses 
reinstatement of drug seeking (Cornish et al., 1999, Heidbreder and 
Groenewegen, 2003, Voorn et al., 2004, Peters et al., 2008, LaLumiere et al., 
2010, LaLumiere et al., 2012). Interestingly, the target region for dialysis in 
Westerink et al., (1998) is consistent with the ventral medial prefrontal cortex. 
Therefore, increasing dopamine in infralimbic cortex via intra-VTA GABAB 
receptor antagonism would be hypothesized increase dopamine in the infralimbic 
cortex and therefore block reinstatement of drug-seeking by both footshock and 
intra-VTA CRF delivery.  
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Figure 44: Corticolimbic subregion specific neurociruitry. Illustration of the “Go” 
circuit of the glutamatergic projection from the prelimbic cortex to the nucleus 
accumbens core that is associated with reinstatement, and the “No Go” circuit of 
the glutamatergic projection from the infralimbic cortex to the nucleus accumbens 
shell that is associated with extinction/reinstatement prevention. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRA-VTA GABAB ANTAGONISM INCREASES PFC DOPAMINE: POSSIBLE 
COMPETITIVE ROLE INHIBITING COCAINE-SEEKING 
 
 The prelimbic as well as the infralimbic cortices both receive extensive 
VTA dopaminergic inputs (Berger et al., 1976, Bjorklund et al., 1978, Emson and 
Koob, 1978, Van Eden et al., 1987, Westerink et al., 1998, Carr et al., 1999). 
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Dopamine inputs into the prelimbic cortex are essential for stress-induced 
reinstatement of cocaine-seeking behavior to occur; D1 receptor blockade in the 
prelimbic cortex blocks footshock-induced reinstatement (Capriles et al., 2003, 
Sanchez et al., 2003, McFarland et al., 2004). Pathways involved in the inhibition 
(infralimbic cortex) of drug seeking (Peters et al., 2008, Peters et al., 2009) can 
inhibit pathways involved in the activation (prelimbic) of drug seeking (McFarland 
and Kalivas, 2001, McFarland et al., 2003, McFarland et al., 2004) through a 
feedforward mechanism (Ferrante et al., 2009). To this end, evidence suggests 
that activation of the infralimbic cortex inhibits prelimbic cortex output (Ji and 
Neugebauer, 2012). Since GABAB antagonism increases dopamine in the 
infralimbic cortex, it may inhibit prelimbic output. Perhaps the ability of 2-
hydroxysaclofen to block both footshock and intra-VTA CRF-induced 
reinstatement of extinguished LgA cocaine-seeking is related to its ability to 
increase dopamine in the infralimbic cortex which competitively inhibits the 
glutamatergic input to the nucleus accumbens core from the prelimbic cortex. 
With this in mind, it is also important to note that activation of both the prelimbic 
and infralimbic cortices also regulate ventral tegmental area dopamine neuron 
activity (Patton et al., 2013).  
Figure 45: Schematic representing competitive signaling between prelimbic and 
infralimbic cortices in drug-seeking behavior. Activation of the infralimbic can 
inhibit pyramidal neuron output in the prelimbic cortex which is essential for drug-
seeking behavior. In this way infralimbic cortex activation may inhibit prelimbic 
cortex output and facilitate extinction while prelimbic cortex activation may inhibit 
infralimbic cortex output and facilitate reinstatement. 
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Figure 46: Proposed effects of GABAB antagonism on mesocortical input. 
GABAB antagonism may block reinstatement by increasing mesocortical 
dopamine input into the infralimbic cortex, increasing glutamate input into the 
nucleus accumbens shell “No Go” circuit. 
 
 
GABAB AND G PROTEIN-COUPLED INWARDLY RECTIFYING POTASSIUM 
CHANNELS 
 
 GABAB receptors are thought to localize primarily to VTA DA neurons (Xi 
and Stein, 1998, Margeta-Mitrovic et al., 1999, Wu et al., 1999, Laviolette and 
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van der Kooy, 2001, Wirtshafter and Sheppard, 2001, Giorgetti et al., 2002, 
Beckstead et al., 2004, Laviolette et al., 2004, Laviolette and van der Kooy, 2004, 
Labouebe et al., 2007, Beckstead et al., 2009, Margolis et al., 2012). However, 
there is emerging evidence that GABAB receptors can also be expressed on 
GABA neurons where they can induce inhibitory currents (Cruz et al., 2004, 
Padgett et al., 2012). In the VTA, GABAB receptors are also expressed 
presynaptically on GABAergic and glutamatergic neuronal terminals (Bonci and 
Williams, 1997, Manzoni and Williams, 1999, Wu et al., 1999, Giorgetti et al., 
2002, Michaeli and Yaka, 2010). Presynaptic GABAB receptors can decrease 
presynaptic glutamate and GABA release in the rat VTA by inhibiting Ca2+ 
conductance (Olpe et al., 1977, Pinnock, 1984, Lacey et al., 1988, Seabrook et 
al., 1990, Bonci and Williams, 1997, Shen and Johnson, 1997, Wu et al., 1999, 
Giorgetti et al., 2002, Michaeli and Yaka, 2010). 
GABAB RECEPTOR-MEDIATED GIRK CHANNEL CONDUCTANCE IN THE 
VTA 
 
One prominent inhibitory signaling mechanism that is regulated by GABAB 
receptors is G protein-coupled inwardly rectifying potassium (GIRK/Kir3) 
channels (Johnson and North, 1992b, Beckstead et al., 2004). GIRK channels 
can be activated through GABAB-receptor activation of Gi/o G-proteins which 
increases membrane conductance, thereby producing inhibitory postsynaptic 
currents (IPSCs) through potassium ion efflux (Misgeld et al., 1995, Watts et al., 
1996) and inhibiting neuronal activity (Dascal, 1997, Beckstead et al., 2004, Cruz 
et al., 2004, Ford et al., 2006, Labouebe et al., 2007).  
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GABAB RECEPTOR-MEDIATED GIRK CHANNEL REGULATION OF VTA 
DOPAMINE NEURON EXCITABILITY 
 
 GABAB activation of GIRK conductance hyperpolarizes dopamine neurons 
on a millisecond time scale (Beckstead et al., 2004) which is consistent with its 
role in channel conductance. Moreover, it contributes to the pause of DA 
excitation following action potential bursts, thereby strongly inhibiting midbrain 
dopamine cell firing (Lacey et al., 1987, Pucak and Grace, 1994, Davila et al., 
2003, Beckstead et al., 2004, Koyrakh et al., 2005). GABAB receptor-regulated 
GIRKs not only play an inhibitory role but also a facilitatory role in phasic burst 
firing of VTA dopamine neurons. Specifically, GABAB receptor-regulated GIRKs 
allow for optimal coding of phasic bursts by inducing the pause before and after 
the burst (Beckstead et al., 2004, Ford et al., 2009). Therefore, GABAB receptors 
may be necessary for optimal phasic bursts at the time of stress-induced relapse. 
This suggests that GABAB receptors could be inhibiting phasic firing or 
paradoxically optimizing phasic firing at the time of stress-induced reinstatement.  
DRUG-INDUCED NEUROPLASTICITY AND GABAB RECEPTOR-MEDIATED 
GIRK SIGNALING IN THE VTA 
 
 Inhibitory Gi/o G protein-coupled receptors (GPCRs), such as the GABAB 
receptor, have been implicated in both acute and chronic effects of drug-induced 
neuroadaptations (Nestler et al., 1990, Filip and Frankowska, 2007, Vlachou and 
Markou, 2010). Psychostimulant administration has been shown to decrease 
GABAB receptor-regulated GIRK channel conductance on both VTA DA and 
GABA neurons leading to enhanced dopamine signaling or GABA signaling, 
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respectively (Giorgetti et al., 2002, Beckstead et al., 2009, Arora et al., 2011, 
Padgett et al., 2012).  
GABAB receptor mRNA expression doesn’t appear to change as a result of 
cocaine exposure (Nestler et al., 1990, Arora et al., 2011). In contrast, decreased 
GIRK expression in conjunction with decreased GABAB receptor-mediated 
inhibition has been reported at somatodendritic sites of VTA dopamine neurons 
(Arora et al., 2011). Moreover, this inhibition of GABAB signaling is blocked by 
intracellular calcium chelation, independently from NMDA and AMPA receptor 
calcium entry (Malenka and Bear, 2004, Beckstead and Williams, 2007). 
Therefore, decreased GABAB GIRK conductance in VTA neurons is a drug-
induced neuroadaptation that is independent of ionotropic glutamate receptor 
calcium entry (Beckstead et al., 2004). 
Notably, neuroadaptations decreasing GABAB regulated inhibition of VTA 
dopamine neurons have only been observed during acute withdrawal from non-
contingent drug administration (Beckstead et al., 2009, Padgett et al., 2012). 
These studies utilized ex vivo slice electrophysiology in post mortem brain slices 
where neuronal circuitry is not intact and in the presence of numerous drugs to 
isolate GABAB receptor function (Beckstead et al., 2009, Padgett et al., 2012). 
However, psychostimulant-induced changes in GABAB receptor coupling and 
neurotransmission have also been reported in vivo.  
Diminished functional coupling of the GABAB receptor to Gi/o G proteins has 
been observed during times of inhibited GABAB signaling in vivo following 
repeated cocaine administration (Striplin and Kalivas, 1992, 1993, Kushner, 
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2001). Importantly, both GABAB signaling and G protein-coupling recovers within 
two weeks of the last exposure to cocaine (Striplin and Kalivas, 1992, 1993, 
Arora et al., 2011). Our ability to block stress-induced relapse with a GABAB 
receptor antagonist within at least 14 days since the last cocaine exposure is 
more consistent with intact GABAB regulation of dopamine neuron excitability.  
One of the only studies characterizing drug-induced neuroplastic effects of 
intra-VTA GABAB signaling in vivo was done using intra-VTA microdialysis in 
animals that had received noncontingent repeated amphetamine administration 
(Giorgetti et al., 2002). Repeated amphetamine administration was reported to 
produce an increase, rather than a decrease, in GABAB inhibitory tone in the VTA 
(Giorgetti et al., 2002). Specifically, intra-VTA GABAB receptor antagonism 
produced a dose-dependent increase in somatodendritic dopamine release 
without affecting glutamate concentrations in drug-naïve animals (Giorgetti et al., 
2002). In contrast, GABAB antagonism in animals receiving repeated 
amphetamine displayed an augmented ability to increase somatodendritic 
dopamine release, and an emergent ability for it to presynaptically increase 
presynaptic release (Giorgetti et al., 2002). This suggests that somatodendritic 
dopamine release in the VTA is normally under tonic inhibition by GABAB 
receptors and that presynaptic inhibition of glutamate release in the VTA by 
GABAB can be recruited by drugs of abuse. These results are opposite of 
expected based on our findings that GABAB receptor antagonism blocked intra-
VTA CRF-induced reinstatement and reports of the effects of CRF receptor 
antagonism in the VTA in response to repeated contingent cocaine self-
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administration. Wang et al., (2005) reported that CRF receptor blockade prevents 
a recruited increase in both presynaptic glutamate release and somatodendritic 
dopamine release, inconsistent with a potential GABAB receptor-mediated 
mechanism for our studies. 
In summary, the net effect of intra-VTA GABAB receptor blockade on 
dopaminergic neurotransmission likely involves increased presynaptic release of 
both GABA and glutamate, increased somatodendendritic dopamine release, and 
increased dopamine release in the prefrontal cortex but not the nucleus 
accumbens (Westerink et al., 1996, Shen and Johnson, 1997, Westerink et al., 
1998, Giorgetti et al., 2002, Beckstead et al., 2009). The exact role of GABAB 
receptor activation during stress-induced reinstatement still remains 
undetermined. However, emerging evidence from chapter four suggests that 
GABAB receptor function in the VTA can regulate cocaine-seeking, particularly 
during stress. 
POSSIBLE CRF AND GABAB INTERACTIONS IN THE VTA 
 
 
 Importantly, coordinated function between CRF-R1 and GABAB receptors 
has been proposed in the regulation of VTA dopamine neuron activity. This 
coordinated function may involve both presynaptic and postsynaptic 
mechanisms. In terms of a presynaptic mechanism, the GABAB receptor shares 
a common sushi domain structure with the N-terminus of the CRF-R1 receptor 
suggesting these receptors may interact to augment inhibition of presynaptic 
release (Blein et al., 2004, Perez-Garci et al., 2006, Perrin et al., 2006, Grace et 
al., 2007b). These sushi repeats on the N-terminus of the GABAB receptor are 
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important determinants of the formation of heterocomplexes (Vigot et al., 2006). 
Although, molecular biologists suggest the possibility, there still remains lack of 
evidence for a coordinated inhibition of presynaptic release between CRF-R1 
and GABAB receptors. 
There is also evidence of a coordinated postsynaptic mechanism implicating 
both GABAB and CRF-R1 receptors. Specifically, intra-VTA CRF signaling can 
act postsynaptically on CRF-R1 receptors to enhance GABAB regulated GIRK 
conductance on DA neurons (Beckstead et al., 2009).  This enhancement likely 
occurs through CRF-R1 Gs activation of PKA (Sadja et al., 2001, Raveh et al., 
2009, Grammatopoulos, 2012). An increase in GIRK channel activity can be 
induced by protein kinase A (PKA) following the activation of a GPCR linked to 
Gαs G-proteins (Figure 38). CRF-R1 receptors appear to be necessary for CRF 
actions on GIRK currents whereas CRF-R2 receptors appear not to be 
(Beckstead et al., 2009). 
 
Figure 47: The G protein-coupled potassium (GIRK) channel signaling complex 
viewed from the intracellular side of the membrane. GIRK channels are gated 
following the activation of GPCRs associated with G proteins Gi/o (pertusses 
toxin-sensitive) that release Gβγ dimers to gate the channel directly (blue). A 
reduction in membrane activity can be induced by activation Gq coupled 
receptors (green). In contrast, an increase in GIRK channel activity can be 
induced by activation of Gαs dependent protein kinase A (PKA) (yellow), which is 
the predominant coupling for CRF receptors in the CNS (Grammatopoulos, 
2012). Both PLC and PKA can be soluble not having to be directly associated 
with the GIRK channel complex to affect conductance (Sadja et al., 2001, Raveh 
et al., 2009). 
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It is interesting to speculate that reinstatement under LgA conditions involves 
an increase in CRF-R1 and GABAB receptor coupling. As intriguing as this 
possibility is, there is no direct evidence that CRF-R1 and GABAB receptors form 
a heterocomplex to regulate motivated behavior. The observation that both 
GABAB antagonism (Gi coupled) and CRF-R1 antagonism (Gs coupled) block 
reinstatement suggests it is not simplay a case of convergence of a specific G-
protein signaling cascade. Considering the complexities of CRF-R1 and GABAB 
receptor-mediated secondary messaging both Gs and Gi are good candidates to 
provide augmentation of GIRK conductance on dopamine neurons. Unlike CRF 
receptors (Liu et al., 2005) GABAB receptor coupling is unlikely to change within 
the VTA as a result of drug abuse (Zhang et al., 2007). However, it is more likely 
that CRF-R1 Gs activation of PKA activity is facilitating GIRK conductance, since 
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Gs coupling is the predominant coupling for CRF receptors in the CNS 
(Grammatopoulos, 2012).   
 
In summary, CRF-R1 and GABAB receptor antagonists block footshock- and 
intra-VTA CRF-induced reinstatement of cocaine-seeking behavior following LgA 
SA. The finding that CRF-R1 is necessary and sufficient for reinstatement 
suggests that intra-VTA CRF-R1 signaling is recruited following LgA cocaine self-
administration. This may take the form of increased CRF release, increased CRF 
receptor responsiveness, increased CRF receptor expression, or even changes 
in G protein-coupling. The ability for GABAB antagonism to block footshock- and 
intra-VTA CRF-induced reinstatement implicates inhibitory GABA regulation of 
the circuit. This may take the form of increased inhibition of postsynaptic 
dopamine neurons by GIRK IPSCs, inhibiting presynaptic glutamate or GABA 
release, or even changes in GABAB/GIRK expression.  
As mentioned in chapter one, increasing GABA input or intra-VTA GABA 
neuron activity produces aversive/anxiogenic behavioral responses, while 
increasing glutamatergic input or disinhibiting VTA dopamine neurons both 
produce reward/anxiolytic behavioral responses (Lammel et al., 2012, Jennings 
et al., 2013). Aversive stimuli target the medial prefrontal cortex while rewarding 
stimuli targets the nucleus accumbens (Lammel et al., 2011). Following drug-
induced neuroplasticity, CRF signaling is likely recruited at both CRF-
glutamatergic and CRF-GABAergic synapses (Tagliaferro and Morales, 2008). 
These inputs are hypothesized to provide complex and highly coordinated 
regulation of the VTA in response to stress. In this way, CRF acting as a 
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neuromodulator is likely setting the stage for glutamatergic and GABAergic inputs 
to manage activity of the mesocorticolimbic system in such a way to facilitate 
relapse. 
Notably, the majority of studies reporting excitatory regulation of VTA 
dopamine neurons by CRF receptors have involved animals under conditions 
that most resemble our ShA animals. It is possible that, under ShA SA 
conditions, CRF blockade may prevent excitatory drive on VTA dopamine 
neurons to prevent relapse. Alternatively, under LgA SA conditions, GABA 
signaling may be recruited to combat excessive cocaine-induced excitatory drive 
of the circuit. This inhibitory tone may be present into the protracted abstinence 
phase. Prevention of overwhelming drug craving and motivation to use which 
results in reinstatement of drug seeking may be prevented by blocking aversive 
drive of the motive circuit, via CRF-R1 and GABAB receptors, when in the self-
administration context and under stress. 
CONCLUDING REMARKS  
 Importantly, both a decrease and an increase in dopamine signaling can 
precipitate relapse in human addicts (Volkow et al., 2006, Laskowitz et al., 2012). 
Addiction involves a transition from chasing drug-induced euphoria (positive 
reinforcement) to eventually using the drug to avoid dysphoria (negative 
reinforcement) (Solomon and Corbit, 1974, Gawin and Kleber, 1986, Koob et al., 
2004, DSM-V, 2013). Future studies are needed to further characterize the 
intricacies of excitatory and inhibitory regulation of mesocortical versus 
mesolimbic circuits, how these circuits are changed by drug-induced 
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neuroplasticity, and how these changes promote relapse. It is my hope that the 
findings and discussions reported in this dissertation will help with the 
understanding and eventual long-term management of stressor-induced relapse 
in abstinent cocaine addicts. 
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